levodopa has been researched along with oxidopamine in 819 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (4.27) | 18.7374 |
| 1990's | 136 (16.61) | 18.2507 |
| 2000's | 254 (31.01) | 29.6817 |
| 2010's | 305 (37.24) | 24.3611 |
| 2020's | 89 (10.87) | 2.80 |
| Authors | Studies |
|---|---|
| Kohsaka, S; Nagatsu, T; Tsuzaki, N; Uchida, K | 1 |
| Breese, GR; Criswell, HE; Duncan, GE; Johnson, KB; Jurevics, HA; Mueller, RA; Napier, TC; Simson, PE | 1 |
| Di Chiara, G; Fenu, S; Morelli, M | 1 |
| De Ceballos, ML; Jenner, P; Marsden, CD; Rose, S; Taylor, MD | 1 |
| Blunt, SB; Jenner, P; Marsden, CD | 3 |
| De Klippel, N; Deleu, D; Devrieze, A; Ebinger, G; Herregodts, P; Michotte, Y; Sarre, S | 1 |
| Breese, GR; Criswell, HE; Mueller, RA | 1 |
| Carey, RJ | 3 |
| Abercrombie, ED; Hastings, TG; Zigmond, MJ | 1 |
| Greiner, HE; Haase, AF; Seyfried, CA | 1 |
| Collier, TJ; Sladek, JR; Steece-Collier, K; Yurek, DM | 1 |
| Britton, DR; Curzon, P; Kebabian, JW | 1 |
| Chase, TN; Engber, TM; Gerfen, CR; Kuo, S; Susel, Z | 1 |
| Ariano, MA; Chase, TN; Engber, TM; Susel, Z | 1 |
| Joyce, JN; Neal, BS | 1 |
| Honoré, T; Jähnig, P; Jenner, P; Kunow, M; Lange, KW; Löschmann, PA; Marsden, CD; Rettig, KJ; Turski, L; Wachtel, H | 1 |
| Aceves, J; Floran, B; Hernandez, S; Mariscal, S; Martinez-Fong, D; Sierra, A | 1 |
| Blunt, S; Jenner, P; Marsden, CD | 1 |
| Buhrfiend, CM; Carvey, PM; Goetz, CG; Klawans, HL; Lin, DH; Lo, ES; Ptak, LR | 1 |
| Breese, GR; Criswell, HE; Iorio, LC; McQuade, RD; Mueller, RA | 1 |
| Di Chiara, G; Morelli, M | 1 |
| Snyder, GL; Zigmond, MJ | 1 |
| Buu, NT; Lussier, C | 1 |
| Bhardwaj, A; Brannan, T; Martinez-Tica, J; Weinberger, J; Yahr, M | 1 |
| Kaakkola, S; Männistö, PT; Toivonen, M; Törnwall, M; Tuomainen, P | 1 |
| Chase, TN; Engber, TM; Susel, Z; Walters, JR; Weick, BG | 1 |
| Abercrombie, ED; Bonatz, AE; Zigmond, MJ | 1 |
| Ceresoli, G; Groppetti, A; Mandelli, V; Parenti, M | 1 |
| Brannan, T; Kaufmann, H; Knott, P; Yahr, M | 1 |
| Gibb, JW; Hanson, GR; Sonsalla, PK | 1 |
| Dragunow, M; Herrera, DG; Robertson, GS; Robertson, HA | 1 |
| Etemadzadeh, E; Kaakkola, S; Koskinen, L | 1 |
| Chase, TN; Engber, TM; Juncos, JL; Susel, Z | 1 |
| Igarashi, N; Minami, S; Okabe, T; Sato, T | 1 |
| Borisov, MM | 1 |
| Flauto, C; Groppetti, A; Parati, E; Parenti, M; Vescovi, A | 1 |
| Chen, SD; Pan, GB; Xu, DL; Yu, WC | 1 |
| Cooper, DR; Jenner, P; Marrel, C; Marsden, CD; Testa, B; van de Waterbeemd, H | 1 |
| Boyce, S; Jenner, P; Marsden, CD | 1 |
| Flauto, C; Groppetti, A; Parati, E; Parenti, M; Rusconi, L; Vescovi, A | 1 |
| Fozard, JR; Palfreyman, MG; Robin, M; Zreika, M | 1 |
| Herrera-Marschitz, M; Ungerstedt, U; Zetterström, T | 1 |
| Abe, Y; Kisara, K; Tadano, T; Yonezawa, A | 1 |
| Boismare, F; Daoust, M; Moore, N; Saligaut, C | 2 |
| Breese, GR; Criswell, H; Mueller, RA | 1 |
| Akiyama, A; Nakazato, T | 1 |
| Ervin, GN; Nemeroff, CB | 1 |
| Liskowsky, DR; Potter, LT | 1 |
| Chang, JP; Cook, AF; Marchant, TA; Nahorniak, CS; Peter, RE | 1 |
| Watanabe, H | 1 |
| Buu, NT | 1 |
| Baumeister, A; Breese, GR; Frye, GD; Mueller, RA; Napier, TC | 1 |
| Kelley, AE; Stinus, L | 1 |
| Belton, P; Davison, AJ; Wilson, BD | 1 |
| Bell, C | 1 |
| Baumeister, AA; Breese, GR; Crotty, K; Emerick, SG; Frye, GD; McCown, TJ; Mueller, RA | 1 |
| Prée, J; Rutschke, E | 1 |
| McGrath, BP; Smith, GC; Willis, GL | 1 |
| Deupree, JD; Murrin, LC; Pfeiffer, RF; Schneider, MB | 1 |
| Baumeister, AA; Breese, GR; Emerick, SG; Frye, GD; McCown, TJ; Mueller, RA | 1 |
| Armstrong, D; Courtney, CL; Palfai, T | 1 |
| Cabbat, FS; Duvoisin, RC; Heikkila, RE; Manzino, L | 1 |
| Akiba, K; Kisara, K; Kohno, H; Matsumura, H; Satoh, S; Suzuki, T; Tadano, T | 1 |
| Bédard, PJ; Côté, PY; Grégoire, L; Parent, A; Roy, E | 1 |
| Ossowska, K | 1 |
| Carey, RJ; Dai, H; Huston, JP; Pinheiro-Carrera, M; Schwarting, RK; Tomaz, C | 1 |
| Jenner, P; Jolkkonen, J; Marsden, CD; Zeng, BY | 1 |
| Bankiewicz, KS; Finberg, JP; Goldstein, DS; Kopin, IJ; Wang, J | 1 |
| Grace, AA; Harden, DG | 1 |
| Inoue, A; Misu, Y; Nakata, Y; Okumura, F; Ozaki, N; Sato, K; Ueda, H; Yue, JL | 1 |
| Brannan, T; Martínez-Tica, J; Yahr, MD | 1 |
| Baetge, EE; Doherty, E; Frydel, B; Gentile, FT; Hammang, JP; Lindner, MD; McDermott, PE; Schallert, T; Ullman, MD; Winn, SR | 1 |
| Fukuchi, H; Kihira, K; Kimura, Y; Kitaura, T; Miyake, K | 1 |
| Bentlage, C; Björklund, A; Nikkhah, G; Olsson, M | 1 |
| Carey, RJ; Dai, H; Huston, JP; Pinheiro-Carrera, M; Tomaz, C | 2 |
| Asanuma, M; Kawai, M; Kohno, M; Masumizu, T; Mori, A; Ogawa, N; Tanaka, K | 1 |
| Barone, P; Campanella, G; Cicarelli, G; Di Chiara, G; Morelli, M; Popoli, M | 1 |
| Chase, TN; Engber, TM; Kask, AM; Papa, SM | 1 |
| Adams, CE; Boyson, SJ; Hoffer, BJ; Hoffman, AF; Hudson, JL | 1 |
| Carta, A; Cozzolino, A; Di Chiara, G; Fenu, S; Morelli, M; Pinna, A | 1 |
| Boldry, RC; Chase, TN; Engber, TM | 1 |
| Goshima, Y; Misu, Y; Miyamae, T; Yue, JL | 1 |
| Gash, DM; Sakai, K | 1 |
| Di Chiara, G; Fenu, S; Morelli, M; Pinna, A | 1 |
| Gayrard, V; Malpaux, B; Thiéry, JC; Tillet, Y | 1 |
| Goshima, Y; Misu, Y; Miyamae, T; Nakamura, S; Ueda, H; Yue, JL | 1 |
| Bankiewicz, KS; de Jesus, S; Sheng, J; Takubo, H; Thomas, J; Wang, J | 1 |
| De Klippel, N; Ebinger, G; Herregodts, P; Michotte, Y; Sarre, S | 1 |
| Cole, DG; Hyman, SE; Kobierski, LA; Konradi, C | 1 |
| Bräutigam, K; Morgenstern, R; Sohr, R | 1 |
| Gnanalingham, KK; Robertson, RG | 2 |
| Anderson, JJ; Boldry, RC; Chase, TN; Engber, TM; Kuo, S; Papa, SM | 1 |
| Asanuma, M; Kawada, Y; Kondo, Y; Mori, A; Ogawa, N; Yamamoto, M | 1 |
| Moorman, SJ; Whalen, LR | 1 |
| Gurevich, V; Jiao, S; Wolff, JA | 1 |
| Kuno, S; Mizuta, E | 1 |
| Abercrombie, ED; Wachtel, SR | 1 |
| Bédard, PJ; Di Paolo, T; Gagnon, C; Gaudin, DP; Rioux, L | 1 |
| Abercrombie, ED; Jackson, D; Zigmond, MJ | 1 |
| Andrew, R; Best, SA; Midgley, JM; Petty, RK; Watson, DG; Wenlong, H | 1 |
| Hossain, MA; Weiner, N | 1 |
| Goshima, Y; Misu, Y; Yue, JL | 1 |
| Egorova, LK | 1 |
| Cole, DG; DiFiglia, M; Growdon, JH | 1 |
| Abercrombie, ED; DeBoer, P; Heeringa, M; Westerink, BH | 1 |
| Ahier, RG; Ashworth, S; Brooks, DJ; Hume, SP; Lammertsma, AA; Myers, R; Opacka-Juffry, J | 1 |
| Boldry, RC; Chase, TN; Kask, AM; Papa, SM | 1 |
| Misu, Y; Okumura, F; Sato, K; Ueda, H | 1 |
| Fisher, H; Myers, CS; Wagner, GC | 1 |
| Hashiguchi, H; Ishida, Y; Kuwahara, I; Mitsuyama, Y; Todaka, K | 1 |
| Bennett, JP; Hubbard, CA; Trugman, JM | 1 |
| Hashiguchi, H; Ishida, Y; Kuwahara, I; Mitsuyama, Y; Nishimori, T; Todaka, K | 1 |
| Atlas, D; Djaldetti, R; Melamed, E | 1 |
| Cousins, MS; Salamone, JD | 1 |
| Boldry, RC; Chase, TN; Engber, TM; Kask, AM; Papa, SM | 1 |
| Bonnet, JJ; Costentin, J; Naudin, B | 1 |
| Bonastre, M; Chase, TN; Engber, TM; Marin, C; Papa, S; Tolosa, E | 1 |
| Huston, JP; Schwarting, RK | 1 |
| Marshall, JF; O'Dell, SJ | 1 |
| Dluzen, DE; Xu, K | 1 |
| Ibata, Y; Murakami, T; Nakamura, T; Okamura, H; Yokoyama, C | 1 |
| Fenu, S; Morelli, M; Ongini, E; Pinna, A | 1 |
| Clarkson, ED; Donovan, DM; Freed, CR; Horellou, P; Kaddis, FG; Mallet, J; Uhl, GR; Vandenbergh, DJ; Weber, MJ | 1 |
| Blaney, TJ; Emerich, DF; Francis, JM; Lindner, MD; Plone, MA; Salamone, JD | 1 |
| Agid, Y; Dziewczapolski, G; Gershanik, O; Murer, G; Raisman-Vozari, R | 1 |
| Chang, WY; Webster, RA | 1 |
| Dziewczapolski, G; Gershanik, OS; Nieoullon, A; Raisman-Vozari, R; Salin, P | 1 |
| Hastings, TG; Zigmond, MJ | 1 |
| Drukarch, B; Morelli, M; Pinna, A; Stoof, JC | 1 |
| Barlas, C; Chugh, A; Johnson, RL; Marcotte, ER; Mishra, RK; Whan, D | 1 |
| d'Agostini, F; Damsma, G; DaPrada, M; DeBoer, P; Heeringa, MJ | 1 |
| Allen, SM; Davis, WM; Freeman, JN | 1 |
| Barone, P; DiChiara, G; Morelli, M; Pellecchia, MT; Vallone, D; Verde, P | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| el-Kadi, AO; Sharif, SI | 1 |
| Hashiguchi, H; Ishida, Y; Ishizuka, Y; Kuwahara, I; Mitsuyama, Y; Nakane, H; Nishimori, T; Todaka, K; Uchimura, D | 1 |
| Hashitani, T; Kumazaki, M; Mizukawa, K; Nishino, H | 1 |
| Agid, Y; Dziewczapolski, G; García, MC; Gershanik, O; Menalled, LB; Murer, MG; Raisman-Vozari, R | 1 |
| Brotchie, JM; Crossman, AR; Henry, B | 2 |
| Honey, CR; Shen, H | 1 |
| Ebinger, G; Izurieta-Sánchez, P; Michotte, Y; Sarre, S | 1 |
| Björklund, A; Cenci, MA; Lee, CS | 1 |
| Feldon, J; Mintz, M; Mura, A | 3 |
| Drukarch, B; Stoof, JC; van de Witte, SV; Voorn, P | 1 |
| Kannari, K; Maeda, T; Matsunaga, M; Suda, T | 1 |
| Bennett, JP; Khan, SM; Smith, TS | 1 |
| Chen, CF; Chueh, FS; Chueh, FY; Hsieh, MT; Lin, MT; Lin, SM | 1 |
| Chase, TN; Oh, JD; Vaughan, CL | 1 |
| Abercrombie, ED; Miller, DW | 1 |
| Kannari, K; Maeda, T; Matsunaga, M; Suda, T; Tanaka, H; Tomiyama, M | 2 |
| Damhaut, P; Dethy, S; Goldman, S; Laute, MA | 1 |
| Consolo, S; Di Chiara, G; Giorgi, S; Morelli, M; Rimoldi, M | 1 |
| Bonnet, JJ; Cleren, C; Costentin, J; Dourmap, N; Vilpoux, C | 1 |
| Peng, L; Tang, Z; Ying, Q | 1 |
| Delfino, M; Dziewczapolski, G; Ferrario, J; Gershanik, OS; Murer, MG; Raisman-Vozari, R | 1 |
| Agid, Y; Hirsch, EC; Jimenez, A; Marin, C; Raisman-Vozari, R; Ruberg, M; Tolosa, E; Vila, M | 1 |
| Bigge, CF; Boxer, PA; Cai, SX; Gregory, TF; Hawkinson, JE; Konkoy, CS; Meltzer, LT; Serpa, K; Whittemore, ER; Wise, LD; Woodward, RM; Wright, JL; Zhou, ZL | 1 |
| Ichinose, H; Mogi, M; Nagatsu, T; Ogawa, N; Tanaka, K; Togari, A | 1 |
| Bonastre, M; Jiménez, A; Marin, C; Tolosa, E | 1 |
| Boxer, PA; Gregory, TF; Meltzer, LT; Serpa, KA; Wise, LD; Wright, JL | 1 |
| Adams, AC; Keefe, KA | 1 |
| Andersson, M; Cenci, MA; Hilbertson, A; Tranberg, A | 1 |
| Cannizzaro, C; Dass, B; Jenner, P; Owen, A; Rose, S; Tel, BC; Zeng, BY | 1 |
| Asanuma, M; Furuta, H; Miyazaki, I; Ogawa, N; Sogawa, CA; Sogawa, N | 1 |
| Dunah, AW; Huganir, RL; Kameyama, K; Standaert, DG; Wang, Y; Wolfe, BB; Yasuda, RP | 1 |
| Mandel, RJ | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Sonesson, C; Tedroff, J | 1 |
| Camp, DM; LeWitt, PA; Loeffler, DA | 1 |
| Brotchie, JM; Fox, SH | 1 |
| Stoessl, AJ; Van Kampen, JM | 1 |
| McGeer, EG; Stoessl, AJ; Van Kampen, JM | 1 |
| Bordet, R; Ridray, S; Schwartz, JC; Sokoloff, P | 1 |
| Hashiguchi, H; Ishida, Y; Ishizuka, Y; Mitsuyama, Y; Todaka, K | 1 |
| Cross, AJ; Georger, M; Howell, A; Hudzik, TJ | 1 |
| Davis, M; Meloni, EG | 1 |
| Andren, PE; Gunne, L; Svenningsson, P | 1 |
| Bergmann, R; Gasparini, F; Kuhn, R; Spooren, WP | 1 |
| Asanuma, M; Higashi, Y; Miyazaki, I; Nakanishi, T; Ogawa, N; Sogawa, CA; Tanaka, KI | 1 |
| Ebinger, G; Jonkers, N; Michotte, Y; Sarre, S | 2 |
| Abe, K; Kashihara, K; Manabe, Y; Shiro, Y; Warita, H | 1 |
| Burkhardt, K; Ludolph, AC; Schwarz, J; Storch, A | 1 |
| Koga, K; Kurokawa, M; Kuwana, Y; Nakamura, J; Ochi, M | 1 |
| Jenner, P; Rose, S; Treseder, SA | 1 |
| Casas, M; Pérez, V; Prat, G; Rubi, A; Unzeta, M | 1 |
| Fenu, S; Morelli, M; Pinna, A | 1 |
| Andersson, KE; Andersson, M; Cenci, MA; Johansson, PA | 1 |
| Andrén, PE; Gunne, L; Hurd, YL; Pirker, W; Pontén, H; Tedroff, J | 1 |
| Carroll, P; Diaz, J; Griffon, N; Guillin, O; Schwartz, JC; Sokoloff, P | 1 |
| Blunt, SB; Datla, KP; Dexter, DT | 1 |
| Carta, A; Fenu, S; Morelli, M | 1 |
| Morelli, M; Pinna, A | 1 |
| Ballermann, M; Farr, T; Metz, GA; Whishaw, IQ | 1 |
| Bankiewicz, KS; Cunningham, J; Harvey-White, J; Sánchez-Pernaute, R | 1 |
| Ferger, B; Schmidt, N; Schulz, JB; Teismann, P; Xia, XG | 1 |
| Agid, Y; Bonastre, M; Hirsch, EC; Jiménez, A; Marin, C; Tolosa, E; Vila, M | 1 |
| Charles, KJ; Gray, J; Hunter, AJ; Jenner, P; Medhurst, AD; Reavill, C; Shale, JA; Zeng, BY | 1 |
| Andersson, M; Cenci, MA; Lundblad, M; Westin, JE | 1 |
| Andersson, M; Cenci, MA; Konradi, C | 1 |
| Groenewegen, HJ; Van De Witte, SV; Voorn, P | 1 |
| Chen, JF; Cuellar, B; Fredduzzi, S; Impagnatiello, F; Monopoli, A; Moratalla, R; Ongini, E; Schwarzschild, MA; Xu, K | 1 |
| Abe, K; Kashihara, K; Manabe, Y; Murakami, T | 1 |
| Andersson, M; Cenci, MA; Kirik, D; Lundblad, M; Wierup, N; Winkler, C | 1 |
| Rassoulpour, A; Schwarcz, R; Wu, HQ | 1 |
| Metz, GA; Whishaw, IQ | 1 |
| Brotchie, JM; Nash, JE | 1 |
| Björklund, A; Cenci, MA; Kirik, D; Winkler, C | 1 |
| Cenci, MA | 1 |
| Archer, T; Fredriksson, A | 1 |
| Andrén, PE; Gunne, L; Klintenberg, R; Svenningsson, P | 1 |
| Cimini, MG; Haas, JV; Nichols, NF; Staton, BA; Svensson, KA; Tedroff, J | 1 |
| Andren, PE; Arts, J; Gunne, L; Svenningsson, P | 1 |
| Bibbiani, F; Chase, TN; Oh, JD | 1 |
| Battaglia, G; Bernardi, G; Calabresi, P; Centonze, D; Nicoletti, F; Picconi, B; Pisani, A; Storto, M | 1 |
| Hirsch, EC; Muriel, MP; Orieux, G | 1 |
| Bonastre, M; Hirsch, EC; Marin, C; Périer, C; Tolosa, E | 1 |
| Cenci, MA; Lundblad, M; Vaudano, E | 1 |
| Arai, A; Kannari, K; Matsunaga, M; Shen, H; Yamato, H | 1 |
| Arai, A; Kannari, K; Maeda, T; Matsunaga, M; Shen, H; Suda, T | 1 |
| Bari, M; Battista, N; Bernardi, G; Calabresi, P; Centonze, D; Finazzi-Agrò, A; Gubellini, P; Maccarrone, M; Picconi, B | 1 |
| Ahmed, SM; Chartisathian, K; Chase, TN; Oh, JD | 1 |
| Nielsen, KM; Soghomonian, JJ | 2 |
| Gilgun-Sherki, Y; Melamed, E; Offen, D; Ziv, I | 1 |
| Gilgun-Sherki, Y; Mechoulam, R; Melamed, E; Offen, D | 1 |
| Bonastre, M; Hirsch, EC; Jimenez, A; Marin, C; Périer, C; Tolosa, E | 1 |
| Bonastre, M; Bové, J; Marin, C; Tolosa, E | 1 |
| Albin, RL; Desmond, TJ; Frey, KA; Kemmerer, ES; Kilbourn, MR | 1 |
| Cao, F; Sun, S; Tong, ET | 1 |
| Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D | 1 |
| Bergman, J; Eskola, O; Forsback, S; Grönroos, T; Haapalinna, A; Haaparanta, M; Marjamäki, P; Niemi, R; Rinne, J; Solin, O | 1 |
| Bonastre, M; Bové, J; Jiménez, A; Marin, C; Tolosa, E | 1 |
| Carta, AR; Fenu, S; Morelli, M; Pala, P; Tronci, E | 1 |
| Delfino, MA; Douhou, A; Ferrario, JE; Gershanik, OS; Murer, MG; Raisman-Vozari, R; Stefano, AV; Zbarsky, V | 1 |
| Bibbiani, F; Castagnoli, N; Chase, TN; Chen, JF; Oh, JD; Petzer, JP; Schwarzschild, MA | 1 |
| Carta, AR; Morelli, M; Pinna, A; Tronci, E | 2 |
| Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L | 1 |
| Aoyama, S; Bedard, P; Borrelli, E; Chase, TN; Hauser, RA; Ichimura, M; Ikeda, K; Ishii, A; Jenner, P; Kanda, T; Kase, H; Koga, K; Koike, N; Kurokawa, M; Kuwana, Y; Mori, A; Nakamura, J; Nonaka, H; Ochi, M; Richardson, PJ; Saki, M; Shimada, J; Shindou, T; Shiozaki, S; Suzuki, F; Takeda, M; Yanagawa, K | 1 |
| Ghil, GS; Joo, WS; Kim, EY; Kim, YS; Lee, YJ; Lim, J; Park, S; Wang, KC | 1 |
| Brotchie, JM; Chalon, S; Crossman, AR; Ravenscroft, P | 1 |
| Bastia, E; Dunah, AW; Fienberg, AA; Schwarzschild, MA; Sirianni, AC; Standaert, DG | 1 |
| Nakagawa, M; Nishizawa, Y; Ogura, H; Ohgoh, M | 1 |
| Harris, RC; Kelsey, JE; Kleckner, NW; Mague, SD; Matthews, RT; Pijanowski, RS | 1 |
| Kase, H; Ochi, M; Shiozaki, S | 1 |
| Baba, M; Kannari, K; Kimura, T; Maeda, T; Tanaka, H; Tomiyama, M | 1 |
| De Groote, C; Fischer, G; Jenner, P; Kemp, JA; Klockgether, T; Löschmann, PA; Smith, L; Wüllner, U | 1 |
| Schmidt, WJ; Srinivasan, J | 1 |
| Brachet, P; Damier, P; Paillé, V | 1 |
| Ben Shachar, D; Stephenson, G; Youdim, MB | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Picconi, B; Rossi, S | 1 |
| Gluck, MR; Granson, H; Santana, LA; Yahr, MD | 1 |
| Aubin, N; Barneoud, P; Burnier, P; Caille, D; Carter, C; Charieras, T; Curet, O; Gardes, A; George, P; Jegham, S; Le Kim, A; Lolivier, J; Marc, C; Pandini, M; Perron, C; Puech, F; Scatton, B; Sontag, N | 1 |
| Bernardi, G; Calabresi, P; Cenci, MA; Centonze, D; Di Luca, M; Gardoni, F; Mauceri, D; Picconi, B | 1 |
| Itakura, T; Kakishita, K; Nakao, N; Shintani-Mizushima, A | 1 |
| Cenci, MA; Lindgren, H; Lundblad, M; Picconi, B | 1 |
| Ahmed, SM; Chase, TN; Dunbar, GL; Menniti, FS; Oh, JD; Wessell, RH | 1 |
| Linazasoro, G | 1 |
| Corvol, JC; Féger, J; Girault, JA; Hanoun, N; Hervé, D; Hirsch, EC; Muriel, MP; Valjent, E | 1 |
| Delfino, MA; Ferrario, JE; Gershanik, O; Mourlevat, S; Murer, MG; Raisman-Vozari, R; Ruberg, M; Stefano, A; Taravini, IR | 1 |
| Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV | 1 |
| Dhanasekaran, M; Hare, TA; Manyam, BV | 1 |
| Blaha, C; Bremen, D; Gerlach, M; Riederer, P; van den Buuse, M | 1 |
| Harsing, LG; Juranyi, Z; Levay, G; Marko, B; Sziray, N | 1 |
| Delville, Y; Fleming, SM; Schallert, T | 1 |
| Ogawa, N; Tanaka, K | 1 |
| Baba, M; Ichinohe, N; Kimura, T; Matsunaga, M; Mori, F; Tomiyama, M; Wakabayashi, K | 1 |
| Bielicki, G; Chassain, C; Donnat, JP; Durif, F; Eschalier, A; Renou, JP | 1 |
| Cheetham, SC; Jenner, P; Lane, EL | 2 |
| Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E | 1 |
| Brotchie, JM; Collingridge, GL; Garner, CC; Johnston, TH; Nash, JE | 1 |
| Katz, J; Nielsen, KM; Soghomonian, JJ | 1 |
| Coccurello, R; Domenici, MR; Martire, A; Pèzzola, A; Popoli, P; Potenza, RL; Reggio, R; Tebano, MT | 1 |
| Baunez, C; Bernardi, G; Calabresi, P; Centonze, D; Gubellini, P; Picconi, B; Pisani, A; Rossi, S | 1 |
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Ogawa, N; Shimizu, M; Tanaka, K | 1 |
| Bishop, C; Taylor, JL; Walker, PD | 1 |
| Diguet, E; Fernagut, PO; Ghorayeb, I; Tison, F | 1 |
| Glavan, G; Zivin, M | 1 |
| Berk, L; Clackson, T; Cunningham, J; Feng, L; Forsayeth, JR; Rivera, VM; Sanftner, LM; Suzuki, BM; Zhou, S | 1 |
| Martín, AB; Mendialdua, A; Moratalla, R; Pavón, N | 1 |
| Chen, JF; Schwarzschild, MA; Yu, L | 1 |
| Benabid, AL; Berger, F; Buggia, V; Gilbert, F; Lévesque, D; Sgambato-Faure, V | 1 |
| Daya, S; Maharaj, H; Mokokong, R; Scheepers, M; Sukhdev Maharaj, D | 1 |
| Cauli, O; Morelli, M; Pinna, A | 1 |
| Dunnett, SB; Monville, C; Torres, EM | 1 |
| Goto, S; Kaji, R; Kuratsu, J; Yamada, K | 1 |
| Bontempi, S; Busi, C; Collo, G; Fiorentini, C; Missale, C; Rizzetti, MC; Spano, P | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Winkler, C | 1 |
| Bishop, C; Rice, KC; Taylor, JL; Ullrich, T; Walker, PD | 1 |
| Aguilar, E; Marin, C; Obeso, JA | 1 |
| Aguilar, E; Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J | 1 |
| Funabashi, T; Goshima, Y; Kimura, F; Kuroiwa, Y; Misu, Y; Shimamura, M; Shimizu, M; Yagami, T | 1 |
| Bernardi, G; Calabresi, P; Centonze, D; Gulino, A; Napolitano, M; Picconi, B | 1 |
| Bezard, E; Bioulac, B; Boraud, T; Gross, CE; Harnack, D; Klitgaard, H; Kupsch, A; Meissner, W; Morgenstern, R; Ravenscroft, P; Reese, R | 1 |
| Carta, M; Cenci, MA; Fadda, F; Lindgren, HS; Lundblad, M; Stancampiano, R | 1 |
| Bagetta, V; Bernardi, G; Calabresi, P; Cattabeni, F; Di Luca, M; Gardoni, F; Ghiglieri, V; Picconi, B; Polli, F | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Pietraszek, M; Schaefer, D | 1 |
| Bilbao, G; Garibi, J; Gómez-Urquijo, S; Linazasoro, G; Miguens, N; Ruiz-Ortega, JA; Ugedo, L; Ulibarri, I | 1 |
| Morelli, M; Pinna, A; Pontis, S | 1 |
| Konitsiotis, S; Tsironis, C | 1 |
| Soghomonian, JJ | 1 |
| Andren, PE; Svenningsson, P; Zhang, X | 1 |
| Aceves, J; Cortes, H; Erlij, D; Escartín, E; Florán, B; Florán, L; Rangel, C; Silva, I | 1 |
| Baltazar, G; Carvalho, CM; Duarte, EP; Saavedra, A; Santos, P | 1 |
| Baraldi, PG; Fenu, S; Morelli, M; Simola, N; Tabrizi, MA | 1 |
| Bishop, C; Eskow, KL; Kuhn, DM; Park, JY; Taylor, JL; Walker, PD | 1 |
| Brundin, P; Cenci, MA; Gardi, J; Lindgren, HS; Mohapel, P; Nyengaard, JR; Westin, JE | 1 |
| Eusebio, A; Gubellini, P; Kerkerian-Le Goff, L; Melon, C; Oueslati, A; Salin, P | 1 |
| Pierce, RC; Soghomonian, JJ; Yamamoto, N | 1 |
| Ba, M; Chen, S; Kong, M; Liu, Z; Lu, G; Ma, G; Yang, H | 1 |
| Andersson, M; Cenci, MA; Lindgren, HS; Valastro, B | 1 |
| Avila, I; Bibbiani, F; Chase, TN; Collins, MA; Oh, JD; Smith, CP | 1 |
| Köllensperger, M; Poewe, W; Reindl, M; Stefanova, N; Wenning, GK | 1 |
| Cenci, MA; Lindgren, HS; Lundblad, M; Ohlin, KE; Rylander, D | 1 |
| Barker, RA; Kuan, WL; Lin, R; Tyers, P | 1 |
| Bastia, E; Benn, CL; Cha, JH; Chen, JF; Peterson, TS; Schwarzschild, MA; Xiao, D; Xu, YH | 1 |
| Jenner, P; Ramsay Croft, N; Rose, S | 1 |
| Dagostino, P; Katz, J; Soghomonian, JJ; Wang, H | 1 |
| Bartalucci, A; Biagioni, F; Ferrucci, M; Fornai, F; Fulceri, F; Galli, V; Lazzeri, G; Paparelli, A; Ruggieri, S | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA | 2 |
| Gacsalyi, I; Harsing, LG; Juranyi, Z; Levay, G; Marko, B; Megyeri, K; Sziray, N | 1 |
| Marti, M; Morari, M; Trapella, C; Viaro, R | 1 |
| Asai, M; Matsuya, T; Miyoshi, S; Mizoguchi, H; Murakami, Y; Nagai, T; Nishimura, S; Noda, A; Sato, K; Takuma, K; Yamada, K | 1 |
| Finberg, JP; Sader-Mazbar, O | 1 |
| Abin-Carriquiry, JA; Costa, G; Dajas, F; Ferreira, M; Urbanavicius, J; Wonnacott, S | 1 |
| Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D | 1 |
| Chung, EJ; Jeon, MY; Kang, HY; Lee, WY | 1 |
| Bishop, C; Dupre, KB; Eskow, KL; Negron, G | 1 |
| Chen, J; Ma, L; Wang, F; Zhang, H; Zhen, X | 1 |
| Aimi, Y; Arai, R; Kudo, M; Nagatsu, I; Taki, K; Yamada, H | 1 |
| Borgkvist, A; Carta, M; Fisone, G; Girault, JA; Greengard, P; Hervé, D; Santini, E; Usiello, A; Valjent, E | 1 |
| Ahmed, MR; Bychkov, E; Dalby, KN; Gurevich, EV | 1 |
| Juckel, G; Klein, J; Kupsch, A; Lee, T; Morgenstern, R; Mundt, A; Petrus, D; von Rumohr, A; Winter, C | 1 |
| Jing, FC; Wang, DQ; Wang, W | 1 |
| Guan, Q; He, Y; Tan, L; Zhan, Q | 1 |
| Barbanoj, M; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V | 1 |
| Dunnett, S; Lane, E | 1 |
| Cassano, T; Cuomo, V; Giuffrida, A; Morgese, MG | 1 |
| Asanuma, M; Hozumi, H; Miyazaki, I; Miyoshi, K; Sogawa, N | 1 |
| Buck, K; Ferger, B | 3 |
| Armentero, MT; Bazzini, E; Blandini, F; Levandis, G; Nappi, G | 1 |
| García-Horsman, JA; Huotari, M; Kääriäinen, TM; Männistö, PT; Piltonen, M | 1 |
| Angela Cenci, M; Bagetta, V; Barone, I; Bernardi, G; Calabresi, P; Ghiglieri, V; Lindgren, HS; Paillé, V; Picconi, B | 1 |
| Barker, RA; Kuan, WL; Zhao, JW | 1 |
| Brotchie, JM; Gomez-Ramirez, J; Johnston, TH; Lee, J; Visanji, N | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Eslava-Alva, MJ; Higashi, Y; Miyazaki, I; Ogawa, N; Shimizu, M | 1 |
| Cheetham, S; Jenner, P; Lane, EL | 1 |
| Maeda, T; Nagata, K; Yoshida, Y | 1 |
| Andren, PE; Greengard, P; Svenningsson, P; Zhang, X | 1 |
| Bernson, M; Darmopil, S; de Ceballos, ML; Moratalla, R; Muñetón-Gómez, VC | 1 |
| Berger, SP; Brudney, EG; Johnson, SW; Meshul, CK; Paquette, MA; Putterman, DB | 1 |
| Artusi, R; Caselli, G; Lanza, M; Makovec, F; Michotte, Y; Sarre, S | 1 |
| Andren, PE; Chergui, K; Svenningsson, P; Zhang, X | 1 |
| Bankiewicz, KS; Cummins, A; Eberling, J; Kohutnicka, M; Oiwa, Y; Sanchez-Pernaute, R | 1 |
| Cenci, MA; Lundblad, M | 1 |
| Drago, J; Finkelstein, DI; Henderson, J; Horne, MH; Horne, MK; Lawrence, AJ; Lee, J; O'Connor, L; Stanic, D; Tomas, D; Zhu, WM | 1 |
| Abuirmeileh, A; Biggs, CS; Harkavyi, A; Kingsbury, AE; Lever, R; Whitton, PS | 1 |
| Arai, A; Kannari, K; Kawarabayashi, T; Kimura, T; Shen, H; Shoji, M; Suzuki, C; Tomiyama, M; Watanabe, M | 1 |
| Kelly, AM; Kennedy, GA; Willis, GL | 1 |
| Carta, AR; Frau, L; Morelli, M; Pinna, A; Pontis, S | 1 |
| Aceves, J; Erlij, D; Florán, B; Floran, L; García-Ramírez, M; Rangel-Barajas, C; Sánchez-Lemus, E; Silva, I | 1 |
| Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR | 1 |
| Busi, C; Fiorentini, C; Missale, C; Spano, P | 1 |
| Collier, TJ; Freeman, TB; McGuire, SO; Meredith, G; Soderstrom, KE; Sortwell, CE; Steece-Collier, K; Wu, Q | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Soulet, D; Vercammen, L | 1 |
| Barnum, CJ; Bishop, C; Blandino, P; Deak, T; Dupre, K; Eskow, KL | 1 |
| Amalric, M; De Leonibus, E; Giordani, F; Lopez, S; Managò, F; Mele, A; Oliverio, A; Petrosino, F | 1 |
| Jin, GZ; Mo, J; Sun, PH; Yu, LP; Zhang, H; Zhen, X | 1 |
| Bernardi, G; D'Angelo, V; Esposito, Z; Giorgi, M; Martorana, A; Nuccetelli, V; Sancesario, G; Sorge, R; Stefani, A | 1 |
| Glavan, G | 1 |
| Ferrario, JE; Gomes, MZ; Hunot, S; Raisman-Vozari, R; Rojas-Mayorquín, AE; Saldaña-Ortega, M; Salum, C | 1 |
| Danysz, W; Dekundy, A; Quack, G; Valastro, B | 1 |
| Kelsey, JE; Langelier, NA; Oriel, BS; Reedy, C | 1 |
| Allbutt, HN; Billing, R; Coster, MJ; Henderson, JM; Kassiou, M; Radford, J; Warraich, ST | 1 |
| Wang, J; Ye, Q; Yuan, CG; Yuan, CX; Zhang, Y | 1 |
| Aubert, I; Berthet, A; Bezard, E; Bloch, B; Cenci, MA; Doudnikoff, E; Hengerer, B; Ittrich, C; Rylander, D; Schuster, S; Surmeier, DJ | 1 |
| Allbutt, HN; Coster, MJ; Henderson, JM; Kassiou, M; Truong, L | 1 |
| Antonelli, T; Cassano, T; Cuomo, V; Dipasquale, P; Ferraro, L; Gaetani, S; Giuffrida, A; Laconca, L; Macheda, T; Morgese, MG | 1 |
| Marti, M; Morari, M; Trapella, C | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Mattsson, B; Muñoz, A; Winkler, C | 1 |
| Dunnett, SB; Lane, EL; Monville, C; Pekarik, V; Torres, EM | 1 |
| Barnum, CJ; Bishop, C; Deak, T; Dupre, KB; Eskow, KL; Krolewski, DM; Walker, PD | 1 |
| Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP | 1 |
| Aguilar, E; Bartoszyk, GD; Marin, C; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Alcacer, C; Cacciatore, S; Fisone, G; Girault, JA; Greengard, P; Heiman, M; Hervé, D; Santini, E; Valjent, E | 1 |
| García-Horsman, JA; Kääriäinen, TM; Männistö, PT; Piltonen, M | 1 |
| Benabid, AL; Berger, F; Buggia-Prevot, V; El Atifi-Borel, M; Platet, N; Sgambato-Faure, V | 1 |
| Ba, M; Kong, M; Liu, Z; Song, L | 1 |
| Caron, MG; Fuentes, R; Nicolelis, MA; Petersson, P; Siesser, WB | 1 |
| Del-Bel, EA; Echeverry, MB; Padovan-Neto, FE; Tumas, V | 1 |
| Ugrumov, MV | 1 |
| Brundin, P; Cenci, MA; Lane, EL | 1 |
| Ballero, M; Kasture, S; Longoni, R; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Spina, L | 1 |
| Ba, M; Kong, M; Liu, Z; Ma, Y; Song, L | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Vercammen, L | 1 |
| Cassin, J; Harris, O; Kelsey, JE | 1 |
| García-Gutiérrez, MS; Ledent, C; Leiva, C; Leza, JC; Manzanares, J; Molina, JA; Pérez-Nievas, BG; Pérez-Rial, S | 1 |
| Chen, JF; Herm, L; Kalda, A; Rinken, A; Zharkovsky, A | 1 |
| Barbanoj, M; Gich, I; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V | 1 |
| Bittner, A; Dziewczapolski, G; Kamme, F; Meurers, BH; Shi, T; Shults, CW | 1 |
| Ballion, B; Chetrit, J; Frenois, F; Gonon, F; Murer, MG; Zold, CL | 1 |
| Ares, S; Darmopil, S; De Diego, IR; Martín, AB; Moratalla, R | 1 |
| Cenci, MA; Lindgren, HS; Ohlin, KE | 1 |
| Kerkerian-Le Goff, L; Khaindrava, V; Lacombe, E; Melon, C; Oueslati, A; Salin, P | 1 |
| Bishop, C; Dupre, KB; Jaunarajs, KL; Kelly, C; Klioueva, A; Moore, A; Steiniger, A | 1 |
| Aguilar, E; Bonastre, M; Jiménez, A; Marin, C | 1 |
| Soghomonian, JJ; Yamamoto, N | 1 |
| Ikeda, K; Kurokawa, T; Mochizuki, H; Nakao, K; Yoshikawa, S; Yuzawa, N | 1 |
| Aguilar, E; Barbanoj, M; Kulisevsky, J; Marin, C; Pérez, V; Rubio, A | 1 |
| Brocco, M; Mela, F; Millan, MJ; Morari, M | 1 |
| Kostrzewa, RA; Kostrzewa, RM; Nowak, P; Skaba, D | 1 |
| Borah, A; Mohanakumar, KP | 4 |
| Buck, K; Ferger, B; Voehringer, P | 2 |
| Avila, I; Bergstrom, DA; Brazhnik, E; Castañeda, E; Parr-Brownlie, LC; Walters, JR | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Tronci, E; Volpini, R | 1 |
| Chung, CY; Hallett, PJ; Isacson, O; Koprich, JB | 1 |
| Chen, L; Wang, H; Xue, Y; Yung, WH; Zhang, SJ | 1 |
| Andersson, DR; Cenci, MA; Lagerkvist, S; Lindgren, HS; Nissbrandt, H | 1 |
| Anderson, AM; Johnson, SW; Lewis, JR; Meshul, CK; Paquette, MA; Paul Berger, S | 1 |
| Bioulac, B; De Deurwaerdère, P; Gross, C; Navailles, S | 1 |
| Benazzouz, A; Bioulac, B; De Deurwaerdère, P; Gross, C; Navailles, S | 1 |
| Gil, S; Koh, H; Lee, J; Park, C | 1 |
| Boulamery, A; Bruguerolle, B; Simon, N; Vidal, J | 1 |
| Ahmed, MR; Aubert, I; Berthet, A; Bezard, E; Bioulac, BH; Bloch, B; Bychkov, E; Carl, YT; Doudnikoff, E; Dovero, S; Gurevich, EV; Gurevich, VV; Kook, S; Li, Q; Porras, G | 1 |
| Dunnett, SB; Lane, EL | 1 |
| Baishen, R; Bezard, E; Cenci, MA; Danysz, W; Dekundy, A; Iderberg, H; Li, H; Li, Q; Rylander, D; Zhang, J | 1 |
| Cenci, MA; Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Guan, Q; He, Y; Jin, L; Liu, X; Zhao, L | 1 |
| Cao, X; Mochizuki, H; Mouradian, MM; Papa, SM; Uthayathas, S; Watts, RL; Yasuda, T | 1 |
| Belujon, P; Grace, AA; Lodge, DJ | 1 |
| Campbell, B; Hider, RC; Hobbs, CJ; Jairaj, M; Jenner, P; Rose, S; Syme, A; Tayarani-Binazir, KA; Zhou, T | 1 |
| Jouve, L; Kerkerian-Le Goff, L; Melon, C; Salin, P | 1 |
| Fang, C; Gao, C; Wang, Y; Xu, H; Xu, Z; Yin, J; Zhou, H | 1 |
| Aceves, J; Erlij, D; Florán, B; Lopéz-Santiago, LM; Rangel-Barajas, C; Silva, I | 1 |
| Burdett, TC; Cassin, JJ; Chen, JF; Fredholm, BB; Healy, B; Schwarzschild, MA; Xiao, D | 1 |
| Bishop, C; Button, T; Deak, T; Dupre, KB; Eskow Jaunarajs, KL; Ostock, CY | 1 |
| Bezard, E; Cenci, MA; Descarries, L; Dovero, S; Lees, AJ; O'Sullivan, SS; Parent, M; Rylander, D | 1 |
| Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B | 1 |
| Auguet, M; Chabrier, PE; Ferrandis, E; Grandoulier, AS; Marin, JG; Mautino, G; Rocher, MN; Spinnewyn, B | 1 |
| Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M | 1 |
| Gil, SJ; Koh, HC; Lee, JE; Minn, YK; Park, CH | 1 |
| Bagetta, V; Calabresi, P; Di Filippo, M; Fusco, FR; Ghiglieri, V; Giampà, C; Paillè, V; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A | 1 |
| Gerlach, M; Grünblatt, E; Riederer, P; Scheller, DK; Schmidt, WJ | 1 |
| Daly, CS; Dunnett, SB; Lane, EL; Smith, GA | 1 |
| Campos, C; Huang, LZ; Ivy Carroll, F; Ly, J; Quik, M | 1 |
| Bartoszyk, GD; Dean, O; Gerlach, M; Riederer, P; van den Buuse, M | 1 |
| Beck, J; Gerlach, M; Riederer, P; van den Buuse, M | 1 |
| Andersson, D; Cenci, MA; Francardo, V; Nissbrandt, H; Popovic, N; Recchia, A | 1 |
| Bishop, C; Button, T; Dupre, KB; Eskow Jaunarajs, KL; Ostock, CY; Savage, LM; Wolf, W | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Lindenbach, D; Ostock, CY | 1 |
| Franchi, G; Morari, M; Viaro, R | 1 |
| Af Bjerkén, S; Gerhardt, GA; Lundblad, M; Nevalainen, N; Strömberg, I | 1 |
| Alachkar, A; Brotchie, JM; Jones, OT | 1 |
| Gao, B; Guo, L; Liu, Z; Ye, N; Zhang, A; Zhang, H; Zhen, X; Zheng, L; Zhou, S | 1 |
| Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C | 3 |
| Grady, SR; Huang, LZ; Quik, M | 1 |
| Barroso-Chinea, P; Berthet, A; Bezard, E; Canron, MH; Charron, G; Delalande, F; Doudnikoff, E; Giros, B; Goumon, Y; Laux, A; Li, Q; Nosten-Bertrand, M; Porras, G; Qin, C; Van Dorsselaer, A; Vital, A | 1 |
| Kabuto, H; Yamanushi, TT | 1 |
| Calabresi, P; Di Luca, M; Gardoni, F; Pendolino, V; Picconi, B; Sgobio, C | 1 |
| Dziubina, A; Gołembiowska, K | 1 |
| Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W | 1 |
| Bezard, E; Carta, M | 1 |
| Forsberg, MM; Kääriäinen, TM; Käenmäki, M; Männistö, PT; Oinas, N; Tammimäki, A | 1 |
| Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 2 |
| Bagetta, V; Bonito-Oliva, A; Calabresi, P; Carta, M; Di Luca, M; Errico, F; Fisone, G; Gardoni, F; Marinucci, S; Napolitano, F; Picconi, B; Romano, R; Usiello, A; Vitucci, D; Zianni, E | 1 |
| Dunnett, SB; Heuer, A; Lane, EL; Smith, GA | 1 |
| Geng, XC; Yin, LL; Zhu, XZ | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Goldenberg, AA; Klioueva, A; Lindenbach, D; Surrena, MA; Tignor, S; Walters, H | 1 |
| Babapour, V; Mahmoudi, J; Nayebi, AM; Reyhani-Rad, S; Samini, M | 1 |
| Janssen, ML; Sager, TN; Temel, Y; Westin, JE | 1 |
| Chagniel, L; Cyr, M; Lebel, M; Robitaille, C | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Chao, OY; Huston, JP; Mattern, C; Nikolaus, S; Pum, ME; Ruocco, LA; Silva, AM; Wessler, J | 1 |
| Alstrup, AK; Doudet, DJ; Gjedde, A; Høltzermann, M; Jakobsen, S; Landau, AM; Møller, A; Nahimi, A; Simonsen, M; Vang, K; Wegener, G | 1 |
| Chao, OY; Huston, JP; Li, JS; Pum, ME | 1 |
| Barrow, R; Errico, F; Kim, S; Mealer, RG; Napolitano, F; Shahani, N; Snyder, SH; Subramaniam, S; Tyagi, R; Usiello, A | 1 |
| Giuffrida, A; Macheda, T; Martinez, A; Morgese, MG; Trabace, L | 1 |
| Jackson, MJ; Jairaj, M; Jenner, P; Rose, S; Strang, I; Tayarani-Binazir, KA | 1 |
| Adkins, CE; Cenci, MA; Lockman, PR; Lundblad, C; Ohlin, KE; Sebastianutto, I | 1 |
| Konitsiotis, S; Maranis, S; Stamatis, D; Tsironis, C | 1 |
| Björklund, A; Carta, M; Shin, E; Tronci, E | 1 |
| Abuirmeileh, A; Bloom, SR; Harkavyi, A; Lever, R; Rampersaud, N; Tadross, JA; Whitton, PS | 1 |
| Bacolod, MD; Bennouar, KE; Cajina, M; Doller, D; Gubellini, P; Jimenez, HN; Kerkerian-Le Goff, L; Melon, C; Uberti, MA | 1 |
| Abe, M; Inden, M; Kitamura, Y; Minamino, H; Takata, K; Tooyama, I; Yoshimoto, K | 1 |
| Alcacer, C; Gaven, F; Girault, JA; Hervé, D; Santini, E; Valjent, E | 1 |
| Li, Y; Liu, W; Sha, C; Sun, K; Wang, A; Wang, L | 1 |
| Calabresi, P; Costa, C; de Iure, A; Di Filippo, M; Di Luca, M; Gardoni, F; Ghiglieri, V; Latagliata, EC; Marti, M; Morari, M; Pascucci, T; Pendolino, V; Picconi, B; Puglisi-Allegra, S; Sgobio, C; Siliquini, S; Spillantini, MG; Tantucci, M; Tozzi, A | 1 |
| Björklund, A; Carta, M; Garcia, J; Shin, E; Winkler, C | 1 |
| Gerlach, M; Halley, P; Riederer, P; van den Buuse, M | 1 |
| Bishop, C; Eskow Jaunarajs, KL; George, JA | 1 |
| Berger, SP; Giuffrida, A; Johnson, SW; Macheda, T; Martinez, AA; Meshul, CK; Paquette, MA | 1 |
| Aristieta, A; Azkona, G; Miguelez, C; Ruiz-Ortega, JÁ; Sagarduy, A; Sanchez-Pernaute, R; Ugedo, L | 1 |
| Cassano, T; Cimmino, CS; Denora, N; Giuffrida, A; Laconca, L; Laquintana, V; Lopalco, A; Trapani, A; Trapani, G | 1 |
| Gittis, A | 1 |
| Breger, LS; Dunnett, SB; Lane, EL | 1 |
| Kanemaru, A; Kojima, T; Tokashiki, S; Ueda, Y | 1 |
| Jenner, P; McCreary, AC; Papathanou, M; Rose, S; van der Laan, R | 1 |
| Kullingsjö, J; Ponten, H; Sonesson, C; Tedroff, J; Waters, N; Waters, S | 1 |
| Bezard, E; Brambilla, R; Calabresi, P; Fasano, S; Guerrini, R; Li, Q; Marti, M; Morari, M; Morella, I; Rodi, D; Simonato, M; Tozzi, A | 1 |
| Cenci, MA; Halje, P; Mohammed, M; Petersson, P; Richter, U; Tamtè, M | 1 |
| Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Bagetta, V; Calabresi, P; Del Papa, G; Gardoni, F; Ghiglieri, V; Giampà, C; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A; Zianni, E | 1 |
| Apple, DM; Chotibut, T; Jefferis, R; Salvatore, MF | 1 |
| Barbon, A; Fiorentini, C; Missale, C; Savoia, P; Savoldi, D | 1 |
| Authier, N; Chassain, C; Denizot, H; Durif, F; Hafidi, A; Llorca, PM; Zengin-Toktas, Y | 1 |
| Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
| Gago, B; Marin, C; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| da Silva, CA; de Aguiar, D; de Oliveira-Tavares, D; Del Bel, E; Ferreira, NR; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Graybiel, AM; Hernandez, LF; Howe, MW; Hu, D; Kubota, Y; Lemaire, N | 1 |
| Choi, HS; Choi, SO; Kwon, IH; Lee, MK; Shin, KS; Suh, KH; Zhao, TT | 1 |
| Aguiar, AS; Córdova, FM; Cunha, RA; Glaser, V; Hoeller, AA; Latini, A; Leal, RB; Moreira, EL; Oliveira, PA; Prediger, RD; Walz, R | 1 |
| Bian, JS; Dawe, GS; Del Soldato, P; Hu, LF; Sparatore, A; Tazzari, V; Teo, XQ; Tiong, CX; Xie, L | 1 |
| Auberson, YP; Budri, M; Calcagno, M; Dekundy, A; Mabrouk, OS; Mela, F; Morari, M; Parsons, CG; Viaro, R | 1 |
| Campos, FL; Carvalho, MM; Coimbra, B; Lima, R; Pêgo, JM; Rodrigues, AJ; Rodrigues, C; Salgado, AJ; Sousa, N | 1 |
| Caramés, JM; Moratalla, R; Murer, MG; Solís, JM; Solís, O; Suárez, LM; Taravini, IR | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Higashi, Y; Miyazaki, I; Namba, M; Ogawa, N | 1 |
| Anselmo-Franci, J; da-Silva, CA; Del-Bel, E; Guimaraes, FS; Padovan-Neto, FE; Raisman-Vozari, R; Romano-Dutra, AC; Szawka, RE | 1 |
| Carlsson, T; Liss, B; Prinz, A; Roeper, J; Selesnew, LM | 1 |
| Bleickardt, C; Hodgson, R; Jones, N; Mullins, D; Parker, E | 1 |
| Dunnett, SB; Heuer, A; Klein, A; Lane, EL; Smith, GA; Vinh, NN | 1 |
| Acher, F; Bonito-Oliva, A; Fisone, G; Lopez, S; Pallottino, S | 1 |
| Dominguez-Meijide, A; Garrido-Gil, P; Guerra, MJ; Labandeira-Garcia, JL; Sierrra-Paredes, G; Villar-Cheda, B | 1 |
| Finberg, JP; Loboda, Y; Rabey, MJ; Sader-Mazbar, O | 1 |
| Carta, M; Collu, M; Devoto, P; Fidalgo, C; Lisci, C; Stancampiano, R; Tronci, E | 1 |
| Bishop, C; Conti, MM; Dell'isola, R; Goldenberg, AA; Kampton, E; Katzman, AC; Lindenbach, D; Ostock, CY | 1 |
| Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Lorenc-Koci, E | 2 |
| Czarnecka, A; Domin, H; Konieczny, J; Lenda, T; Lorenc-Koci, E; Smiałowska, M | 1 |
| González-Aparicio, R; Moratalla, R | 1 |
| Cenci, MA; Francardo, V | 1 |
| Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Oertel, WH; Ries, V | 1 |
| Chae, Y; Choo, HJ; Doo, AR; Kim, SN; Lee, B; Lee, H; Park, HJ; Park, JJ; Park, JY; Shim, I | 1 |
| Bonastre, M; Cortés, R; Giralt, A; Marin, C; Mengod, G; Obeso, JA; Schapira, AH | 1 |
| Arai, A; Baba, M; Migita, K; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T; Yamada, J | 1 |
| Kelsey, JE; Neville, C | 1 |
| Armentero, MT; Baqi, Y; Bonaventura, J; Canela, EI; Casadó, V; Cortés, A; Costa, G; Farré, D; Franco, R; Lanciego, JL; Lluís, C; Mallol, J; Martínez-Pinilla, E; McCormick, P; Müller, CE; Pinna, A; Sánchez, M; Simola, N | 1 |
| Carta, M; Collu, M; Fidalgo, C; Gardoni, F; Morelli, M; Stancampiano, R; Tronci, E; Zianni, E | 1 |
| Liu, J; Wang, HS; Wang, T; Wang, Y; Zhang, QJ | 1 |
| André, E; Calo', G; Cavalcante, JC; Costa, MS; Didonet, JJ; Gavioli, EC; Guerrini, R; Soares-Rachetti, Vde P; Souza, Lde S | 1 |
| Corrigan, F; Hassall, MM; Thornton, E; Vink, R | 1 |
| Doo, AR; Hahm, DH; Jeon, S; Kim, J; Kim, SN; Lee, H; Park, HJ; Park, JY; Park, SU; Yoo, HH | 1 |
| Chen, CH; Chen, NF; Chen, WF; Feng, CW; Hsiao, CD; Huang, SY; Hung, HC; Wang, HM; Wen, ZH; Yang, SN | 1 |
| Björklund, A; Carta, M; Devoto, P; Rogers, JT; Shin, E | 1 |
| Bishop, C; Goldenberg, AA; Kampton, E; Lindenbach, D; Ostock, CY | 1 |
| Bagetta, V; Brambilla, R; Calabresi, P; Cerovic, M; Fasano, S; Ghiglieri, V; Giampà, C; Hardingham, N; Heuer, A; Marchisella, F; Morella, I; Papale, A; Pendolino, V; Picconi, B | 1 |
| Mellstrom, B; Moratalla, R; Naranjo, JR; Ruiz-DeDiego, I; Vallejo, M | 1 |
| Ampe, B; Aourz, N; Bentea, E; De Deurwaerdère, P; El Arfani, A; Massie, A; Michotte, Y; Sarre, S; Smolders, I; Van Eeckhaut, A | 1 |
| Alken, RG; Feltmann, K; Konradsson-Geuken, Å; Malmlöf, T; Schilström, B; Schneider, F; Svensson, TH | 1 |
| Fang, X; Guo, L; Jia, J; Liu, Z; Lu, W; Yang, Z; Ye, N; Zhang, A; Zhao, B; Zhao, J; Zhao, R; Zhen, X; Zheng, L | 1 |
| Bezard, E; Crossman, AR; Ko, WK; Martin-Negrier, ML; Ravenscroft, P | 1 |
| Huang, C; Liu, J; Wang, HS; Wang, T; Wang, Y | 1 |
| Bagetta, V; Branchi, I; Calabresi, P; Ghiglieri, V; Latagliata, EC; Morelli, E; Pascucci, T; Pendolino, V; Picconi, B; Poggini, S; Puglisi-Allegra, S; Sgobio, C | 1 |
| Brazhnik, E; Cruz, AV; McCoy, AJ; Novikov, N; Walters, JR | 1 |
| Bastide, MF; Bezard, E; Boué-Grabot, E; Bourdenx, M; Dehay, B; Doudnikoff, E; Engeln, M; Fernagut, PO; Gross, CE; Li, Q; Pisani, A; Toulmé, E | 1 |
| Iravani, M; Jackson, M; Jenner, P; McCreary, AC; Papathanou, M; Rose, S; Stockwell, K; Strang, I; Zeng, BY | 1 |
| Dominguez-Meijide, A; Garrido-Gil, P; Labandeira-Garcia, JL; Muñoz, A | 1 |
| Brotchie, JM; Chen, B; Gertler, TS; Lo, C; Nash, JE; Surmeier, JD; Thiele, SL; Warre, R | 1 |
| Caboche, J; Feyder, M; Fisone, G; Hansen, K; LaPlant, Q; Nestler, EJ; Santini, E; Södersten, E; Spigolon, G; Vialou, V; Watts, EL | 1 |
| Anselmo-Franci, J; Carolino, RO; Cavalcanti-Kiwiatkoviski, R; Del Bel, E; Padovan-Neto, FE | 1 |
| Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG | 1 |
| Danysz, W; Dekundy, A; Hofmann, M; Mela, F | 1 |
| Garcia-Rubio, S; Giuliano, C; Karasawa, H; Pietra, C; Taché, Y; Wang, L; Xu, X; Yakabi, S | 1 |
| Canela, EI; Canet-Pons, J; Casadó, V; Cortés, A; Dopeso-Reyes, IG; Farré, D; Franco, R; Labandeira-García, JL; Lanciego, JL; Lluís, C; Mallol, J; Moreno, E; Muñoz, A; Navarro, G; Reyes-Resina, I; Rico, AJ | 1 |
| Liu, Z; Wang, Q; Xie, C; Zhang, S | 1 |
| Liu, Z; Ma, Y; Song, L; Wu, N; Yang, X | 1 |
| Jeon, SR; Kim, YH; Shin, ES; Yoon, HH | 1 |
| Greengard, P; Heiman, M; Heintz, N; Kaplitt, MG; Logan, SM; Musatov, S; Peterson, JD; Sagi, Y; Scarduzio, M; Surmeier, DJ | 1 |
| Deng, MZ; Fang, YQ; He, YP; Huang, LP | 1 |
| Bastide, MF; Bézard, E; Boraud, T; de la Crompe, B; Doudnikoff, E; Fernagut, PO; Gross, CE; Mallet, N | 1 |
| Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A | 1 |
| Che, JY; Gan, J; Liu, ZG; Song, L; Wang, WW; Xie, CL; Yuan, ML; Yuan, WE; Zhang, SF | 1 |
| Downey, P; Michel, A; Nicolas, JM; Scheller, D | 1 |
| Ba, M; Kong, M; Ma, G | 1 |
| Bamford, NS; Borgkvist, A; Choi, SJ; Mosharov, EV; Sulzer, D; Wong, MY | 1 |
| Limón, ID; Palafox-Sánchez, V; Ramírez-García, G | 1 |
| Cenci, MA; Iderberg, H; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Bortolanza, M; Del-Bel, E; Issy, AC; Lazzarini, M; Padovan-Neto, FE | 1 |
| Ariza, D; Crestani, CC; Dias, DP; Martins-Pinge, MC; Silva, AS | 1 |
| Bubser, M; Cenci, MA; Conn, PJ; Hopkins, CR; Iderberg, H; Jones, CK; Lindsley, CW; Maslava, N; Niswender, CM; Thompson, AD | 1 |
| Collier, TJ; Gebremedhin, KG; O'Malley, J; Paumier, KL; Rademacher, DJ; Sisson, KA; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Cao, X; Chen, Z; Shi, Q; Tang, B; Wang, T; Zhang, T | 1 |
| Gut, NK; Winn, P | 1 |
| Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M | 1 |
| Bhide, N; Bishop, C; Conti, M; George, JA; Hallmark, J; Ostock, CY; Palumbo, N | 1 |
| Chiu, WH; Depboylu, C; Hermanns, G; Höglinger, GU; Maurer, L; Oertel, WH; Ries, V; Windolph, A | 1 |
| Bankiewicz, K; Beyer, J; Ciesielska, A; Forsayeth, J; Sharma, N | 1 |
| Carlsson, T; Depboylu, C; Höglinger, GU; Keber, U; Klietz, M; Oertel, WH; Schäfer, MK; Weihe, E | 1 |
| Hwang, BY; Lee, CK; Lee, MK; Park, HJ; Park, KH; Shin, KS; Zhao, TT | 1 |
| Bezard, E; Carta, M; Chuan, Q; Fidalgo, C; Ko, WK; Li, Q; Stancampiano, R; Tronci, E | 1 |
| Duan, SJ; Han, B; Lu, Y; Wang, LJ; Wang, SY; Wang, T; Zhu, Q | 1 |
| Bass, CE; Bezard, E; Bido, S; Caron, MG; Daigle, TL; Gainetdinov, RR; Peterson, SM; Urs, NM | 1 |
| Cruz, AV; Delaville, C; Gerber, CM; McCoy, AJ; Walters, JR | 1 |
| Li, L; Sagot, B; Zhou, FM | 1 |
| Fernández, E; Fresno, C; Gershanik, OS; Gomez, G; González, GA; Larramendy, C; Murer, MG; Saborido, MD; Spaans, F; Taravini, IR | 1 |
| Cui, G; Hua, F; Shen, X; Shi, H; Wang, X; Yang, X; Zhang, S; Zhang, W; Zhang, Z; Zhao, H; Zu, J | 1 |
| Bortolanza, M; Cavalcanti-Kiwiatkoski, R; Del-Bel, E; Dos Santos-Pereira, M; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Bardin, L; Cenci, MA; Depoortère, R; Iderberg, H; Kleven, MS; Koek, W; McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Chen, C; Fan, Q; Huang, J; Pan, X; Wei, H | 1 |
| Bonastre, M; Cortés, R; Marin, C; Mengod, G; Rodríguez-Oroz, MC | 1 |
| Cavanagh, JF; Chen, KH; Kingyon, JR; Narayanan, NS; Parker, KL | 1 |
| Chammas, C; Soghomonian, JJ; Zhang, K | 1 |
| De Deurwaerdère, P; Di Giovanni, G; Navailles, S | 1 |
| Arcuri, L; Brugnoli, A; Mercatelli, D; Morari, M; Paolone, G | 1 |
| Czarnecka, A; Konieczny, J; Lenda, T; Lorenc-Koci, E | 1 |
| De Wolf, C; Downey, P; Michel, A; Scheller, D; Schwarting, R; Van Damme, X | 1 |
| Franklin, A; Miguelez, C; Raskind, MA; Sikkema, C; Szot, P; Ugedo, L; Vidaurrazaga, I; Wang, Y; Wilkinson, CW | 1 |
| Bishop, C; Conti, MM; Dupre, KB; Lindenbach, D; Ostock, CY | 1 |
| Lee, KE; Lee, MK; Park, HJ; Park, KH; Shin, KS; Zhao, TT | 1 |
| Daniels, WM; Mabandla, MV; Ndlovu, BC | 1 |
| Alvarsson, A; Kadkhodaei, B; Millan, MJ; Perlmann, T; Schintu, N; Stan, TL; Svenningsson, P; Zhang, X | 1 |
| Cruz, AV; Delaville, C; Dupre, KB; Eyring, KW; Gerber, CM; McCoy, AJ; Walters, JR | 1 |
| Cacace, F; Calabresi, P; Carta, M; di Maio, A; Fidalgo, C; Gardoni, F; Ghiglieri, V; Mancini, M; Mellone, M; Mineo, D; Napolitano, F; Pendolino, V; Picconi, B; Stancampiano, R; Stanic, J; Tronci, E; Usiello, A; Vannelli, A | 1 |
| Llorente, J; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Sagarduy, A; Ugedo, L | 1 |
| Daumas, S; El Mestikawy, S; Gangarossa, G; Guzman, M; Prado, MA; Prado, VF; Valjent, E | 1 |
| Alam, M; Jin, X; Krauss, JK; Schwabe, K | 1 |
| Abe, H; Ebihara, K; Ikarashi, Y; Imamura, S; Ishida, Y; Kase, Y; Koganemaru, G; Mizoguchi, K; Sekiguchi, K; Tabuchi, M | 1 |
| Kokare, DM; Shelkar, GP; Subhedar, NK; Upadhya, MA | 1 |
| McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Bishop, C; Conti, MM; Eissa, S; Goldenberg, AA; Kuberka, A; Lindenbach, D; Mohamed, M | 1 |
| De Deurwaerdère, P; Miguelez, C; Navailles, S; Ugedo, L | 1 |
| Aristieta, A; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Ugedo, L | 2 |
| Atlas, D | 1 |
| Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Park, HY; Park, TS; Rhee, M; Ryu, YK | 1 |
| Cheng, J; Fan, Q; Gan, J; Hu, R; Li, L; Liu, Z; Song, L; Wu, N; Zhang, Z; Zhou, M | 1 |
| Asensio, MJ; García-Sanz, P; Herranz, AS; Moratalla, R; Solís, O | 1 |
| Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM | 1 |
| Deng, M; Fang, Y; He, Y; Huang, L; Lu, S; Ma, R | 1 |
| Lin, JY; Liu, ZG; Wang, MH; Wang, XJ; Xie, CL; Zhang, SF; Zhang, Y | 1 |
| Brauer, AF; Ciucci, MR; Kelm-Nelson, CA | 1 |
| Bariotto-Dos-Santos, KD; Bortolanza, M; da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M | 1 |
| Capper-Loup, C; Kaelin-Lang, A; Paganetti, P; Sgroi, S | 1 |
| Boon, WC; Chua, HK; Horne, M; Stanic, D; Tomas, D; White, K | 1 |
| Aguilera, J; Candalija, A; Limón, ID; Mendieta, L; Palafox-Sánchez, V; Ramírez-García, G | 1 |
| Chang, J; Li, M; Li, X; Luo, F; Wang, J; Wang, N; Wang, Q; Wen, P; Xiao, H; Xie, Z; Yang, Y; Zhang, W; Zhou, M | 1 |
| Cirnaru, MD; Di Luca, M; Gardoni, F; Mellone, M; Perez-Carrion, M; Piccoli, G; Stanic, J; Zianni, E | 1 |
| Eskow Jaunarajs, KL; Figge, DA; Standaert, DG | 1 |
| Bez, F; Cenci, MA; Francardo, V | 1 |
| Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Keber, U; Klietz, M; Schäfer, MK; Weihe, E | 1 |
| da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M; Guimarães, FS | 1 |
| Asatryan, L; Davies, DL; Garcia, D; Jakowec, MW; Khoja, S; Shah, V | 1 |
| Geng, X; Han, H; Hou, Y; Lei, C; Li, M; Wang, M; Wang, X; Xie, J; Yao, X; Zhang, Q; Zhang, X | 1 |
| Agorastos, S; Bimpisidis, Z; Cenci, MA; Dewey, SL; Eidelberg, D; Lerner, RP; Scherrer, S | 1 |
| Amalric, M; Beurrier, C; Camon, J; Guiraudie-Capraz, G; Kerkerian-Le Goff, L; Liberge, M; Maurice, N; Ztaou, S | 1 |
| Cenci, MA; Hopkins, CR; Maslava, N; Sebastianutto, I | 1 |
| Aguado, C; Lujan, R; Moratalla, R; Solis, O; Suarez, LM | 1 |
| Bishop, C; Conti, MM; George, JA; Goldenberg, AA; Lindenbach, D; Melikhov-Sosin, M; Nuss, EE; Ostock, CY | 1 |
| Hardy, GA; Lee, HJ; Schallert, T; Smith, ES | 1 |
| Angius, F; Batetta, B; Carboni, E; Carta, AR; Cossu, G; Espa, E; Fenu, S; Giuffrida, A; Jadžić, D; Lecca, D; Mulas, G; Pillai, E; Simbula, G; Spiga, S; Spolitu, S | 1 |
| Cao, LF; Chen, LH; Cheng, RX; Huang, Y; Liu, T; Luo, WF; Peng, XY; Wang, B; Zhou, FM | 1 |
| Czarnecka, A; Dudek, M; Kamińska, K; Knutelska, J; Lorenc-Koci, E; Zygmunt, M | 1 |
| Miki, Y; Mori, F; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T | 1 |
| Bordia, T; Perez, XA; Quik, M; Zhang, D | 1 |
| Castela, I; F Hernández, L; Moratalla, R; Obeso, JA; Ruiz-DeDiego, I | 1 |
| A Figge, D; Standaert, DG | 1 |
| Ben, J; de Oliveira, PA; Matheus, FC; Moreira, ELG; Prediger, RD; Rial, D; Schwarzbold, ML; Walz, R | 1 |
| Asensio, MJ; García-Montes, JR; Garcia-Sanz, P; Herranz, AS; Hiroi, N; Kang, G; Moratalla, R; Solís, O | 1 |
| Funamizu, Y; Mizukami, H; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T; Yagihashi, S | 1 |
| Alam, M; Grothe, C; Jin, X; Krauss, JK; Ratzka, A; Rumpel, R; Schwabe, K; Tschirner, SK; von Wrangel, C | 1 |
| Hu, LF; Li, SY; Liu, CF; Liu, WW; Lyu, DJ; Mao, CJ; Wang, F; Wang, YL; Yang, YP | 1 |
| Bonito-Oliva, A; Fisone, G; Johansson, Y; Ketzef, M; Silberberg, G; Spigolon, G | 1 |
| Antonioli, L; Ballabeni, V; Barocelli, E; Bernardini, N; Blandini, F; Blandizzi, C; Cerri, S; Colucci, R; Fornai, M; Gentile, D; Ippolito, C; Levandis, G; Pellegrini, C; Segnani, C; Tirotta, E | 1 |
| Casteels, C; de Vries, EFJ; Dierckx, RAJO; Doorduin, J; Elsinga, PH; Zhou, X | 1 |
| Bishop, C; Cantu, MA; Chotibut, T; Kasanga, EA; McInnis, T; Meadows, S; Salvatore, MF | 1 |
| Björklund, A; Carta, M; Fidalgo, C; Muñoz, A; Napolitano, F; Rossi, F; Tronci, E; Usiello, A | 1 |
| Deng, M; Fang, Y; Gui, X; Huang, L; Lu, S; Zhang, S | 1 |
| Cai, J; Li, M; Li, N; Luo, F; Wang, J; Wang, N; Wang, Q; Xiao, H; Xie, Z; Zhang, W | 1 |
| Bezard, E; Calabresi, P; De Rosa, A; Di Luca, M; Gardoni, F; Ghiglieri, V; Li, Q; Longhi, A; Mellone, M; Minocci, D; Napolitano, F; Picconi, B; Racca, C; Stanic, J; Thiolat, ML; Usiello, A; Zianni, E | 1 |
| Babapour, V; Hashemzadeh, M; Panahi, N; Zendehdel, M | 1 |
| Baekelandt, V; Casteels, C; Crabbé, M; Himmelreich, U; Van der Perren, A; Van Laere, K; Weerasekera, A | 1 |
| Cronin, A; Grealy, M | 1 |
| Ando, K; Inoue, R; Kawai, K; Nishime, C; Nishinaka, E; Tsutsumi, H; Urano, K | 1 |
| Brotchie, JM; Corey, R; Fox, SH; Hill, MP; Howson, PA; Johnston, TH; Ravenscroft, P; Reidenberg, BE; Versi, E | 1 |
| Arcuri, L; Brambilla, R; Fasano, S; Frassineti, M; Journigan, BV; Mercatelli, D; Meyer, ME; Morari, M; Morella, I; Novello, S; Pisanò, CA; Polgar, WE; Zaveri, NT | 1 |
| Francardo, V; Tronci, E | 1 |
| Aparicio-Juárez, A; Ávila-Cascajares, F; Bargas, J; Calderón, V; Duhne, M; Galarraga, E; Lara-González, E | 1 |
| Cui, G; Ding, X; Hua, F; Wang, X; Xiang, J; Yang, X; Zhu, Z | 1 |
| Alcázar, JP; Caro Aponte, PA; Guzmán, JC; Mayorga, EL; Otálora, CA; Turner, LF | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Du, CX; Liu, J; Sun, YN; Wang, HS; Wang, Y; Yao, L; Zhang, GJ; Zhang, L | 1 |
| Bariotto-Dos-Santos, K; Bortolanza, M; Del-Bel, EA; Leite-Panissi, CRA; Nascimento, GC | 1 |
| Baufreton, J; Bessière, B; Bezard, E; Chazalon, M; Courtine, G; Farjot, G; Ko, WKD; Li, Q; McGuire, S; Milekovic, T; Milet, A; Moraud, EM; Morin, S; Normand, E; Pioli, E; Porras, G; Pype, J; Sun, S | 1 |
| Hänninen, R; Koski, SK; Leino, S; Rannanpää, S; Salminen, O; Tapanainen, T | 1 |
| Choi, DH; Go, J; Han, PL; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Noh, JR; Park, HY; Rhee, M; Ryu, YK | 1 |
| Bariotto-Dos-Santos, K; Bortolanza, M; Del Bel, E; Dos-Santos-Pereira, M; Padovan-Neto, FE; Raisman-Vozari, R; Tumas, V | 1 |
| Ahn, S; Jeon, SH; Kim, J; Kim, YK; Lee, AR; Park, H; Park, HJ; Yoo, J | 1 |
| Chen, SY; Shao, B; Wang, XS; Xie, CL; Zhang, XR; Zhang, ZR | 1 |
| Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Parent, KL; Polt, R; Porreca, F; Root, BK; Sherman, SJ | 1 |
| Kamińska, K; Konieczny, J; Lenda, T; Lorenc-Koci, E; Wardas, J | 1 |
| Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S | 1 |
| Barta, C; Glennon, J; Hengerer, B; Hildebrandt, T; Nespoli, E; Pagliaroli, L; Poelmans, G; Widomska, J | 1 |
| Avnor, Y; Bishop, C; Chambers, NE; Conti, MM; Gross, L; Lanza, K; Meadows, SM; Ostock, CY | 1 |
| Denibaud, AS; Drieu La Rochelle, C; Loiodice, S; Méot, B; Montagne, P; Rion, B; Viel, R; Wing Young, H | 1 |
| Nambu, A; Sano, H | 1 |
| Gao, G; Gao, Y; Geng, X; Han, H; He, F; Wang, M; Wang, X; Wang, Y; Xie, J; Yao, X; Zhang, H; Zhang, X | 1 |
| Belforte, JE; Escande, MV; Gershanik, OS; Gomez, G; Moratalla, R; Murer, MG; Rela, L; Suarez, LM; Taravini, IRE | 1 |
| Morris, GP; Rentsch, P; Stayte, S; Vissel, B | 1 |
| Arias-Montaño, JA; Avila-Luna, A; Bueno-Nava, A; Gálvez-Rosas, A; Montes, S; Ríos, C | 1 |
| Keifman, E; Moratalla, R; Murer, MG; Pafundo, DE; Paz, RM; Ruiz-DeDiego, I; Solís, O | 1 |
| Cacace, F; Calabresi, P; Campanelli, F; Cardinale, A; Ghiglieri, V; Mancini, M; Marino, G; Mineo, D; Natale, G; Picconi, B; Vannelli, A | 1 |
| Collier, NJ; Collier, TJ; Manfredsson, FP; Mercado, NM; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Jia, J; Jiang, X; Su, W; Wang, K; Wei, J; Yan, Y | 1 |
| Goto, S; Kasahara, J; Ogawa, M; Tsuji, R; Zhou, Y | 1 |
| Alam, T; Ali, J; Baboota, S; Gaba, B; Haider, MF; Khan, T; Parvez, S | 1 |
| Boi, L; Carboni, E; Carta, AR; Fenu, S; Greig, NH; Mulas, G; Pisanu, A; Scerba, MT; Spiga, S; Tweedie, D | 1 |
| Albarrán-Bravo, S; Ávalos-Fuentes, JA; Cortés, H; Erlij, D; Florán, B; Leyva-García, N; Rangel-Barajas, C; Rodriguez-Sánchez, M | 1 |
| Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X | 1 |
| Afonso, ND; Chapela, D; Coelho, JE; Ferreira, JJ; Lopes, LV; Outeiro, TF; Sousa, S; Vaz, RL | 1 |
| Bergquist, F; Carlsson, T; Nilsson, A; Samoudi, G | 1 |
| Afonso, ND; Chapela, D; Correia, AD; Outeiro, TF; Sousa, S; van der Linde, HC; Vaz, RL; Willemsen, R | 1 |
| Khalili, A; Peimani, AR; Rezai, P; Safarian, N; Youssef, K; Zoidl, G | 1 |
| Campos, J; Domingues, AV; Salgado, AJ; Teixeira, FG; Vilaça-Faria, H | 1 |
| Castello, J; Cortés, M; Friedman, E; Kottmann, A; Malave, L; Rebholz, H; Sibley, DR | 1 |
| Cao, X; Chen, G; Cheng, C; Nie, S; Tan, Y; Wang, J; Xu, Y; Yang, X; Zeng, W; Zhang, Z; Zheng, C | 1 |
| Bastioli, G; Caccia, C; Calabresi, P; Cardinale, A; Ghiglieri, V; Keywood, C; Mazzocchetti, P; Melloni, E; Mosci, P; Padoani, G; Picconi, B; Sciaccaluga, M; Tozzi, A; Vailati, S | 1 |
| Arakawa, K; Maehara, S; Yuge, N | 1 |
| Chen, X; Cheng, C; Le, W; Wang, Y; Wu, H | 1 |
| Koski, SK; Leino, S; Panula, P; Rannanpää, S; Salminen, O | 1 |
| Altwal, F; Collier, TJ; Kordower, JH; Manfredsson, FP; Sandoval, IM; Sellnow, RC; Sortwell, CE; Steece-Collier, K; West, AR | 1 |
| Shao, M; Wang, R | 1 |
| Cuboni, E; Di Giovanni, G; Fedele, E; Galati, S; Grandi, LC; Kaelin-Lang, A; Orban, G; Salvadè, A; Song, W; Stefani, A | 1 |
| Aragão Catunda Junior, FE; Basto Souza, R; da Cunha Ferreira, NM; de Sousa Dos Reis, TD; Hardy Lima Pontes, N; Maranguape Silva da Cunha, R; Moreira Vasconcelos, CF; Vasconcelos Aguiar, LM | 1 |
| Aristieta Arbelaiz, A; Degos, B; Derousseaux, W; Gangarossa, G; Piette, C; Touboul, J; Valverde, S; Vandecasteele, M; Venance, L | 1 |
| Bermúdez de León, M; González-Hernández, B; González-Horta, A; Leija-Salazar, M | 1 |
| Gao, H; Li, W | 1 |
| Bonastre, M; Fuentes, M; Marin, C; Mullol, J | 2 |
| Brugnoli, A; Morari, M; Pisanò, CA | 1 |
| Altinbas, B; Buyukuysal, RL; Duyu, G; Gul, Z | 1 |
| Labandeira, CM; Labandeira-Garcia, JL; Lopez-Lopez, A; Muñoz, A | 1 |
| Anderson, C; Booth, S; Jackson, MF; Kirouac, G; Ko, JH; Lu, L; Ramadan, A; Zhang, D | 1 |
| Boezwinkle, SA; Collier, TJ; Duffy, MF; Fischer, DL; Manfredsson, FP; Mercado, NM; Mueller, RL; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Cai, J; Chen, J; Huang, S; Li, M; Li, N; Luo, F; Lv, S; Wang, J; Wang, N; Wang, Q; Wang, Y; Wen, H; Zhang, W | 1 |
| Altschüler, J; Böckmann, S; Güttler, C; Haumesser, JK; Kühn, AA; Nikulin, VV; Tanev, K; van Riesen, C | 1 |
| Bédard, D; Frouni, I; Hamadjida, A; Huot, P; Kwan, C | 1 |
| Feng, J; Gao, S; Liu, J; Liu, W; Sun, Y; Wang, Y; Yao, L; Zhang, G; Zhang, Q; Zhou, Y | 1 |
| Bishop, C; Chambers, NE; Clark, SD; Coyle, M; Lanza, K; Saito, C; Sergio, J; Topping, B | 1 |
| Altun, M; Bezard, E; Borgkvist, A; Dehay, B; Feyder, M; Fisone, G; Li, Q; Lieberman, OJ; Nilsson, P; Piccin, A; Plewnia, C; Santini, E; Spigolon, G; Sulzer, D; Urbina, L | 1 |
| Choi, YK; Go, J; Kim, KS; Lee, CH; Lee, IB; Park, HY; Ryu, YK | 1 |
| Amarillo, Y; Murer, MG; Paz, RM; Rela, L; Stahl, AM; Tubert, C | 1 |
| Azandeh, SS; Farbood, Y; Ghasemi Dehcheshmeh, M; Jalali, MS; Mansouri, E; Saki, G; Sarkaki, A | 1 |
| Geng, X; Kan, D; Li, Y; Liu, C; Liu, H; Wei, S; Xie, J; Zhang, H | 1 |
| Bartlett, MJ; Cowen, SL; Falk, T; Sherman, SJ; Ye, T | 1 |
| Aristieta, A; Bengoetxea, H; Lafuente, JV; Miguelez, C; Requejo, C; Ugedo, L; Vegas-Suárez, S | 1 |
| Bortolanza, M; Del Bel, EA; Ferrari, DP | 1 |
| Beck, G; Fong, K; Mochizuki, H; Mouradian, MM; Papa, SM; Zhang, J | 1 |
| Bortolanza, M; Del-Bel, E; do Nascimento, GC; Raisman-Vozari, R | 1 |
| Liu, Z; Song, L; Yan, A; Yang, S; Zhao, J | 1 |
| Murer, MG; Paz, RM | 1 |
| Dehghani Ashkezari, M; Seifati, SM; Zarrin, P | 1 |
| Contu, L; Costa, G; Morelli, M; Pinna, A; Serra, M | 1 |
| Fan, HX; Li, JJ; Li, XX; Sheng, S; Zhang, F; Zheng, CQ | 1 |
| Hsu, CC; Huang, CL; Lin, YA; Ma, YF; Tsai, YC; Wang, S; Yeh, SR | 1 |
| Gilmour, TP; Handly, E; Iyer, V; Kunselman, AR; Lieu, CA; Savaliya, S; Subramanian, T; Venkiteswaran, K | 1 |
| Berghauzen-Maciejewska, K; Konieczny, J; Lenda, T; Matłoka, M; Ossowska, K; Pieczykolan, J; Wieczorek, M | 1 |
| Kaneko, S; Kusaka, H; Morise, S; Murakami, A; Nakamura, M; Oki, M; Takenouchi, N; Tohge, R; Yakushiji, Y | 1 |
| Bariotto-Dos-Santos, K; Guimarães, RP; Padovan-Neto, FE; Ribeiro, DL | 1 |
| Caulfield, ME; Stancati, JA; Steece-Collier, K | 1 |
| Davies, JS; Elabi, OF; Lane, EL | 1 |
| Bédard, D; Clarke, PB; Frouni, I; Hamadjida, A; Huot, P; Kwan, C; Lévesque, C; Lévesque, D; Yesuf, JM | 1 |
| Kimura, T; Kinoshita, I; Kon, T; Miki, Y; Mori, F; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M; Wakabayashi, K | 1 |
| Arias-García, M; Bargas, J; Calderón, VM; Galarraga, E; Gómez-Paz, A; Lara-González, E; Luna-Leal, A; Ramírez-López, F | 1 |
| Chen, H; Chen, J; Chen, S; Li, Q; Liu, J; Lu, Y; Shao, F; Tang, M; Wu, W; Xu, Z; Yang, D; Zhai, L | 1 |
| Drummond, N; Elabi, OF; Kirkeby, A; Kunath, T; Lane, EL; Nolbrant, S; Parmar, M; Pass, R; Sormonta, I | 1 |
| Bishop, C; Budrow, C; Centner, A; Cohen, SR; Coyle, M; Glinski, J; Lipari, N; Manfredsson, FP; Smith, S; Terry, ML; Wheelis, E | 1 |
| Murer, MG; Paz, RM; Rela, L; Stahl, AM; Tubert, C | 1 |
| Chen, YH; Hoffer, BJ; Huang, EY; Kuo, TT; Ma, KH; Olson, L; Tseng, KY; Wang, V | 1 |
| Bédard, D; Belliveau, S; Bourgeois-Cayer, É; Frouni, I; Hadj-Youssef, S; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Ohlund, L; Sleno, L | 1 |
| Anceaume, E; Caboche, J; Calabrese, V; Calabresi, P; Campanelli, F; Charvin, D; Conquet, F; Cuoc, E; Ghiglieri, V; Heck, N; Marino, G; Natale, G; Picconi, B; Sciaccaluga, M; Tozzi, A | 1 |
| Christensen, KV; Fryland, T; Hansen, JB; Mikkelsen, JD; Stoica, A; Thomsen, M | 1 |
| Kamińska, K; Konieczny, J; Lenda, T; Lorenc-Koci, E | 1 |
| Azar, YO; Badawi, GA; Ibrahim, SM; Zaki, HF | 1 |
| Casado-Polanco, R; Castela, I; Costa, RM; da Silva, JA; Hernandez, LF; Marquez, R; Moratalla, R; Obeso, J; Pro, B; Redgrave, P; Rubio, YV | 1 |
| Blandini, F; Cerri, S; Cesaroni, V | 1 |
| Bishop, C; Centner, A; Cohen, S; Glinski, J; Lipari, N; Manfredsson, FP | 1 |
| Franco, R; Labandeira-García, JL; Lillo, A; Lillo, J; Muñoz, A; Navarro, G; Raïch, I; Rivas-Santisteban, R; Rodríguez-Pérez, AI | 1 |
| Cenci, MA; Espa, E; Fanni, S; Skovgård, K; Song, L | 1 |
| Cao, X; Lian, P; Wu, Y; Xu, Y; Yuan, Y; Zhang, X | 1 |
| Braccagni, G; Carta, M; Caruso, D; Cioffi, L; Corsi, S; Diviccaro, S; Fanni, S; Frau, R; Gambarana, C; Gentile, M; Melcangi, RC; Pardu, A; Scheggi, S; Stancampiano, R | 1 |
| Chen, YH; Choi, HI; Greig, NH; Hoffer, BJ; Huang, EY; Jung, J; Kuo, TT; Ma, KH; Olson, L; Tseng, KY; Wang, V | 1 |
| Feng, J; Gao, R; Gao, S; Liu, K; Song, M; Wang, L; Wang, Y; Yao, L; Zhang, L | 1 |
| Furukawa, T; Kinoshita, I; Kon, T; Murakami, Y; Nakamura, T; Nishijima, H; Suzuki, C; Tomiyama, M | 1 |
| Aguirre-Pérez, A; Alfaro-Rodriguez, A; Arias-Montaño, JA; Avila-Luna, A; Bueno-Nava, A; Gálvez-Rosas, A; Hidalgo-Bravo, A; Ríos, C | 1 |
| Buberwa, W; Gao, D; Kambey, PA; Liu, WY; Nyalali, AMK; Saro, A; Tang, C; Wu, J | 1 |
| Bishop, C; Centner, A; Conti Mazza, MM; Werner, DF | 1 |
| Cenci, MA; Espa, E; Grigoriou, S; Jakobsson, A; Odin, P; Timpka, J; von Grothusen, G | 1 |
| Girault, JA; Hervé, D; Nakamura, Y; Pelosi, A | 1 |
| Del-Bel, E; Dias, FJ; Escobar-Espinal, D; Jacob, G; Leal-Luiz, G; Malzone, BL; Milan, BA; Nascimento, GC; Vivanco-Estela, AN | 1 |
| Coizet, V; David, O; Duveau, V; Gronlier, E; Habermacher, C; Paccard, A; Roche, Y; Roucard, C; Volle, J | 1 |
| Alberquilla, S; Coll, C; Keifman, E; Moratalla, R; Murer, MG; Reig, R; Sáez, M | 1 |
| Abe, Y; Dantsuji, M; Hata, J; Inoue, T; Matsumoto, M; Mochizuki, A; Nambu, A; Ohno, N; Okano, H; Sano, H; Suematsu, M; Sugiura, Y; Suzuki, T; Taira, S; Takeuchi, H; Tanaka, KF; Watanabe, M; Yagishita, S; Yoshimaru, D | 1 |
| Bartlett, MJ; Falk, T; Flores, AJ; Heien, ML; Lu, D; Porreca, F; Samtani, G; Seaton, BT; Sexauer, MR; Sherman, SJ; Siegenthaler, JR; Weintraub, NC | 1 |
| Dunnett, SB; Lane, EL; Lelos, MJ; Lindgren, HS; Murphy, EM | 1 |
| Egan, T; Kuriakose, A; Rentsch, P; Stayte, S; Vissel, B | 1 |
20 review(s) available for levodopa and oxidopamine
| Article | Year |
|---|---|
Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
Topics: Animals; Brain; Dopamine; Humans; Levodopa; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats | 1992 |
[Role of the catecholaminergic system of the brain in addiction to alcohol (review)].
Topics: Acetaldehyde; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alcohol Deterrents; Alcoholism; Amphetamine; Animals; Brain; Brain Chemistry; Catecholamines; Cholinergic Fibers; Cricetinae; Dopamine; Ethanol; Humans; Hydroxydopamines; Hypothalamus; Isoquinolines; Levodopa; Mice; Norepinephrine; Oxidopamine; Rats; Receptors, Adrenergic; Receptors, Adrenergic, beta; Receptors, Catecholamine; Serotonin; Synaptic Transmission | 1985 |
Receptor changes during chronic dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Dopamine; Humans; Hydroxydopamines; Injections, Intraperitoneal; Levodopa; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Pergolide; Primates; Pyridines; Receptors, Dopamine; Substance Withdrawal Syndrome | 1988 |
Dopamine as a postganglionic autonomic neurotransmitter.
Topics: Animals; Autonomic Fibers, Postganglionic; Cats; Dogs; Dopamine; Dopamine beta-Hydroxylase; Ferrets; Ganglia, Sympathetic; Guanethidine; Guinea Pigs; Hydroxydopamines; Levodopa; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Rabbits; Rats; Reserpine; Synaptic Transmission | 1982 |
The role of excitatory amino acids in experimental models of Parkinson's disease.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Catalepsy; Disease Models, Animal; Excitatory Amino Acids; Levodopa; N-Methylaspartate; Oxidopamine; Parkinson Disease; Rats | 1994 |
The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.
Topics: Animals; Antiparkinson Agents; Brain; Dopamine Agonists; Functional Laterality; Humans; Levodopa; Motor Activity; Neurotoxins; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Receptors, Dopamine; Stereotyped Behavior | 1996 |
Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites.
Topics: Animals; Antioxidants; Dopamine; Humans; Incidence; Levodopa; Middle Aged; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Reactive Oxygen Species | 1997 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Primates; Purines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine D2 | 2003 |
Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Globus Pallidus; Humans; Levodopa; Movement Disorders; Neurons; Neurosurgical Procedures; Oxidopamine; Parkinson Disease; Treatment Failure | 2004 |
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Reproducibility of Results; Sympatholytics | 2008 |
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence.
Topics: Animals; Antiparkinson Agents; Behavior; Brain Chemistry; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Efferent Pathways; Gene Expression Regulation; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2008 |
Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Models, Molecular; Oxidopamine; Parkinson Disease; Protein Subunits; Rats; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate | 2008 |
[Synthesis of monoamines by non-monoaminergic neurons: illusion or reality?].
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain; Corpus Striatum; Dopamine; Humans; Hypothalamus; Levodopa; Nerve Tissue Proteins; Neurodegenerative Diseases; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Serotonin; Substantia Nigra; Tyrosine; Tyrosine 3-Monooxygenase | 2009 |
Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Presynaptic Terminals; Rats; Serotonergic Neurons; Serotonin | 2011 |
Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinson Disease; Tyrosine 3-Monooxygenase | 2014 |
Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats | 2018 |
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinson Disease; Rats | 2020 |
Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited.
Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease | 2021 |
Dyskinesia and Parkinson's disease: animal model, drug targets, and agents in preclinical testing.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Neurodegenerative Diseases; Oxidopamine; Parkinson Disease; Quality of Life | 2022 |
Impaired cognitive and motor function are coincident with L-DOPA-induced dyskinesia in a model of Parkinson's disease.
Topics: Animals; Cognition; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
1 trial(s) available for levodopa and oxidopamine
| Article | Year |
|---|---|
The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain Tissue Transplantation; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Female; Ganglia, Sympathetic; Graft Survival; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Neurons; Neuropeptides; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reserpine; Transplantation, Heterologous; Tyrosine 3-Monooxygenase; Up-Regulation; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2004 |
798 other study(ies) available for levodopa and oxidopamine
| Article | Year |
|---|---|
Tetrahydrobiopterin-dependent functional recovery in 6-hydroxydopamine-treated rats by intracerebral grafting of fibroblasts transfected with tyrosine hydroxylase cDNA.
Topics: Animals; Apomorphine; Behavior, Animal; Biopterins; Brain; Cell Line, Transformed; DNA; Female; Fibroblasts; Levodopa; Oxidopamine; Rats; Rats, Wistar; Stereotyped Behavior; Transfection; Tyrosine 3-Monooxygenase | 1992 |
Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenylyl Cyclases; Animals; Animals, Newborn; Autoradiography; Corpus Striatum; Female; Guanosine Triphosphate; Levodopa; Nucleus Accumbens; Oxidopamine; Pregnancy; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tyrosine 3-Monooxygenase | 1992 |
Blockade of N-methyl-D-aspartate receptors potentiates dopaminergic responses in the 6-OHDA model of Parkinson: differential role of D-1 and D-2 receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Dizocilpine Maleate; Dopamine; Drug Synergism; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate | 1992 |
Effects of a unilateral 6-hydroxydopamine lesion and prolonged L-3,4-dihydroxyphenylalanine treatment on peptidergic systems in rat basal ganglia.
Topics: Animals; Carbidopa; Cholecystokinin; Chromatography, High Pressure Liquid; Corpus Striatum; Enkephalin, Leucine; Enkephalin, Methionine; Levodopa; Male; Neuropeptides; Neurotensin; Oxidopamine; Prosencephalon; Rats; Rats, Wistar; Substance P; Substantia Nigra | 1992 |
Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa.
Topics: Animals; Apomorphine; Autoradiography; Brain Tissue Transplantation; Carbidopa; Corpus Striatum; Dextroamphetamine; Female; Fetal Tissue Transplantation; In Vitro Techniques; Levodopa; Mesencephalon; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D2; Time Factors | 1992 |
Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Anesthetics; Animals; Biotransformation; Corpus Striatum; Dialysis; Dopamine; Extracellular Space; Homovanillic Acid; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra | 1992 |
Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors.
Topics: Animals; Animals, Newborn; Benzazepines; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Female; Levodopa; Motor Activity; Oxidopamine; Papaverine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Self Mutilation; Sympathectomy, Chemical; Tetrahydroisoquinolines | 1992 |
Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa.
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Female; Fetal Tissue Transplantation; Gliosis; Graft Survival; Immunohistochemistry; Levodopa; Mesencephalon; Neuroglia; Oxidopamine; Psychomotor Performance; Rats; Rats, Inbred Strains; Stereotaxic Techniques; Stereotyped Behavior; Sympathectomy, Chemical | 1992 |
Pavlovian conditioning of L-dopa induced movement.
Topics: Animals; Behavior, Animal; Conditioning, Classical; Dopamine; Levodopa; Male; Movement; Oxidopamine; Rats; Rats, Inbred Strains; Rotation; Sympathectomy, Chemical | 1992 |
Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist.
Topics: Animals; Biogenic Amines; Brain; Clonidine; Corpus Striatum; Dopamine; Dopamine Agents; Drug Interactions; Ergolines; Heart; Hypothalamus; Indoles; Levodopa; Male; Motor Activity; Norepinephrine; Oxidopamine; Pyridines; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Reserpine; Sulpiride | 1991 |
Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Animals; Brain Tissue Transplantation; Dopamine; Dopamine Agents; Dopamine Antagonists; Ergolines; Female; Fetal Tissue Transplantation; Levodopa; Male; Mesencephalon; Oxidopamine; Pregnancy; Quinpirole; Rats; Rats, Inbred F344; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Stereotyped Behavior; Sympathectomy, Chemical | 1991 |
Rapid reversal of denervation supersensitivity of dopamine D1 receptors by l-dopa or a novel dopamine D1 receptor agonist, A68930.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Chromans; Denervation; Dopamine Agents; Levodopa; Male; Motor Activity; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1 | 1991 |
Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.
Topics: Animals; Choline O-Acetyltransferase; Corpus Striatum; Drug Administration Schedule; Dynorphins; Enkephalins; Functional Laterality; Globus Pallidus; Glutamate Decarboxylase; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substance P; Substantia Nigra | 1991 |
Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Carbidopa; Corpus Striatum; Denervation; Drug Tolerance; Functional Laterality; Homovanillic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Rats; Rats, Inbred Strains; Substance Withdrawal Syndrome | 1991 |
Striatal D1 dopamine receptor morphochemistry following continuous or intermittent L-dopa replacement therapy.
Topics: Animals; Benserazide; Benzazepines; Corpus Striatum; Drug Administration Schedule; Hydroxydopamines; Levodopa; Male; Microscopy, Fluorescence; Myelin Sheath; Neurotoxins; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1 | 1991 |
Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aging; Analysis of Variance; Animals; Animals, Newborn; Apomorphine; Autoradiography; Corpus Striatum; Haloperidol; Hydroxydopamines; Levodopa; Mazindol; Motor Activity; Neurotoxins; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Stereotyped Behavior; Tritium | 1991 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Callithrix; Disease Models, Animal; Drug Synergism; Ibotenic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 1991 |
Naloxone reverses L-dopa induced overstimulation effects in a Parkinson's disease animal model analogue.
Topics: Animals; Carbidopa; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Male; Mesencephalon; Naloxone; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Time Factors | 1991 |
L-dopa stimulates the release of [3H]gamma-aminobutyric acid in the basal ganglia of 6-hydroxydopamine lesioned rats.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia; Benzazepines; Brain Chemistry; Dopamine Antagonists; gamma-Aminobutyric Acid; Hydrazines; Hydroxydopamines; In Vitro Techniques; Levodopa; Male; Nerve Degeneration; Oxidopamine; Potassium; Rats; Rats, Inbred Strains; Sulpiride; Sympathectomy, Chemical | 1991 |
The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
Topics: Animals; Apomorphine; Body Weight; Carbidopa; Corpus Striatum; Drinking; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Nervous System; Oxidopamine; Parkinson Disease; Rats; Rotation; Stereotyped Behavior; Time Factors | 1991 |
Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures.
Topics: Animals; Axons; Behavior, Animal; Carbidopa; Cell Survival; Cells, Cultured; Corpus Striatum; Growth Substances; Levodopa; Oxidopamine; Regression Analysis; Rotation; Tegmentum Mesencephali; Tissue Extracts | 1991 |
Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aggression; Animals; Antipsychotic Agents; Avoidance Learning; Benzazepines; Dopamine Antagonists; Female; Hydroxydopamines; Levodopa; Oxidopamine; Pregnancy; Raclopride; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides | 1990 |
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Dizocilpine Maleate; Dopamine Agents; Ergolines; Hydroxydopamines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereoisomerism; Stereotyped Behavior | 1990 |
The effects of L-dopa on in vitro dopamine release from striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Calcium; Corpus Striatum; Dopamine; Hydroxydopamines; In Vitro Techniques; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains | 1990 |
Origin of dopamine in the rat adrenal cortex.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenal Cortex; Animals; Dopamine; Epinephrine; Hydroxydopamines; Levodopa; Male; Monoamine Oxidase; Norepinephrine; Oxidopamine; Rats; Rats, Inbred Strains | 1990 |
Striatal L-dopa metabolism studied in vivo in rats with nigrostriatal lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra | 1990 |
Effect of acute levodopa on brain catecholamines after selective MAO and COMT inhibition in male rats.
Topics: Animals; Carbidopa; Catechol O-Methyltransferase; Catecholamines; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Hydroxydopamines; Hypothalamus; Levodopa; Male; Monoamine Oxidase; Neurotoxins; Oxidopamine; Rats; Rats, Inbred Strains | 1990 |
Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Electrophysiology; gamma-Aminobutyric Acid; Hydroxydopamines; Injections, Intravenous; Iontophoresis; Levodopa; Male; Neurons; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra; Sympathectomy, Chemical | 1990 |
Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats.
Topics: Animals; Catecholamines; Corpus Striatum; Dialysis; Dopamine; Extracellular Space; Hydroxydopamines; Levodopa; Male; Motor Activity; Nomifensine; Oxidopamine; Rats; Rats, Inbred Strains | 1990 |
The effect of L-dopa and carbidopa on behavioural recovery produced by ventral mesencephalic grafts in rats.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain Tissue Transplantation; Carbidopa; Corpus Striatum; Female; Fetal Tissue Transplantation; Hydroxydopamines; Levodopa; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1990 |
Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Corpus Striatum; Drug Interactions; Hydroxydopamines; Levodopa; Male; Morphine; Naltrexone; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Opioid | 1990 |
In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Corpus Striatum; Dopamine; Homovanillic Acid; Hydroxydopamines; Levodopa; Male; Neural Pathways; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Substantia Nigra; Synaptic Transmission | 1990 |
Nigrostriatal dopamine actions on the D2 receptors mediate methamphetamine effects on the striatonigral substance P system.
Topics: 5,7-Dihydroxytryptamine; alpha-Methyltyrosine; Animals; Corpus Striatum; Dopamine; Hydroxydopamines; Levodopa; Male; Methamphetamine; Methyltyrosines; Oxidopamine; Rats; Rats, Inbred Strains; Substance P; Substantia Nigra; Synaptic Transmission; Tryptophan Hydroxylase | 1986 |
L-dopa activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra.
Topics: Animals; Corpus Striatum; Globus Pallidus; Hydroxydopamines; Levodopa; Male; Oxidopamine; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred Strains; Substantia Nigra | 1989 |
Computerized rotometer apparatus for recording circling behavior.
Topics: Animals; Apomorphine; Carbidopa; Computers; Dextroamphetamine; Hydroxydopamines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Psychology, Experimental; Rats; Rats, Inbred Strains; Software; Stereotyped Behavior | 1989 |
Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agents; Hydroxydopamines; Levodopa; Male; Motor Activity; Neural Pathways; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra | 1989 |
Role of renal catecholamines in the control of sodium and water excretion: lack of natriuresis by endogenous dopamine in the rat kidney.
Topics: Animals; Body Water; Cyclic AMP; Epinephrine; Haloperidol; Hydroxydopamines; Kidney; Levodopa; Natriuresis; Norepinephrine; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Sodium; Sodium-Potassium-Exchanging ATPase | 1987 |
Differential effect of repeated treatment with L-dopa on dopamine-D1 or -D2 receptors.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Benzazepines; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone | 1986 |
Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Topics: Aged; Animals; Antiparkinson Agents; Brain; Enkephalin, Leucine; Female; Humans; Hydroxydopamines; Levodopa; Male; Middle Aged; MSH Release-Inhibiting Hormone; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Stereotyped Behavior | 1987 |
L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Female; Hydroxydopamines; Levodopa; Male; Mice; Movement Disorders; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Reserpine; Stereotyped Behavior | 1987 |
Dopamine receptor changes in response to prolonged treatment with L-dopa.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Benzazepines; Carbidopa; Corpus Striatum; Dopamine; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Spiperone; Stereotyped Behavior; Substantia Nigra; Sulpiride | 1986 |
Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-dopa without modifying its cardiovascular effects.
Topics: Allylamine; Amines; Animals; Blood Pressure; Brain; Decerebrate State; Dose-Response Relationship, Drug; Drug Synergism; Heart Rate; Hydroxydopamines; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Rats; Rats, Inbred Strains; Selegiline | 1986 |
Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Corpus Striatum; Denervation; Dialysis; Dopamine; Extracellular Space; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Reference Values | 1986 |
Suppressive effects of intraventricular injected dopamine and nomifensine on muricide induced by thiamine deficiency.
Topics: Aggression; Animals; Apomorphine; Dopamine; Hydroxydopamines; Injections, Intraventricular; Levodopa; Male; Mice; Nomifensine; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Thiamine Deficiency | 1987 |
Circling behavior in normoxic or hypoxic rats with unilateral 6-OHDA nigrostriatal lesion. Part 1. Effects of apomorphine and L-dopa.
Topics: Animals; Apomorphine; Corpus Striatum; Hydroxydopamines; Hypoxia; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1987 |
Circling behaviour in rats with unilateral lesions of the nigrostriatum induced by 6-hydroxydopamine: changes induced by oral administration of cytidine-5'-diphosphocholine.
Topics: Administration, Oral; Amphetamine; Animals; Apomorphine; Behavior, Animal; Choline; Corpus Striatum; Cytidine Diphosphate Choline; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra | 1987 |
Assessment of purine-dopamine interactions in 6-hydroxydopamine-lesioned rats: evidence for pre- and postsynaptic influences by adenosine.
Topics: Adenosine; Animals; Female; Hydroxydopamines; Hypoxanthine Phosphoribosyltransferase; Lesch-Nyhan Syndrome; Levodopa; Motor Activity; Oxidopamine; Pregnancy; Purines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Purinergic; Theophylline | 1988 |
In vivo voltammetric study of 6-hydroxydopamine-induced neuronal degradation.
Topics: Animals; Behavior, Animal; Brain; Corpus Striatum; Dopamine; Electrochemistry; Hydroxydopamines; Injections, Intraventricular; Levodopa; Male; Neurons; Oxidopamine; Rats; Rats, Inbred Strains | 1988 |
Antagonization of the behavioral activation produced by direct stimulation of forebrain dopamine receptors caused by intraaccumbens injections of neurotensin.
Topics: Animals; Ascorbic Acid; Brain; Dopamine; Hydroxydopamines; Injections; Levodopa; Male; Motor Activity; Neurotensin; Norepinephrine; Nucleus Accumbens; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Septal Nuclei; Stereotyped Behavior | 1988 |
A pre-positron emission tomography study of L-3,4-dihydroxy-[3H]phenylalanine distribution in the rat.
Topics: Animals; Apomorphine; Autoradiography; Brain; Corpus Striatum; Desipramine; Dopamine; Hydroxydopamines; Levodopa; Male; Oxidopamine; Rats; Rats, Inbred Strains; Substantia Nigra; Tissue Distribution; Tomography, Emission-Computed | 1985 |
Influences of catecholamines on growth hormone release in female goldfish, Carassius auratus.
Topics: alpha-Methyltyrosine; Animals; Apomorphine; Carbidopa; Catecholamines; Cyprinidae; Dopamine; Female; Goldfish; Growth Hormone; Hydroxydopamines; Levodopa; Methyltyrosines; Norepinephrine; Oxidopamine; Phentolamine; Preoptic Area | 1985 |
Simple method for evaluation of stimulatory effect of drugs on presynaptic dopamine receptors in mice.
Topics: Animals; Apomorphine; Haloperidol; Hydrazines; Hydroxydopamines; Levodopa; Male; Mice; Mice, Inbred Strains; Oxidopamine; Receptors, Dopamine | 1985 |
Relationship between catechol-O-methyltransferase and phenolsulfotransferase in the metabolism of dopamine in the rat brain.
Topics: Animals; Arylsulfotransferase; Brain; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Dopamine; Hydroxydopamines; Kinetics; Levodopa; Male; Oxidopamine; Pargyline; Pyrogallol; Rats; Rats, Inbred Strains; Sulfurtransferases; Tranylcypromine; Tropolone | 1985 |
Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Benzazepines; Dihydroxyphenylalanine; Drug Interactions; Ergolines; Female; Flupenthixol; Haloperidol; Hydroxydopamines; Levodopa; Male; Motor Activity; Oxidopamine; Pregnancy; Quinpirole; Rats; Receptors, Dopamine; Self Mutilation; Stereotyped Behavior | 1985 |
Disappearance of hoarding behavior after 6-hydroxydopamine lesions of the mesolimbic dopamine neurons and its reinstatement with L-dopa.
Topics: Animals; Behavior, Animal; Body Weight; Brain Mapping; Dopamine; Drinking Behavior; Feeding Behavior; Hydroxydopamines; Levodopa; Limbic System; Male; Mesencephalon; Motor Activity; Oxidopamine; Rats; Rats, Inbred Strains | 1985 |
Deterioration of axonal membranes induced by phenolic pro-oxidants. Roles of superoxide radicals and hydrogen peroxide.
Topics: Animals; Astacoidea; Axons; Catalase; Electric Conductivity; Electric Stimulation; Hydrogen Peroxide; Hydroxydopamines; Levodopa; Nerve Degeneration; Oxidopamine; Superoxide Dismutase; Superoxides | 1984 |
Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
Topics: Age Factors; Animals; Antipsychotic Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine beta-Hydroxylase; Dose-Response Relationship, Drug; Female; Humans; Hydroxydopamines; Lesch-Nyhan Syndrome; Levodopa; Motor Activity; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Dopamine; Serotonin | 1984 |
[Changes in the dopamine content in the brain of Periplaneta americana L. after application of structural analogs of dopamine and reserpine].
Topics: alpha-Methyltyrosine; Animals; Brain; Cockroaches; Dopamine; Fenclonine; Hydroxydopamines; Kinetics; Levodopa; Methyltyrosines; Oxidopamine; Reserpine; Structure-Activity Relationship | 1983 |
Deficits in locomotor behaviour and motor performance after central 6-hydroxydopamine or peripheral L-DOPA.
Topics: Animals; Fluorescent Antibody Technique; Hydroxydopamines; Injections, Intraperitoneal; Injections, Intraventricular; Levodopa; Locomotion; Male; Motor Activity; Oxidopamine; Rats; Rats, Inbred Strains | 1983 |
Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; Hydroxydopamines; Kinetics; Levodopa; Male; Membranes; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Strains; Receptors, Dopamine; Spiperone; Stereotyped Behavior; Substantia Nigra | 1984 |
Neonatal-6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome.
Topics: Age Factors; Animals; Animals, Newborn; Disease Models, Animal; Humans; Hydroxydopamines; Lesch-Nyhan Syndrome; Levodopa; Male; Oxidopamine; Rats; Receptors, Dopamine; Self Mutilation | 1984 |
Effect of l-dopa or bromocriptine on feeding and motor behavior of rats with lesions in the globus pallidus.
Topics: Animals; Body Weight; Brain Mapping; Bromocriptine; Carbidopa; Drinking; Eating; Globus Pallidus; Hydroxydopamines; Levodopa; Male; Motor Activity; Neural Pathways; Oxidopamine; Rats; Receptors, Dopamine; Sex Factors | 1984 |
Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats.
Topics: Animals; Clorgyline; Dopamine; Humans; Hydroxydopamines; Isomerism; Levodopa; Male; Oxidopamine; Phenethylamines; Rats; Rats, Inbred Strains; Selegiline; Stereotyped Behavior; Substantia Nigra | 1981 |
[Effect of d-pseudoephedrine on the central nervous system in mice].
Topics: Animals; Body Temperature; Central Nervous System; Drug Synergism; Ephedrine; Hydroxydopamines; Injections, Intraperitoneal; Levodopa; Locomotion; Male; Mice; Oxidopamine; Pentobarbital; Sleep | 1982 |
Mesencephalic grafts partially restore normal nigral dynorphin levels in 6-hydroxydopamine-lesioned rats treated chronically with L-dihydroxyphenylalanine.
Topics: Amphetamine; Animals; Apomorphine; Brain Tissue Transplantation; Dihydroxyphenylalanine; Dopamine Agents; Dopamine Agonists; Dynorphins; Female; Fetal Tissue Transplantation; Image Processing, Computer-Assisted; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 1995 |
L-DOPA metabolism in cortical and striatal tissues in an animal model of parkinsonism.
Topics: Animals; Dopamine; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Stereotaxic Techniques; Tyrosine | 1995 |
Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat.
Topics: Animals; Base Sequence; Behavior, Animal; Carbidopa; Enkephalins; Female; Gene Expression Regulation, Enzymologic; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Molecular Sequence Data; Neostriatum; Oligonucleotide Probes; Oxidopamine; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Tachykinins | 1995 |
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanillic Acid; Indans; Levodopa; Male; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 1995 |
Activation of dopamine cell firing by repeated L-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to L-DOPA treatment.
Topics: Animals; Dopamine; Electrophysiology; Levodopa; Male; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1995 |
Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats.
Topics: Acetylcholine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; GTP Phosphohydrolases; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1995 |
Effect of repeated electroconvulsive shock on striatal L-dopa and dopamine metabolism: an in vivo study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Corpus Striatum; Dopamine; Electroshock; Extracellular Space; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1993 |
Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms.
Topics: Animals; Base Sequence; Behavior, Animal; Capsules; Cell Line; Cloning, Molecular; Corpus Striatum; Dopamine; Drug Implants; Glial Cell Line-Derived Neurotrophic Factor; Kidney; Levodopa; Male; Molecular Sequence Data; Nerve Growth Factors; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease; PC12 Cells; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 1995 |
Effects of L-dopa on cholecystokinin octapeptide tissue levels in normal and 6-hydroxydopamine-treated rat brain.
Topics: Animals; Brain Chemistry; Dopamine; Levodopa; Male; Oxidopamine; Radioimmunoassay; Rats; Rats, Wistar; Sincalide; Sulpiride | 1995 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Disease Models, Animal; Dopamine; Dopamine Agonists; Ergolines; Female; Fetal Tissue Transplantation; Forelimb; Functional Laterality; Levodopa; Motor Activity; Movement Disorders; Norepinephrine; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Transplantation, Heterotopic | 1995 |
'Priming' enhances the relationship of striatal L-dopa concentration to behavior.
Topics: Animals; Behavior, Animal; Brain Chemistry; Dopamine; Homovanillic Acid; Levodopa; Male; Neostriatum; Oxidopamine; Rats; Rats, Sprague-Dawley; Stereotaxic Techniques | 1994 |
Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro.
Topics: Animals; Bromocriptine; Carbidopa; Corpus Striatum; Desipramine; Dopamine; Free Radical Scavengers; Hydroxyl Radical; Injections, Intraventricular; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine | 1994 |
Behavioural sensitization in 6-hydroxydopamine lesioned rats involves the dopamine signal transduction: changes in DARPP-32 phosphorylation.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Autoradiography; Behavior, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Electrophoresis, Polyacrylamide Gel; Immunoblotting; Levodopa; Male; Nerve Tissue Proteins; Oxidopamine; Phosphoproteins; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Signal Transduction; Sympathectomy, Chemical | 1994 |
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.
Topics: Amphetamine; Animals; Apomorphine; Denervation; Immunohistochemistry; Levodopa; Male; Medial Forebrain Bundle; Movement; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Tyrosine 3-Monooxygenase | 1994 |
Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats.
Topics: Animals; Behavior, Animal; Fetal Tissue Transplantation; Levodopa; Male; Mesencephalon; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotation; Selegiline; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase | 1994 |
Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats.
Topics: Animals; Dizocilpine Maleate; Dose-Response Relationship, Drug; Gene Expression; Genes, fos; Immunohistochemistry; Levodopa; Male; Neostriatum; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Scopolamine; Stereotyped Behavior | 1994 |
Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Brain Diseases; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Levodopa; Male; Motor Activity; N-Methylaspartate; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1993 |
Evidence for L-dopa relevant to modulation of sympathetic activity in the rostral ventrolateral medulla of rats.
Topics: alpha-Methyltyrosine; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Blood Pressure; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Electrochemistry; Heart Rate; Hydrazines; Levodopa; Medulla Oblongata; Methyltyrosines; Microdialysis; Microinjections; Oxidopamine; Rats; Rats, Wistar; Sympathetic Nervous System; Tyrosine 3-Monooxygenase | 1993 |
Effect of bilateral 6-OHDA lesions of the substantia nigra on locomotor activity in the rat.
Topics: Amphetamine; Animals; Apomorphine; Body Weight; Immunohistochemistry; Levodopa; Male; Motor Activity; Nerve Fibers; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Substantia Nigra; Tyrosine 3-Monooxygenase | 1994 |
Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine; Animals; Antihypertensive Agents; Autoradiography; Basal Ganglia; Benserazide; Binding Sites; Dopamine Agents; Ergolines; Levodopa; Male; Neural Pathways; Neurons; Oxidopamine; Phenethylamines; Quinolinic Acid; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Purinergic P1; Stereotyped Behavior | 1994 |
Estradiol increases tyrosine hydroxylase activity of the A15 nucleus dopaminergic neurons during long days in the ewe.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Dialysis; Dopamine; Estradiol; Female; Homovanillic Acid; Hypothalamus; Levodopa; Luteinizing Hormone; Neurons; Nomifensine; Norepinephrine; Ovariectomy; Oxidopamine; Photoperiod; Sheep; Tyrosine 3-Monooxygenase | 1994 |
Non-effective dose of exogenously applied L-dopa itself stereoselectively potentiates postsynaptic D2 receptor-mediated locomotor activities of conscious rats.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Desipramine; Dopamine Agents; Ergolines; Hydrazines; Injections, Intraventricular; Levodopa; Male; Microdialysis; Motor Activity; Nerve Fibers; Oxidopamine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereoisomerism | 1994 |
A 6-hydroxydopamine-induced selective parkinsonian rat model: further biochemical and behavioral characterization.
Topics: Amphetamine; Animals; Brain; Carbidopa; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Combinations; Functional Laterality; Immunohistochemistry; Levodopa; Male; Mesencephalon; Models, Neurological; Motor Activity; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Tyrosine 3-Monooxygenase | 1994 |
Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Biotransformation; Corpus Striatum; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Homovanillic Acid; Levodopa; Male; Microdialysis; Nomifensine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Tetrodotoxin | 1994 |
6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Calcium-Calmodulin-Dependent Protein Kinases; Cells, Cultured; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Dopamine; Embryo, Mammalian; Ergolines; Gene Expression; Genes, fos; Levodopa; Male; Neurons; Oxidopamine; Phosphorylation; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Substantia Nigra | 1994 |
3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
Topics: Animals; Apomorphine; Carbidopa; Catechol O-Methyltransferase Inhibitors; Corpus Striatum; Levodopa; Male; Methyldopa; Motor Activity; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra | 1994 |
The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat--an autoradiographic study.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Benzazepines; Dopamine; Levodopa; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior; Sulpiride | 1994 |
Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Autoradiography; Brain; Carbon Radioisotopes; Deoxyglucose; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Organ Specificity; Oxidopamine; Quinoxalines; Rats; Rats, Sprague-Dawley | 1994 |
L-dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation.
Topics: Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympathectomy, Chemical; Uric Acid; Ventral Tegmental Area | 1994 |
Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Homovanillic Acid; Levodopa; Lipid Peroxidation; Male; Mice; Mice, Inbred ICR; Nerve Tissue Proteins; Neurons; Oxidopamine; Thiobarbituric Acid Reactive Substances | 1994 |
A model system to determine the effects of specific neurotransmitters on segmental reflexes in the spinal cord of the rat.
Topics: Animals; Clonidine; Decerebrate State; Dopamine; Electromyography; Electrophysiology; Female; Hindlimb; Levodopa; Models, Neurological; Muscle Contraction; Nerve Fibers; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Phentolamine; Rats; Rats, Sprague-Dawley; Reflex; Spinal Cord; Sympathectomy, Chemical | 1993 |
Long-term correction of rat model of Parkinson's disease by gene therapy.
Topics: Animals; Animals, Newborn; Apomorphine; Brain; Cells, Cultured; Dopamine; Drug Carriers; Female; Genetic Therapy; Levodopa; Motor Activity; Muscles; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylethanolamines; Plasmids; Rats; Rats, Sprague-Dawley; Time Factors; Transplantation, Heterotopic; Tyrosine 3-Monooxygenase | 1993 |
Rotations induced by L-dopa in parkinsonian rats are reduced by an ingestion of amino acids.
Topics: Amino Acids; Animals; Levodopa; Male; Neostriatum; Neural Pathways; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotation; Stereotyped Behavior; Substantia Nigra | 1993 |
L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Levodopa; Male; Monoamine Oxidase Inhibitors; Nerve Endings; Oxidopamine; Picolinic Acids; Rats; Rats, Sprague-Dawley; Selegiline | 1994 |
A fetal nigral graft prevents behavioral supersensitivity associated with repeated injections of L-dopa in 6-OHDA rats. Correlation with D1 and D2 receptors.
Topics: Animals; Brain Tissue Transplantation; Corpus Striatum; Female; Fetal Tissue Transplantation; Levodopa; Mesencephalon; Motor Activity; Neurons; Ovariectomy; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra | 1993 |
Impact of L-dopa on striatal acetylcholine release: effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Corpus Striatum; Dopamine; Extracellular Space; Levodopa; Male; Neurons; Nomifensine; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 1993 |
The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls.
Topics: Biogenic Monoamines; Dopamine; Gas Chromatography-Mass Spectrometry; Humans; Hydroxydopamines; Levodopa; Norepinephrine; Oxidopamine; Parkinson Disease; Tyramine | 1993 |
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyclic AMP; Disease Models, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred F344; Receptors, Dopamine D1; Receptors, Dopamine D2; Sensitivity and Specificity; Substantia Nigra; Time Factors | 1993 |
Transmitter-like L-3,4-dihydroxyphenylalanine tonically functions to mediate vasodepressor control in the caudal ventrolateral medulla of rats.
Topics: Animals; Blood Pressure; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dopamine; Electrochemistry; Hemodynamics; Levodopa; Male; Medulla Oblongata; Microdialysis; Microinjections; Norepinephrine; Oxidopamine; Rats; Rats, Wistar; Stereotaxic Techniques | 1993 |
Chronic continuous and intermittent L-3,4-dihydroxyphenylalanine treatments differentially affect basal ganglia function in 6-hydroxydopamine lesioned rats--an autoradiographic study using [3H]flunitrazepam.
Topics: Animals; Autoradiography; Basal Ganglia; Behavior, Animal; Brain; Flunitrazepam; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Time Factors; Tissue Distribution; Tritium | 1993 |
[The effect of L-DOPA and 6-hydroxydopamine on the intracellular cAMP level in the kidneys of rats with impaired neurotrophic support of the organs].
Topics: Adrenalectomy; Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Cyclic AMP; Kidney; Levodopa; Male; Mineralocorticoids; Oxidopamine; Rats; Receptors, Mineralocorticoid; Receptors, Steroid; Sciatic Nerve; Time Factors | 1993 |
Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra.
Topics: Animals; Brain; Corpus Striatum; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1993 |
Differential effect of systemic administration of bromocriptine and L-dopa on the release of acetylcholine from striatum of intact and 6-OHDA-treated rats.
Topics: Acetylcholine; Animals; Bromocriptine; Corpus Striatum; Dialysis; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar | 1993 |
Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET.
Topics: Animals; Binding, Competitive; Corpus Striatum; Dopamine Antagonists; Dose-Response Relationship, Drug; Levodopa; Male; Microdialysis; Oxidopamine; Raclopride; Rats; Rats, Sprague-Dawley; Salicylamides; Time Factors | 1995 |
MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Ergolines; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Stereotyped Behavior; Sympatholytics | 1995 |
L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats.
Topics: Acetylcholine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Synergism; Ergolines; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes | 1995 |
Uridine reduces rotation induced by L-dopa and methamphetamine in 6-OHDA-treated rats.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Haloperidol; Levodopa; Male; Methamphetamine; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotation; Uridine | 1995 |
Dopaminergic transplants alter in vivo activity of tryptophan hydroxylase in the striatum in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Female; Fetal Tissue Transplantation; Levodopa; Mesencephalon; Microdialysis; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Tryptophan Hydroxylase | 1996 |
Dose-related effects of continuous levodopa infusion in rats with unilateral lesions of the substantia nigra.
Topics: Animals; Dopamine Agents; Dose-Response Relationship, Drug; Functional Laterality; Infusion Pumps, Implantable; Levodopa; Male; Oxidopamine; Random Allocation; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1996 |
Dopaminergic transplants suppress L-DOPA-induced Fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Topics: Animals; Brain Tissue Transplantation; Caudate Nucleus; Corpus Striatum; Dizocilpine Maleate; Dopamine; Female; Fetal Tissue Transplantation; Levodopa; Mesencephalon; Methamphetamine; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 1996 |
Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: implication for treatment of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Dopamine; Injections, Subcutaneous; Levodopa; Male; Mice; Mice, Inbred C57BL; Neostriatum; Oxidopamine; Prodrugs; Rats; Stereotyped Behavior; Sympatholytics | 1996 |
Skilled motor deficits in rats induced by ventrolateral striatal dopamine depletions: behavioral and pharmacological characterization.
Topics: Analysis of Variance; Animals; Brain Mapping; Conditioning, Operant; Corpus Striatum; Dopamine; Levodopa; Male; Motor Activity; Nucleus Accumbens; Oxidopamine; Rats; Rats, Sprague-Dawley; Reaction Time | 1996 |
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benserazide; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Injections; Injections, Intraventricular; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Stereotyped Behavior; Substantia Nigra | 1995 |
Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice.
Topics: Animals; Carrier Proteins; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Drug Synergism; Electrochemistry; In Vitro Techniques; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Neostriatum; Nerve Tissue Proteins; Neurons; Oxidopamine; Substantia Nigra; Sympatholytics; Synaptosomes | 1995 |
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Dizocilpine Maleate; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Rotation | 1996 |
Chronic L-dopa alters striatal NMDA receptors in rats with dopaminergic injury.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 1996 |
L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympathectomy, Chemical | 1996 |
Self-injurious behavior and dopaminergic neuron system in neonatal 6-hydroxydopamine-lesioned rat: 2. Intracerebral microinjection of dopamine agonists and antagonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Animals, Newborn; Benzazepines; Brain; Caudate Nucleus; Dopamine Agonists; Dopamine Antagonists; Female; Functional Laterality; Levodopa; Microinjections; Neurons; Nucleus Accumbens; Oxidopamine; Pregnancy; Putamen; Rats; Rats, Wistar; Self Mutilation; Substantia Nigra | 1997 |
Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Behavior, Animal; Brain Diseases; Dopamine Agonists; Drug Synergism; Gene Expression; Genes, fos; Levodopa; Male; Oxidopamine; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Dopamine D2; Substantia Nigra; Triazoles | 1997 |
Intrastriatal grafting of Cos cells stably expressing human aromatic L-amino acid decarboxylase: neurochemical effects.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; COS Cells; Denervation; Dopamine; Dopamine Agents; Female; Gene Expression Regulation, Enzymologic; Humans; Levodopa; Neostriatum; Oxidopamine; Rats; Rats, Sprague-Dawley; Sympatholytics; Transfection | 1997 |
Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task.
Topics: Animals; Antiparkinson Agents; Appetitive Behavior; Brain Mapping; Carbidopa; Corpus Striatum; Dominance, Cerebral; Dopamine; Drug Combinations; Levodopa; Male; Mental Recall; Motor Skills; Oxidopamine; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Reinforcement Schedule | 1997 |
Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Autoradiography; Biomarkers; Carbidopa; Female; Functional Laterality; Immunohistochemistry; Levodopa; Motor Activity; Neurons; Neurotoxins; Oxidopamine; Radioimmunoassay; Rats; Rats, Wistar; Substantia Nigra; Sulfur Radioisotopes; Tegmentum Mesencephali; Tyrosine 3-Monooxygenase | 1997 |
Effect of L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats.
Topics: Animals; Benserazide; Drug Interactions; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Visual Cortex | 1997 |
Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat.
Topics: Animals; Corpus Striatum; Enkephalins; Female; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Oxidopamine; Protein Precursors; Rats; Rats, Wistar; Tachykinins; Time Factors | 1997 |
Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue.
Topics: Animals; Benzazepines; Corpus Striatum; Cyclic AMP; Dopamine; Dopamine Agonists; In Vitro Techniques; Levodopa; Male; Oxidopamine; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D1 | 1997 |
Modulation of dopamine receptor agonist-induced rotational behavior in 6-OHDA-lesioned rats by a peptidomimetic analogue of Pro-Leu-Gly-NH2 (PLG).
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Brain; Dopamine; Dopamine Agonists; Drug Synergism; Levodopa; Male; MSH Release-Inhibiting Hormone; Oxidopamine; Pyrrolidinones; Quinpirole; Rats; Rats, Sprague-Dawley; Stereotyped Behavior | 1997 |
Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.
Topics: Animals; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Enzyme Inhibitors; Levodopa; Male; Monoamine Oxidase Inhibitors; Motor Activity; Nitrophenols; Oxidopamine; Picolinic Acids; Rats; Rotation; Thiazoles; Tolcapone | 1997 |
Evaluation of risperidone in the neonatal 6-hydroxydopamine model of Lesch-Nyhan syndrome.
Topics: Animals; Animals, Newborn; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Lesch-Nyhan Syndrome; Levodopa; Male; Motor Activity; Oxidopamine; Rats; Rats, Sprague-Dawley; Risperidone; Self Mutilation; Sympatholytics | 1998 |
Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Cell Nucleus; Corpus Striatum; Denervation; Dizocilpine Maleate; Gene Expression Regulation; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Transcription Factor AP-1 | 1997 |
Effects of repeated administration of l-DOPA and apomorphine on circling behavior and striatal dopamine formation.
Topics: Animals; Apomorphine; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Dopamine Agonists; Electrochemistry; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra | 1998 |
The role of dopamine in the expression of morphine withdrawal.
Topics: Adrenergic Agents; Analgesia; Analgesics, Opioid; Analysis of Variance; Animals; Apomorphine; Dopamine; Dopamine Agents; Dopamine Antagonists; Hypothermia; Levodopa; Male; Mice; Morphine; Naloxone; Narcotic Antagonists; Oxidopamine; Substance Withdrawal Syndrome | 1998 |
Serotonergic activity in the rat striatum after intrastriatal transplantation of fetal nigra as measured by microdialysis.
Topics: 5-Hydroxytryptophan; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Enzyme Inhibitors; Female; Fetal Tissue Transplantation; Hydrazines; Hydroxyindoleacetic Acid; Levodopa; Microdialysis; Oxidopamine; Rats; Rats, Wistar; Serotonin; Substantia Nigra; Transplantation, Heterotopic | 1998 |
Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Brain Tissue Transplantation; Carrier Proteins; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Fetal Tissue Transplantation; Functional Laterality; Haloperidol; Homovanillic Acid; Kinetics; Levodopa; Mazindol; Membrane Glycoproteins; Membrane Transport Proteins; Mesencephalon; Methamphetamine; Microdialysis; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotation; Tritium; Tyrosine 3-Monooxygenase | 1998 |
Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carrier Proteins; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Female; Iodine Radioisotopes; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Fibers; Nerve Tissue Proteins; Neuropeptides; Neurotransmitter Agents; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Radioimmunoassay; Rats; Rats, Wistar; Substantia Nigra; Sulpiride; Sympatholytics; Tyrosine 3-Monooxygenase; Ventral Tegmental Area; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 1998 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Clonidine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Levodopa; Lisuride; Locomotion; Male; Mazindol; Methoxydimethyltryptamines; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley; Sympatholytics; Tritium; Yohimbine | 1998 |
Circling behaviour in 6-hydroxydopamine-lesioned rats given pulsed levodopa is reduced more by lesions in the entopeduncular nucleus/substantia nigra pars reticulata than in the subthalamic nucleus.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Apomorphine; Benserazide; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Quinolinic Acid; Rats; Rats, Wistar; Substantia Nigra; Thalamic Nuclei | 1998 |
Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Biotransformation; Corpus Striatum; Decarboxylation; Dopamine; Drug Interactions; Homovanillic Acid; Levodopa; Male; Microdialysis; Muscarinic Antagonists; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra; Trihexyphenidyl | 1998 |
L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.
Topics: Animals; Autoradiography; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Glutamate Decarboxylase; In Situ Hybridization; Levodopa; Oxidopamine; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; RNA, Messenger; Tachykinins | 1998 |
Reevaluation of the striatal role in the expression of turning behavior in the rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Lidocaine; Male; Motor Activity; Organ Specificity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Tyrosine 3-Monooxygenase | 1998 |
Priming with L-DOPA differently affects dynorphin and substance P mRNA levels in the striatum of 6-hydroxydopamine-lesioned rats after challenge with dopamine D1-receptor agonist.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Brain; Corpus Striatum; Dynorphins; Injections, Intraperitoneal; Injections, Subcutaneous; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Receptors, Dopamine D1; RNA, Messenger; Stereotaxic Techniques; Substance P | 1998 |
Loss of regulation by presynaptic dopamine D2 receptors of exogenous L-DOPA-derived dopamine release in the dopaminergic denervated striatum.
Topics: Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Male; Microdialysis; Neurotoxins; Oxidopamine; Presynaptic Terminals; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D2 | 1999 |
Effects of single and multiple treatments with L-dihydroxyphenylalanine (L-DOPA) on dopamine receptor-G protein interactions and supersensitive immediate early gene responses in striata of rats after reserpine treatment or with unilateral nigrostriatal le
Topics: Animals; DNA-Binding Proteins; Dopamine Agents; Early Growth Response Protein 1; Gene Expression Regulation; Genes, Immediate-Early; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Immediate-Early Proteins; In Situ Hybridization; Levodopa; Male; Neostriatum; Oxidopamine; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Reserpine; Substantia Nigra; Sympatholytics; Transcription Factors; Zinc Fingers | 1999 |
Catecholaminergic mechanisms-mediated hypothermia induced by magnolol in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; alpha-Methyltyrosine; Animals; Anti-Anxiety Agents; Biphenyl Compounds; Body Temperature; Catecholamines; Colon; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epinephrine; Homovanillic Acid; Hypothalamus; Hypothermia, Induced; Injections, Intraperitoneal; Injections, Intraventricular; Levodopa; Lignans; Male; Norepinephrine; Oxidopamine; Rats; Rats, Sprague-Dawley | 1998 |
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antibodies; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Dopamine; Dopamine Agonists; Enzyme Inhibitors; Levodopa; Male; Motor Neurons; Nerve Degeneration; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Phosphoserine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Serine; Sulfonamides; Sympatholytics | 1999 |
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Autoradiography; Behavior, Animal; Bromocriptine; Dopamine Agents; Dopamine Agonists; Dopamine Uptake Inhibitors; Enkephalins; In Situ Hybridization; Levodopa; Lisuride; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oligonucleotide Probes; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1999 |
Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats.
Topics: Animals; Biological Transport; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Extracellular Space; Levodopa; Male; Microdialysis; Nerve Degeneration; Oxidopamine; Piperazines; Rats; Rats, Sprague-Dawley; Sympathomimetics; Tetrodotoxin | 1999 |
Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Dopamine Agents; Extracellular Space; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Rats; Rats, Wistar; Rotation; Serotonin; Serotonin Agents; Stereotyped Behavior | 1999 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Synergism; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Microdialysis; Motor Activity; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Pergolide; Rats; Rats, Wistar | 1999 |
Increased striatal expression of glutamate decarboxylase 67 after priming of 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation, Enzymologic; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; RNA, Messenger; Time Factors; Transcription, Genetic | 1999 |
Acute interactions between L-DOPA and the neurotoxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine in mice.
Topics: 1-Methyl-4-phenylpyridinium; Analysis of Variance; Animals; Biological Transport; Drug Interactions; Hypothalamus; Injections, Intraventricular; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Neuropeptides; Neurotoxins; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 1999 |
[Intracerebral transplantation of genetically modified cells for Parkinson's disease].
Topics: 3T3 Cells; Animals; Corpus Striatum; Fetal Tissue Transplantation; Gene Transfer Techniques; Genetic Therapy; Levodopa; Mice; Oxidopamine; Parkinson Disease, Secondary; Rats; Tyrosine 3-Monooxygenase | 1997 |
Increased [125I]sulpiride binding in the subthalamic nucleus of rats with nigrostriatal lesions.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Brain Mapping; Corpus Striatum; Dopamine; Dopamine Antagonists; Female; Iodine Radioisotopes; Levodopa; Neurons; Oxidopamine; Radioligand Assay; Rats; Rats, Wistar; Substantia Nigra; Sulpiride; Thalamic Nuclei | 1999 |
Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia.
Topics: Animals; Basal Ganglia; Corpus Striatum; Denervation; Dizocilpine Maleate; Dopamine; Electron Transport Complex IV; Excitatory Amino Acid Antagonists; Glutamate Decarboxylase; Isoquinolines; Levodopa; Male; N-Methylaspartate; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, AMPA; RNA, Messenger; Substantia Nigra; Tetrazoles | 1999 |
Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines.
Topics: Animals; Antiparkinson Agents; Drug Synergism; Electrophysiology; Excitatory Amino Acid Antagonists; In Vitro Techniques; Levodopa; Male; Oocytes; Oxidopamine; Phenols; Piperidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Xenopus laevis | 1999 |
Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction.
Topics: Animals; Brain Chemistry; Corpus Striatum; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha | 1999 |
Narrow beneficial effect of dextromethorphan on levodopa-induced motor response alterations in an experimental model of parkinsonism.
Topics: Animals; Antiparkinson Agents; Dextromethorphan; Disease Models, Animal; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Treatment Outcome | 1999 |
Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.
Topics: Animals; Disease Models, Animal; Imidazoles; Levodopa; Ligands; Molecular Structure; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Pyrroles; Rats; Receptors, N-Methyl-D-Aspartate | 1999 |
Buprenorphine potentiates L-DOPA-induced contralateral rotation in 6-hydroxydopamine-treated rats.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Benserazide; Buprenorphine; Drug Synergism; Injections, Intraventricular; Levodopa; Male; Motor Activity; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Opioid | 1999 |
Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment.
Topics: Animals; Corpus Striatum; Denervation; Dopamine; Drug Administration Schedule; Exploratory Behavior; Female; Functional Laterality; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley | 1999 |
Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Denervation; Dopamine; Extracellular Space; Homovanillic Acid; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Reserpine; Substantia Nigra | 2000 |
Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dopamine Agents; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; RNA, Messenger; Tyrosine 3-Monooxygenase | 1999 |
Antioxidants protect against dopamine-induced metallothionein-III (GIF) mRNA expression in mouse glial cell line (VR-2g).
Topics: Adrenergic Agents; Adrenergic alpha-Agonists; Animals; Antioxidants; Ascorbic Acid; Cell Line; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Glutathione; Glycerol-3-Phosphate Dehydrogenase (NAD+); Glycerolphosphate Dehydrogenase; Levodopa; Metallothionein; Mice; Neuroglia; Norepinephrine; Oxidopamine; Protein Isoforms; Receptors, Dopamine D1; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vitamin E | 2000 |
Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Membrane; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2000 |
Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Inbred F344; Rotation; Substantia Nigra; Sympatholytics | 2000 |
Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.
Topics: Adamantane; Animals; Apomorphine; Benzazepines; Benzopyrans; Callithrix; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Quinpirole; Rotation | 2000 |
L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion.
Topics: Animals; Cerebellum; Corpus Striatum; Gentisates; Hydroxybenzoates; Hydroxyl Radical; Injections; Levodopa; Male; Mesencephalon; Methamphetamine; Microdialysis; Osmolar Concentration; Oxidopamine; Rats; Rats, Sprague-Dawley; Salicylates; Substantia Nigra | 2000 |
5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Disease Models, Animal; Dopamine Agonists; Indoles; Levodopa; Locomotion; Male; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Serotonin; Serotonin Antagonists | 2000 |
Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Cocaine; Denervation; Disease Models, Animal; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Phenotype; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Rotation; Substantia Nigra; Sympatholytics; Tritium | 2000 |
Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity.
Topics: 1-Methyl-4-phenylpyridinium; Amphetamine; Animals; Apomorphine; Autoradiography; Carrier Proteins; Cocaine; Corpus Striatum; Cytoprotection; Dopamine Plasma Membrane Transport Proteins; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Microinjections; Motor Activity; Nerve Tissue Proteins; Oligonucleotides, Antisense; Oxidopamine; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Tritium | 2000 |
Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzazepines; Binding, Competitive; Corpus Striatum; Denervation; Dizocilpine Maleate; Dopamine Agonists; Dopamine Antagonists; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression; Levodopa; Male; Neural Pathways; Neurons; Opioid Peptides; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Sympatholytics; Tachykinins; Tetrahydronaphthalenes; Tritium; Ventral Tegmental Area | 2000 |
The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment.
Topics: Animals; Calbindin 2; Calcium-Binding Proteins; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Immunohistochemistry; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Microinjections; Neuropil; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; S100 Calcium Binding Protein G; Tyrosine 3-Monooxygenase | 2000 |
Repeated administration of high dose levodopa enhances hydroxyl radical production in the rat striatum denervated with 6-hydroxydopamine.
Topics: Animals; Corpus Striatum; Denervation; Drug Administration Schedule; Female; Hydroxyl Radical; Injections, Intraperitoneal; Levodopa; Oxidopamine; Rats; Rats, Wistar | 2000 |
Disruption of acquisition and performance of operant response-duration differentiation by unilateral nigrostriatal lesions.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Conditioning, Operant; Corpus Striatum; Dopamine Agents; Histocytochemistry; Image Processing, Computer-Assisted; Levodopa; Male; Oxidopamine; Rats; Rats, Long-Evans; Reinforcement Schedule; Stereotaxic Techniques; Stereotyped Behavior; Substantia Nigra; Sympathectomy, Chemical; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2000 |
Enhancement of the acoustic startle response by dopamine agonists after 6-hydroxydopamine lesions of the substantia nigra pars compacta: corresponding changes in c-Fos expression in the caudate-putamen.
Topics: Acoustic Stimulation; Animals; Benzazepines; Caudate Nucleus; Dopamine Agonists; Gene Expression Regulation; Genes, fos; Levodopa; Male; Oxidopamine; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; Reflex, Startle; Substantia Nigra | 2000 |
L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.
Topics: Animals; Benzazepines; Blotting, Western; Callithrix; Cerebral Cortex; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Antagonists; Enkephalins; Gene Expression; Genes, Immediate-Early; Levodopa; Nerve Degeneration; Oxidopamine; Parkinson Disease; Protein Precursors; Proto-Oncogene Proteins c-fos; Raclopride; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger; Substance P; Substantia Nigra; Sympatholytics; Tritium | 2000 |
Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Dextroamphetamine; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Pyridines; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; Rotation | 2000 |
Expression of metallothionein-III mRNA and its regulation by levodopa in the basal ganglia of hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Levodopa; Male; Metallothionein 3; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2000 |
MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra | 2000 |
Effects of repeated methyl levodopa administration on apomorphine sensitivity of rotational behavior and striatal Fos expression of rats with unilateral 6-OHDA lesions.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Resistance; Globus Pallidus; Levodopa; Male; Oxidopamine; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra | 2000 |
Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Animals; Cell Survival; Cells, Cultured; Chlorides; Dopamine; Dose-Response Relationship, Drug; Energy Metabolism; Ferric Compounds; Humans; Levodopa; Lipid Peroxidation; Neuroglia; Neurons; Oxidative Stress; Oxidopamine; Rats; Riluzole | 2000 |
Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Xanthines | 2000 |
The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Behavior, Animal; Biogenic Monoamines; Brain; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Dopamine Antagonists; Drug Combinations; Enzyme Inhibitors; Haloperidol; Homovanillic Acid; Hydrazines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine | 2001 |
The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
Topics: Adrenergic Agents; Animals; Clorgyline; Corpus Striatum; Dopamine Agents; Dopamine Uptake Inhibitors; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 2000 |
Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Dopamine Agents; Drug Tolerance; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Stereotyped Behavior; Sympathectomy, Chemical; Triazoles | 2001 |
Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Basal Ganglia; Behavior, Animal; Binding Sites; Cerebral Cortex; Diprenorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Narcotic Antagonists; Oxidopamine; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; RNA, Messenger; Sympatholytics; Tritium | 2001 |
Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.
Topics: Animals; Autoradiography; Callithrix; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Therapy, Combination; Enkephalins; Female; In Situ Hybridization; Injections, Subcutaneous; Levodopa; Ligands; Male; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Protein Precursors; Putamen; RNA, Messenger; Tritium | 2001 |
BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization.
Topics: Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Dopamine; Frontal Lobe; Gene Targeting; Levodopa; Male; Mice; Mutation; Neurons; Nucleus Accumbens; Oxidopamine; Rats; Rats, Wistar; Receptor, trkB; Receptors, Dopamine D2; Receptors, Dopamine D3; Ventral Tegmental Area | 2001 |
Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chlorides; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Ferric Compounds; Immunoenzyme Techniques; Levodopa; Male; Neostriatum; Nerve Net; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine Agonists; Down-Regulation; Drug Interactions; Drug Tolerance; Dynorphins; Enkephalins; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Neostriatum; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; RNA, Messenger; Sympatholytics; Up-Regulation | 2001 |
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Levodopa; Male; Motor Activity; Neostriatum; Neural Pathways; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Substantia Nigra; Sympatholytics; Triazoles | 2001 |
Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6-OHDA dopamine-depleted (hemi-Parkinson analogue) rats.
Topics: Animals; Antiparkinson Agents; Arm; Cell Count; Drug Administration Schedule; Female; Immunohistochemistry; Levodopa; Motor Skills; Movement; Neurons; Neuropsychological Tests; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Recovery of Function; Rotation; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2001 |
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Aromatic-L-Amino-Acid Decarboxylases; Dependovirus; Disease Models, Animal; Dopamine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Transduction, Genetic | 2001 |
Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; Animals; Benzazepines; Brain Diseases; Carbidopa; Carrier Proteins; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine D2 Receptor Antagonists; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Malonates; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neuropeptides; Oxidopamine; Rats; Rats, Wistar; Reactive Oxygen Species; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Reserpine; Succinate Dehydrogenase; Sulpiride; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2001 |
LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Isoquinolines; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Tetrazoles | 2001 |
Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment.
Topics: Animals; Apomorphine; Chromogranins; DNA, Complementary; Dopamine Agonists; Drug Administration Schedule; Gene Expression Regulation; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Proteins; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Secretogranin II; Sympatholytics; Up-Regulation | 2001 |
Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.
Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Enkephalins; Female; Gene Expression Regulation; Immunohistochemistry; Levodopa; Neostriatum; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics | 2001 |
cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum.
Topics: Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Denervation; DNA; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Administration Routes; Enkephalins; Female; Gene Expression; Levodopa; Oligonucleotides, Antisense; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcription Factor AP-1 | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Immunohistochemistry; Levodopa; Male; Motor Activity; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tachykinins; Tyrosine 3-Monooxygenase | 2002 |
MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sympatholytics; Synaptic Transmission | 2002 |
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Autoradiography; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Dynorphins; Female; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Knockout; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Receptor, Adenosine A2A; Receptors, Purinergic P1; RNA, Messenger; Substantia Nigra | 2002 |
Effects of short- and long-acting dopamine agonists on sensitized dopaminergic neurotransmission in rats with unilateral 6-OHDA lesions.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Antagonism; Ergolines; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Synaptic Transmission | 2002 |
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Dyskinesia, Drug-Induced; Female; Gait; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Sympatholytics | 2002 |
Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Dopamine; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Space; Kynurenic Acid; Levodopa; Male; Neostriatum; Neurons; Neurotoxins; Oxidopamine; Parkinson Disease; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Substantia Nigra | 2002 |
Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Female; Forelimb; Hindlimb; Levodopa; Motor Activity; Motor Skills; Oxidopamine; Psychomotor Performance; Rats; Rats, Long-Evans; Rotation; Stereotyped Behavior; Substantia Nigra | 2002 |
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Microinjections; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Piperidines; Pyrrolidinones; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2002 |
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Topics: Afferent Pathways; Animals; Bacterial Proteins; Behavior, Animal; Biomarkers; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Female; Image Processing, Computer-Assisted; Levodopa; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Severity of Illness Index; Substantia Nigra; Sympathectomy, Chemical; Transcription Factors | 2002 |
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Sympatholytics; Transcription Factors | 2002 |
Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
Topics: Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Antipsychotic Agents; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Maze Learning; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Sympatholytics | 2002 |
Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Callithrix; Dopamine; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Narcotic Antagonists; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; RNA; Rotation; Stereotyped Behavior; Sympathectomy, Chemical | 2002 |
PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Homovanillic Acid; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Quinpirole; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics | 2002 |
Acute and repeated treatment with L-DOPA increase c-jun expression in the 6-hydroxydopamine-lesioned forebrain of rats and common marmosets.
Topics: Animals; Callithrix; Drug Administration Schedule; Gene Expression Regulation; Genes, fos; Genes, jun; Injections, Intraventricular; Levodopa; Oxidopamine; Prosencephalon; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2002 |
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Dibenzothiazepines; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Quetiapine Fumarate; Rats; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists | 2002 |
Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system.
Topics: Animals; Corpus Striatum; Dyskinesias; Genes, fos; Injections, Intraventricular; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra | 2002 |
Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment.
Topics: Animals; Corpus Striatum; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; In Vitro Techniques; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate | 2002 |
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Cytoplasm; Drug Combinations; Indoles; Levodopa; Male; Microscopy, Immunoelectron; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Synaptic Membranes; Tyrosine 3-Monooxygenase | 2002 |
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Isoquinolines; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tetrazoles | 2002 |
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Treatment Outcome | 2003 |
Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors | 2003 |
Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Amantadine; Analysis of Variance; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Corpus Striatum; Dialysis; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Extracellular Space; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2003 |
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Binding, Competitive; Cannabinoid Receptor Modulators; Cerebellum; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Endocannabinoids; Excitatory Postsynaptic Potentials; Fatty Acids, Unsaturated; Glutamic Acid; Glycerides; In Vitro Techniques; Levodopa; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Phospholipase D; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug | 2003 |
Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats.
Topics: Animals; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Phosphorylation; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Substantia Nigra | 2003 |
Dual effects of intermittent or continuous L-DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6-OHDA lesion.
Topics: Animals; Autoradiography; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Electron Transport Complex IV; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Globus Pallidus; Glutamate Decarboxylase; In Situ Hybridization; Isoenzymes; Levodopa; Male; Mazindol; Neurons; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2003 |
Riluzole, an inhibitor of glutamatergic transmission, suppresses levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Riluzole; Synaptic Transmission | 2003 |
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Apomorphine; Cannabinoids; Carbidopa; Cell Line, Tumor; Dronabinol; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rotation; Substantia Nigra | 2003 |
Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV; Enkephalins; Entopeduncular Nucleus; Globus Pallidus; Glutamate Decarboxylase; In Situ Hybridization; Isoenzymes; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2003 |
Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Administration Schedule; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Time; Treatment Outcome | 2003 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothiazoles; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles; Treatment Outcome; Tritium; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Experimental study on inhibition of neuronal toxical effect of levodopa by ginkgo biloba extract on Parkinson disease in rats.
Topics: Animals; Apoptosis; Dihydroxyphenylalanine; Drug Interactions; Drugs, Chinese Herbal; Ginkgo biloba; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Random Allocation; Rats; Rats, Wistar; Substantia Nigra | 2003 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Chemistry; Cannabinoid Receptor Modulators; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Dyskinesias; Endocannabinoids; Gas Chromatography-Mass Spectrometry; Levodopa; Male; Morpholines; Mouth; Naphthalenes; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Raclopride; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra; Time Factors | 2003 |
Uptake of 6-[18F]fluoro-L-dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Behavior, Animal; Brain; Brain Mapping; Central Nervous System Stimulants; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine Agonists; Functional Laterality; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Propionates; Radioligand Assay; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2004 |
Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Functional Laterality; Levodopa; Male; Motor Activity; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Subthalamic Nucleus; Time Factors | 2004 |
Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Dopamine Agonists; Gene Expression Regulation; Globus Pallidus; Glutamate Decarboxylase; In Situ Hybridization; Isoenzymes; Levodopa; Neostriatum; Neural Pathways; Neurons; Oxidopamine; Rats; Receptors, Dopamine; RNA, Messenger; Substantia Nigra | 2003 |
Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Female; Immunohistochemistry; Injections, Intraventricular; Levodopa; Mesencephalon; Nerve Degeneration; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Time Factors; Tyrosine 3-Monooxygenase | 2003 |
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Apomorphine; Denervation; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Sympatholytics | 2003 |
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Denervation; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine; RNA, Messenger; Time; Triazoles | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles | 2003 |
Genetically modified human embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson's disease.
Topics: Animals; Blotting, Western; Cells, Cultured; Disease Models, Animal; Embryo, Mammalian; Genetic Therapy; Graft Survival; GTP Cyclohydrolase; Humans; Immunohistochemistry; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Stem Cells; Transfection; Tyrosine 3-Monooxygenase | 2003 |
Normalization of glutamate decarboxylase gene expression in the entopeduncular nucleus of rats with a unilateral 6-hydroxydopamine lesion correlates with increased GABAergic input following intermittent but not continuous levodopa.
Topics: Animals; Drug Administration Schedule; Entopeduncular Nucleus; GABA-A Receptor Antagonists; Gene Expression Regulation, Enzymologic; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Oxidopamine; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, GABA-A | 2004 |
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression; In Situ Hybridization; Indoles; Levodopa; Male; Motor Activity; Opioid Peptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Synaptic Transmission | 2004 |
Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Gene Expression; Levodopa; Male; Mice; Mice, Inbred C57BL; Models, Animal; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease; Phosphoproteins; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fyn; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Subcellular Fractions | 2004 |
Dopaminergic agonists and muscarinic antagonists improve lateralization in hemiparkinsonian rats in a novel exploratory Y-maze.
Topics: Animals; Antiparkinson Agents; Cholinergic Antagonists; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agonists; Functional Laterality; Levodopa; Male; Muscarinic Antagonists; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2004 |
NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats.
Topics: Adrenergic Agents; Animals; Brain; Dizocilpine Maleate; Dopamine Agents; Drug Interactions; Gait; Levodopa; Male; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 2004 |
L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease.
Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2004 |
Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
Topics: Animals; Apomorphine; Autoradiography; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Receptor, Adenosine A2A; RNA, Messenger; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics; Up-Regulation | 2004 |
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phenols; Piperidines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate | 2004 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal Ganglia; Behavior, Animal; Benzylamines; Brain Chemistry; Catalepsy; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Locus Coeruleus; Male; Motor Activity; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Statistics, Nonparametric; Tyrosine | 2004 |
Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2004 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; Chromatography, High Pressure Liquid; Deferoxamine; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Exploratory Behavior; Functional Laterality; Homovanillic Acid; Iron; Iron Chelating Agents; Levodopa; Male; Motor Activity; Neurodegenerative Diseases; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperazines; Quinolines; Rats; Rats, Sprague-Dawley; Time Factors | 2004 |
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine Agonists; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Models, Animal; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Wistar; Receptors, Dopamine D2; Synaptic Transmission | 2004 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Isoxazoles; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Zonisamide | 2004 |
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzophenones; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Interactions; Levodopa; Maze Learning; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; MPTP Poisoning; Nervous System Diseases; Nitrophenols; Oxazoles; Oxidopamine; Prefrontal Cortex; Quinolines; Rats; Rats, Sprague-Dawley; Serotonin; Stereotyped Behavior; Tolcapone; Tremor; Tyramine | 2004 |
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism.
Topics: Animals; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Denervation; Disease Models, Animal; Disks Large Homolog 4 Protein; Enzyme Inhibitors; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Motor Activity; Nerve Tissue Proteins; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Peptides; Phosphorylation; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Sulfonamides; Synaptic Transmission | 2004 |
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mazindol; Mice; Mice, Inbred C57BL; Motor Skills; Oxidopamine; Protein Binding; Substantia Nigra | 2004 |
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Topics: Animals; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Locomotion; Male; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rotation; Serine; Stereotyped Behavior; Sympathectomy, Chemical | 2004 |
Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus Striatum; Female; GTP-Binding Protein alpha Subunits; Humans; Levodopa; Male; Middle Aged; Oxidopamine; Parkinson Disease; Putamen; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Sympatholytics | 2004 |
Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain Diseases; Calmodulin; Carrier Proteins; Cell Count; Corpus Striatum; Cytokines; Dopamine Plasma Membrane Transport Proteins; Female; Functional Laterality; Gene Expression; Gene Library; Immunohistochemistry; In Situ Hybridization; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Myelin Basic Protein; Nerve Tissue Proteins; Oligonucleotide Array Sequence Analysis; Oxidopamine; Radioimmunoassay; Rats; Rats, Wistar; Substantia Nigra | 2004 |
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Phenethylamines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2004 |
Neuroprotective effects of the antiparkinson drug Mucuna pruriens.
Topics: Animals; Dose-Response Relationship, Drug; Levodopa; Male; Mitochondria; Mucuna; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Phytotherapy; Plant Components, Aerial; Random Allocation; Rats; Rats, Sprague-Dawley | 2004 |
Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Catechols; Corpus Striatum; Dopamine; Drug Synergism; Levodopa; Male; Nitriles; Oxidopamine; Rats; Rats, Sprague-Dawley | 2004 |
AMPA receptor blockade potentiates the stimulatory effect of L-DOPA on dopamine release in dopamine-deficient corticostriatal slice preparation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzodiazepines; Cerebral Cortex; Dopamine; Dopamine Agents; Electric Stimulation; Homovanillic Acid; In Vitro Techniques; Levodopa; Neostriatum; Oxidopamine; Rats; Receptors, AMPA; Sympatholytics | 2004 |
An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Cell Count; Differential Threshold; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Immunohistochemistry; Levodopa; Male; Methylphenidate; Motor Activity; Movement; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Enzyme Activation; Ergolines; Glutathione; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Neurotoxicity Syndromes; Oxidopamine; Thiobarbituric Acid Reactive Substances | 2005 |
Hypertrophy of medial globus pallidus and substantia nigra reticulata in 6-hydroxydopamine-lesioned rats treated with L-DOPA: implication for L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Dyskinesias; Globus Pallidus; Hypertrophy; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra | 2004 |
Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic (13)C NMS study in the rat.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Carbon Isotopes; Disease Models, Animal; Dopamine; Glutamic Acid; Glutaminase; Glutamine; Infusions, Intravenous; Levodopa; Lipid Metabolism; Magnetic Resonance Spectroscopy; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Sodium Acetate | 2005 |
Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
Topics: Adrenergic Agents; Animals; Chlorobenzenes; Corpus Striatum; Cyclobutanes; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesias; Functional Laterality; Immunohistochemistry; Levodopa; Male; Motor Activity; Neurotransmitter Uptake Inhibitors; Oxidopamine; Rats; Rats, Wistar; Rotation; Stereotyped Behavior; Time Factors | 2005 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2005 |
Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Behavior, Animal; Brain; Brain Chemistry; Cell Membrane; Corpus Striatum; Discs Large Homolog 1 Protein; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesias; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Subcellular Fractions; Synapses | 2005 |
Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.
Topics: Analysis of Variance; Animals; Autoradiography; Cell Count; Corpus Striatum; DNA-Binding Proteins; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Dynorphins; Early Growth Response Protein 1; Enkephalins; Gene Expression Regulation; Immediate-Early Proteins; In Situ Hybridization; Levodopa; Male; Neural Pathways; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Transcription Factors; Transcriptional Activation | 2005 |
Comparative effects of acute or chronic administration of levodopa to 6-hydroxydopamine-lesioned rats on the expression of glutamic acid decarboxylase in the neostriatum and GABAA receptors subunits in the substantia nigra, pars reticulata.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Carrier Proteins; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Endodeoxyribonucleases; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Neostriatum; Nuclear Proteins; Oxidopamine; Protein Subunits; Rats; Rats, Sprague-Dawley; Receptors, GABA-A; RNA, Messenger; Rotarod Performance Test; Substantia Nigra; Time Factors | 2005 |
Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Denervation; Drug Interactions; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glycine; Levodopa; Male; Organ Culture Techniques; Oxidopamine; Parkinson Disease; Phenylacetates; Pyridines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Sympatholytics; Tritium | 2005 |
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Denervation; Glutamic Acid; Levodopa; Male; Movement Disorders; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Subthalamic Nucleus; Sympatholytics; Synaptic Transmission | 2005 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; Benzothiazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electron Spin Resonance Spectroscopy; Functional Laterality; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinson Disease; Pramipexole; Thiazoles; Time Factors | 2005 |
Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Topics: Adrenergic Agents; Animals; Behavior, Animal; Chlorobenzenes; Cyclobutanes; Disease Models, Animal; Dopamine Agents; Drug Interactions; Levodopa; Male; Models, Biological; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotarod Performance Test; Rotation; Stereotyped Behavior; Time Factors | 2006 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpus Striatum; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Hydroxyindoleacetic Acid; Levodopa; Male; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin | 2005 |
In vivo models of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Macaca fascicularis; Mice; MPTP Poisoning; Multiple System Atrophy; Oxidopamine; Parkinsonian Disorders; Point Mutation; Rats; Substantia Nigra | 2005 |
Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Brain; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Interactions; Female; Gene Expression; Gene Expression Regulation; In Situ Hybridization; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Isoforms; Rats; Rats, Wistar; RNA, Messenger; Rotation; Substantia Nigra; Synaptotagmins; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Cell Line; Corpus Striatum; Dependovirus; Dimerization; Disease Models, Animal; Dopamine; Gene Dosage; Gene Expression Regulation; Genetic Therapy; Genetic Vectors; Humans; Levodopa; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Recombination, Genetic; Sirolimus; Stereotyped Behavior; Transduction, Genetic | 2006 |
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Proto-Oncogene Proteins c-fos; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2006 |
Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Caffeine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Levodopa; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease, Secondary; Random Allocation; Time Factors | 2006 |
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic Agents; AIDS-Related Complex; Amphetamine; Analgesics, Non-Narcotic; Animals; Antiparkinson Agents; Behavior, Animal; Carrier Proteins; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Functional Laterality; Homer Scaffolding Proteins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Oxidopamine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2005 |
l-DOPA administration enhances 6-hydroxydopamine generation.
Topics: Animals; Antioxidants; Antiparkinson Agents; Ascorbic Acid; Corpus Striatum; Drug Interactions; Edetic Acid; Hydroxylation; Iron; Levodopa; Lipid Peroxidation; Male; Melatonin; Oxidopamine; Rats; Rats, Wistar | 2005 |
Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Caffeine; Central Nervous System Stimulants; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Oxidopamine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior; Sympathectomy, Chemical; Sympatholytics | 2005 |
Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalin, Methionine; Female; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Reproducibility of Results; Sympatholytics | 2005 |
Modulation of torsinA expression in the globus pallidus internus is associated with levodopa-induced dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Molecular Chaperones; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2006 |
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Protein Subunits; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; Synapses; Transfection | 2006 |
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Selective Serotonin Reuptake Inhibitors; Substantia Nigra; Transplantation Tolerance | 2006 |
Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat.
Topics: Analysis of Variance; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Fluorobenzenes; Functional Laterality; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Rotarod Performance Test; Serotonin Antagonists; Stereotyped Behavior | 2006 |
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors | 2006 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; Adrenergic Agents; Animals; Caffeine; Corpus Striatum; Dynorphins; Dyskinesias; Enkephalins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; RNA, Messenger | 2006 |
L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Cell Count; Central Nervous System; Dopamine Agents; Drug Interactions; Enzyme Inhibitors; Functional Laterality; Gene Expression Regulation; Hydrazines; Immunohistochemistry; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2006 |
L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases.
Topics: Animals; Antiparkinson Agents; Dopamine; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Protein Kinase C; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; src-Family Kinases; Time Factors | 2006 |
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesias; Extracellular Fluid; Homovanillic Acid; Levodopa; Male; Membrane Potentials; Microdialysis; Neurons; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra | 2006 |
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Extracellular Fluid; Female; Levodopa; Microdialysis; Microinjections; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Serotonin; Up-Regulation | 2006 |
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Disks Large Homolog 4 Protein; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Binding; Protein Interaction Mapping; Protein Processing, Post-Translational; Protein Structure, Tertiary; Protein Transport; Protein-Tyrosine Kinases; Psychomotor Performance; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Recombinant Fusion Proteins; Subcellular Fractions; Synapses | 2006 |
Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Functional Laterality; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Quinolines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Thiazoles; Time Factors | 2006 |
Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment.
Topics: Action Potentials; Adrenergic Agents; Animals; Apomorphine; Brain Injuries; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Immunohistochemistry; Levodopa; Male; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; Substantia Nigra; Subthalamic Nucleus; Tyrosine 3-Monooxygenase | 2006 |
Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Environment; Housing, Animal; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Reproducibility of Results | 2006 |
Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Time Factors | 2006 |
L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus.
Topics: Animals; Autoradiography; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Dyskinesias; Functional Laterality; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Mazindol; Neurons; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Substantia Nigra; Subthalamic Nucleus; Time Factors; Tritium | 2006 |
Repeated l-DOPA treatment increases c-fos and BDNF mRNAs in the subthalamic nucleus in the 6-OHDA rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cocaine; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Administration Schedule; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinson Disease; Protein Binding; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Subthalamic Nucleus; Tritium | 2006 |
L-DOPA inhibits depolarization-induced [3H]GABA release in the dopamine-denervated globus pallidus of the rat: the effect is dopamine independent and mediated by D2-like receptors.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Data Interpretation, Statistical; Decarboxylation; Denervation; Dopamine; Dopamine Agents; Dopamine Antagonists; Enzyme Inhibitors; gamma-Aminobutyric Acid; Globus Pallidus; Hydrazines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Potassium; Rats; Rats, Wistar; Receptors, Dopamine D2; Stereotyped Behavior; Sulpiride; Sympathectomy, Chemical; Sympatholytics | 2006 |
Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk.
Topics: Animals; Animals, Newborn; Antibodies; Astrocytes; Cell Communication; Cell Survival; Cells, Cultured; Coculture Techniques; Cytoprotection; Dopamine; Dopamine Agents; Glial Cell Line-Derived Neurotrophic Factor; Hydrogen Peroxide; Levodopa; Nerve Degeneration; Neurons; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; RNA, Messenger; Substantia Nigra; Sympatholytics | 2006 |
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Functional Laterality; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors | 2006 |
MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fenfluramine; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Antagonists; Serotonin Agents | 2006 |
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
Topics: Animals; Antibodies, Monoclonal; Antigens; Basal Ganglia; Biomarkers; Blood-Brain Barrier; Bromodeoxyuridine; Cell Count; Cell Proliferation; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Endothelial Cells; Female; Intermediate Filament Proteins; Levodopa; Motor Activity; Neovascularization, Pathologic; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinsonian Disorders; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Rats; Rats, Sprague-Dawley | 2006 |
Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Interactions; Dyskinesias; Electric Stimulation; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Male; Membrane Potentials; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Subthalamic Nucleus; Time Factors | 2006 |
Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agents; Drug Administration Schedule; gamma-Aminobutyric Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2006 |
Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzylamines; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Enzyme Inhibitors; Female; Immunohistochemistry; Levodopa; Neostriatum; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Stereotyped Behavior; Subcellular Fractions; Sulfonamides; Sympatholytics | 2006 |
Expression pattern of JunD after acute or chronic L-DOPA treatment: comparison with deltaFosB.
Topics: Animals; Antiparkinson Agents; Blotting, Western; Denervation; Female; Gene Expression Regulation; Immunohistochemistry; In Situ Hybridization; Levodopa; Neostriatum; Oxidopamine; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2007 |
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Male; Models, Biological; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Protein Kinase C; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2007 |
Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Functional Laterality; Levodopa; Male; Multiple System Atrophy; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra | 2007 |
The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration.
Topics: Analysis of Variance; Animals; Brain Injuries; Bromocriptine; Cell Count; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Routes; Female; Immunohistochemistry; Levodopa; Lipopolysaccharides; Movement Disorders; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Time Factors; Tyrosine 3-Monooxygenase | 2007 |
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Combined Modality Therapy; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Levodopa; Mesencephalon; Motor Skills; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Severity of Illness Index; Sympatholytics | 2007 |
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders; Prosencephalon; Purines; Receptor, Adenosine A2A | 2006 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles | 2007 |
Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Down-Regulation; Drug Administration Schedule; Enkephalins; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Synaptic Transmission; Up-Regulation; Vesicular Inhibitory Amino Acid Transport Proteins | 2007 |
Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons.
Topics: Adrenergic Uptake Inhibitors; Animals; Cell Death; Desipramine; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Locus Coeruleus; Male; Neurons; Norepinephrine; Oxidopamine; Rats; Rats, Wistar; Rotarod Performance Test; Severity of Illness Index; Tyrosine 3-Monooxygenase | 2007 |
Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study.
Topics: Animals; Behavior, Animal; Brain Injuries; Corpus Striatum; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Rotarod Performance Test; Time Factors | 2007 |
Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Benzodiazepines; Corpus Striatum; Dopamine; Dopamine Agents; Drug Interactions; Functional Laterality; Homovanillic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2007 |
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Bicuculline; Drug Synergism; Drug Therapy, Combination; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Injections; Levodopa; Male; Microdialysis; Motor Activity; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Perfusion; Piperidines; Postural Balance; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Sodium Channel Blockers; Stereotaxic Techniques; Substantia Nigra; Tetrodotoxin; Thalamus | 2007 |
Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred ICR; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Pyrimidines; Receptor, Adenosine A2A; Rotation; Triazoles | 2007 |
Modification of L-DOPA pharmacological activity by MAO inhibitors.
Topics: Animals; Basal Ganglia; Brain; Denervation; Dopamine; Drug Interactions; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra; Synaptic Transmission | 2007 |
Nicotine induces tyrosine hydroxylase plasticity in the neurodegenerating striatum.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Axons; Corpus Striatum; Denervation; Dopamine; Down-Regulation; Levodopa; Male; Nerve Degeneration; Neuronal Plasticity; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2007 |
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrine; Tremor; Triazoles | 2007 |
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Agents | 2007 |
The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Functional Laterality; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2007 |
The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Behavior, Animal; Biogenic Monoamines; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Agents; Drug Interactions; Dyskinesias; gamma-Aminobutyric Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Serotonin Receptor Agonists; Stereotyped Behavior; Triglycerides | 2007 |
Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Movement; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Spiperone; Sympatholytics; Time Factors | 2007 |
Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Interactions; Levodopa; Male; Nerve Fibers; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra | 2007 |
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.
Topics: Animals; Brain; Cyclic AMP; Disease Models, Animal; Dopamine Agonists; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Phosphorylation; Receptors, AMPA; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction | 2007 |
Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Enzyme Activation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Mitogen-Activated Protein Kinase 1; Opioid Peptides; Oxidopamine; Parkinson Disease; Pergolide; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Signal Transduction; Up-Regulation | 2007 |
Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Disease Models, Animal; Functional Laterality; Helplessness, Learned; Levodopa; Male; Nerve Degeneration; Neurons; Oxidopamine; Rats; Rats, Wistar; Reaction Time; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2007 |
[Effects of tetramethylpyrazine on brain oxidative damage induced by intracerebral perfusion of L-DOPA in rats with Parkinson's disease].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Catechols; Chromatography, High Pressure Liquid; Corpus Striatum; Hydroxybenzoates; Levodopa; Male; Microdialysis; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Pyrazines; Random Allocation; Rats; Rats, Sprague-Dawley | 2007 |
Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.
Topics: Amino Acid Sequence; Animals; Basal Ganglia; Brain Chemistry; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Administration Schedule; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Threonine; Time | 2007 |
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Benzylamines; Brain; Caffeine; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Motor Activity; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2007 |
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Basal Ganglia; Benzamides; Benzoxazines; Cannabinoids; Capsaicin; Carbamates; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Endocannabinoids; Levodopa; Male; Morpholines; Naphthalenes; Oxidopamine; Parkinson Disease, Secondary; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; TRPV Cation Channels | 2007 |
Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity.
Topics: Animals; Cell Line; Cytoprotection; Dopamine; Dopamine Agents; Levodopa; Metallothionein; Mice; Mice, Knockout; Oxidopamine; Parkinson Disease, Secondary; RNA, Messenger; Zinc | 2007 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Benserazide; Brain Injuries; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Homovanillic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar | 2008 |
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Subthalamic Nucleus; Time Factors; Tyrosine 3-Monooxygenase | 2008 |
Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Hydroxyindoleacetic Acid; Infusion Pumps, Implantable; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Dopamine D2; Serotonin; Substantia Nigra; Tryptophan Hydroxylase; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Interactions; Dyskinesia, Drug-Induced; Electric Stimulation; In Vitro Techniques; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2008 |
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram.
Topics: Adrenal Cortex Hormones; Amphetamine; Animals; Anxiety; Blotting, Western; Body Weight; Central Nervous System Stimulants; Citalopram; Dopamine Agents; Drinking; Dyskinesia, Drug-Induced; Image Processing, Computer-Assisted; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Selective Serotonin Reuptake Inhibitors; Serotonin; Stereotyped Behavior; Sympatholytics; Synaptic Transmission | 2008 |
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; In Situ Hybridization; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor Activity-Modifying Protein 1; Receptor Activity-Modifying Proteins; RNA, Messenger | 2008 |
Specific induction of PAG608 in cranial and spinal motor neurons of L-DOPA-treated parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; DNA-Binding Proteins; Drug Interactions; Functional Laterality; Gene Expression Regulation; Levodopa; Motor Neurons; Nuclear Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Spinal Cord | 2008 |
Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Chlorobenzenes; Corpus Striatum; Cyclobutanes; Dynorphins; Enkephalins; Gene Expression; In Situ Hybridization; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Substance P; Time | 2008 |
Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
Topics: Animals; Astrocytes; Biomarkers; Calcium-Binding Proteins; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Glial Fibrillary Acidic Protein; Immunohistochemistry; Levodopa; Male; Microfilament Proteins; Microglia; Neural Pathways; Neuroglia; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Substantia Nigra | 2008 |
Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism.
Topics: Animals; Autoradiography; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; RNA, Messenger; Serotonin Receptor Agonists | 2008 |
Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Topics: Animals; Biomarkers; Bromodeoxyuridine; Cell Count; Cell Proliferation; Corpus Striatum; Denervation; Dopamine; Dopamine Plasma Membrane Transport Proteins; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neural Pathways; Neurons; Opioid Peptides; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2008 |
Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
Topics: Adrenergic Agents; Amphetamine; Animals; Anti-Anxiety Agents; Behavior, Animal; Dextromethorphan; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Ligands; Male; N-Methylaspartate; Neurotoxicity Syndromes; Oxidopamine; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors | 2008 |
In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adamantane; Amidines; Animals; Antiparkinson Agents; Basal Ganglia; Denervation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Microdialysis; Oxidopamine; Parkinsonian Disorders; Perfusion; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Time Factors | 2008 |
Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cocaine; Disease Models, Animal; Dopamine; Feedback; Functional Laterality; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Peptide Fragments; Quinolines; Radioisotopes; Rats; Rats, Sprague-Dawley; Receptors, Neurokinin-3; Serine; Substance P; Sympatholytics; Tyrosine 3-Monooxygenase | 2008 |
Preclinical models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Injections, Intra-Arterial; Injections, Intravenous; Levodopa; Macaca fascicularis; Macaca mulatta; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Primates; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Species Specificity | 2001 |
Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats; Sympatholytics | 2007 |
Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Topics: Animals; Callithrix; Corpus Striatum; Dopamine; Levodopa; Male; Medial Forebrain Bundle; Models, Animal; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Presynaptic Terminals; Rats; Rats, Wistar; Substantia Nigra | 2008 |
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Drug Evaluation, Preclinical; Endotoxins; Exenatide; Glucagon-Like Peptide-1 Receptor; Levodopa; Locomotion; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Substantia Nigra; Tyrosine 3-Monooxygenase; Venoms | 2008 |
Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter.
Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Denervation; Desipramine; Disease Models, Animal; Dopamine; Extracellular Matrix; Levodopa; Male; Microdialysis; Neurons; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Synapses; Synaptic Transmission | 2008 |
Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Circadian Rhythm; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Eye Enucleation; Functional Laterality; Hypothalamic Area, Lateral; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Stereotyped Behavior; Substantia Nigra | 2008 |
6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
Topics: 1-Methyl-3-isobutylxanthine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Cyclic AMP; Disease Models, Animal; Dopamine Agents; Functional Laterality; gamma-Aminobutyric Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Receptors, Dopamine D1; Substantia Nigra; Time Factors; Tritium | 2008 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2008 |
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Histocompatibility Antigens Class II; Levodopa; Male; Microscopy, Electron, Transmission; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Synapses; Tissue Transplantation; Tyrosine 3-Monooxygenase | 2008 |
Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
Topics: Adrenergic Agents; Amphetamine; Analgesics, Non-Narcotic; Analysis of Variance; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Dyskinesias; Embryo, Mammalian; Encephalitis; Female; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Levodopa; Mesencephalon; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rats, Wistar; Skin Transplantation | 2008 |
Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Topics: Animals; Anti-Inflammatory Agents; Corpus Striatum; Corticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Encephalitis; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Levodopa; Male; Medial Forebrain Bundle; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Sympatholytics; Up-Regulation | 2008 |
Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.
Topics: Animals; Association Learning; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Levodopa; Male; Memory Disorders; Mice; Movement; Oxidopamine; Parkinson Disease; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Space Perception; Vision Disorders | 2009 |
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Antipsychotic Agents; Benzazepines; Berberine; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Dyskinesias; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin Receptor Agonists; Transfection; Tritium | 2010 |
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Topics: Animals; Animals, Newborn; Brain; Cerebral Cortex; Cyclic AMP; Cyclic GMP; Dopamine; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphorylation; Purinones; Rats; Rats, Sprague-Dawley; Second Messenger Systems; Substantia Nigra; Sympatholytics; Synaptic Transmission | 2008 |
Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Functional Laterality; Gene Expression; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Synaptotagmins; Time Factors | 2008 |
Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Interactions; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor-Like Protein Tyrosine Phosphatases, Class 5; RNA, Messenger; Up-Regulation | 2008 |
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Dyskinesia, Drug-Induced; Energy Metabolism; Enkephalins; Female; In Vitro Techniques; Levodopa; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phosphocreatine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Statistics, Nonparametric | 2009 |
The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Caffeine; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Globus Pallidus; Injections; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Long-Evans | 2009 |
Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antiparkinson Agents; Benzamidines; Disease Models, Animal; Dopamine; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Immunohistochemistry; Levodopa; Medial Forebrain Bundle; Motor Activity; Neurons; Oxidopamine; Parkinson Disease, Secondary; Postural Balance; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Tyrosine 3-Monooxygenase | 2009 |
[Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias].
Topics: Animals; Benserazide; Corpus Striatum; Drugs, Chinese Herbal; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Phytotherapy; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2008 |
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cerebrum; Dendritic Spines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Isradipine; Levodopa; Male; Motor Activity; Nimodipine; Oxidopamine; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Sympatholytics | 2009 |
Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
Topics: Administration, Oral; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Excitatory Amino Acid Antagonists; Female; Immunohistochemistry; Intralaminar Thalamic Nuclei; Levodopa; Medial Forebrain Bundle; N-Methylaspartate; Neurons; Oxidopamine; Parkinson Disease, Secondary; Postural Balance; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Rotation; Tyrosine 3-Monooxygenase | 2009 |
Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2.
Topics: Amphetamine; Animals; Benzoxazines; Calcium Channel Blockers; Cannabinoids; Corpus Striatum; Dopamine; Dyskinesias; Glutamine; Homovanillic Acid; Levodopa; Male; Morpholines; Naphthalenes; Oxidopamine; Rats; Rats, Wistar | 2009 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Motor Activity; Narcotic Antagonists; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Substantia Nigra; Thalamus; Time Factors | 2008 |
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Topics: Animals; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Models, Animal; Nerve Degeneration; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra | 2009 |
Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model.
Topics: Animals; Antiparkinson Agents; Circadian Rhythm; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Injections, Intraperitoneal; Levodopa; Microinjections; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Risk Factors; Rotation; Species Specificity; Sympatholytics; Time Factors; Treatment Outcome | 2009 |
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists | 2009 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger | 2009 |
Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Analysis of Variance; Animals; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Severity of Illness Index | 2009 |
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Apomorphine; Benserazide; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microinjections; Organic Chemicals; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Rotation; Serotonin Receptor Agonists; Stereotyped Behavior; Subthalamic Nucleus; Sympathectomy, Chemical; Sympatholytics | 2009 |
L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Blotting, Western; Dyskinesias; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Receptors, Dopamine D1; Receptors, Dopamine D2; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; Substantia Nigra; Sympatholytics | 2009 |
L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Movement Disorders; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Serotonin; Sympatholytics; Tryptophan Hydroxylase | 2009 |
De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat.
Topics: Animals; Cell Proliferation; Corpus Striatum; Dopamine Agents; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation; In Situ Hybridization; Levodopa; Male; Nerve Regeneration; Neurogenesis; Neuronal Plasticity; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Comparative effects of acute or chronic administration of levodopa to 6-OHDA-lesioned rats on the expression and phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in the striatum.
Topics: Animals; Blotting, Western; Dopamine Agents; Female; Indicators and Reagents; Levodopa; Movement; Neostriatum; Nerve Tissue Proteins; Oxidopamine; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome; Sympatholytics | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopamine; Electric Stimulation Therapy; Electrodes, Implanted; Electrophysiological Phenomena; Humans; Levodopa; Locomotion; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Cortex; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Spinal Cord | 2009 |
Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitroarginine; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra | 2009 |
Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesias; Embryo, Mammalian; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Agents; Transplants; Tyrosine 3-Monooxygenase | 2009 |
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; CD11b Antigen; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Jaw; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Movement; Mucuna; Neuroprotective Agents; Oxidopamine; Parasympathomimetics; Parkinson Disease; Phytotherapy; Rats; Rats, Sprague-Dawley; Seeds; Sympatholytics; Tacrine; Time Factors; Vibrissae | 2009 |
Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Agonists; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Dopamine and cAMP-Regulated Phosphoprotein 32; Levodopa; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Motor Activity; Movement; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Signal Transduction; Up-Regulation | 2009 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Sympatholytics | 2009 |
The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Hypokinesia; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.
Topics: Amphetamine; Analysis of Variance; Animals; Benserazide; Brain; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; In Situ Hybridization; Levodopa; Lipid Peroxidation; Male; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Receptor, Cannabinoid, CB1; Severity of Illness Index | 2011 |
Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Benzazepines; Caffeine; Corpus Striatum; Dopamine Agonists; Drug Therapy, Combination; Guanosine 5'-O-(3-Thiotriphosphate); Levodopa; Lisuride; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Random Allocation; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulfur Radioisotopes | 2009 |
Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benzylamines; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Levodopa; Male; Movement; Neurotoxins; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Recovery of Function; Synaptic Transmission; Time; Treatment Outcome | 2009 |
Dopamine depletion induces distinct compensatory gene expression changes in DARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Gene Expression Profiling; Gene Expression Regulation; Ion Channels; Levodopa; Male; Microarray Analysis; Microdissection; Neural Pathways; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; Signal Transduction; Substantia Nigra; Wheat Germ Agglutinin-Horseradish Peroxidase Conjugate | 2009 |
D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2009 |
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Topics: Acetylation; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; Gene Expression Regulation; Histones; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2; Statistics as Topic; Tyrosine 3-Monooxygenase | 2009 |
Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aminoacetonitrile; Animals; Antiparkinson Agents; Basal Ganglia; Benzazepines; Bromocriptine; Disease Models, Animal; Dopamine Agents; Dopamine D2 Receptor Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Levodopa; Neovascularization, Pathologic; Oxidopamine; Parkinsonian Disorders; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides | 2009 |
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Electron Transport Complex IV; Gene Expression Regulation; Levodopa; Male; Nerve Net; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Protein Subunits; Rats; Rats, Wistar; RNA, Messenger | 2009 |
Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Benzazepines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors | 2009 |
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Homer Scaffolding Proteins; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2009 |
Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Dopamine Agents; Dynorphins; Dyskinesia, Drug-Induced; Dystonia; Excitatory Amino Acid Antagonists; Glutamate Decarboxylase; Levodopa; Male; Neurons; Oxidopamine; Protein Precursors; Pyridines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; RNA, Messenger | 2009 |
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Behavior, Animal; Disease Models, Animal; Dyskinesias; Extracellular Space; Levodopa; Male; Microdialysis; Morphinans; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation; Spiro Compounds; Time Factors | 2009 |
Effect of the additional noradrenergic neurodegeneration to 6-OHDA-lesioned rats in levodopa-induced dyskinesias and in cognitive disturbances.
Topics: Animals; Benzylamines; Cognition Disorders; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Maze Learning; Medial Forebrain Bundle; Memory, Short-Term; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Time Factors | 2009 |
Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dynorphins; Dyskinesias; Electron Transport Complex IV; Enkephalins; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2009 |
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Hypokinesia; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Time Factors; Treatment Outcome | 2010 |
Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Female; Hydroxyindoleacetic Acid; Hydroxyl Radical; Injections, Intraventricular; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Sympatholytics; Time Factors | 2010 |
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebrospinal Fluid; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Plasma; Propranolol; Random Allocation; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Tetralones | 2010 |
Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ascorbic Acid; Brain; Central Nervous System Depressants; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Ferrous Compounds; Levodopa; Male; Melatonin; Mice; Mice, Inbred BALB C; Oxidopamine; Parkinsonian Disorders | 2009 |
The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
Topics: Adrenergic Agents; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Wistar; Tandem Mass Spectrometry | 2010 |
L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation.
Topics: Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Electrochemistry; Levodopa; Male; Mice; Mice, Inbred BALB C; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2010 |
Beta frequency synchronization in basal ganglia output during rest and walk in a hemiparkinsonian rat.
Topics: Action Potentials; Animals; Antiparkinson Agents; Basal Ganglia; Beta Rhythm; Dopamine; Electromyography; Evoked Potentials; Exercise Test; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Long-Evans; Rest; Tyrosine 3-Monooxygenase; Walking | 2010 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Chemistry; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Jaw; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotarod Performance Test; Time Factors; Triazoles; Vibrissae | 2010 |
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Corpus Striatum; Dopamine; Female; Gene Expression; Gene Expression Profiling; Humans; In Vitro Techniques; Leupeptins; Levodopa; Models, Neurological; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Presynaptic Terminals; rab3 GTP-Binding Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Synaptic Vesicles; Ventral Tegmental Area | 2009 |
Site-specific action of L-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic L-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Microdialysis; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra | 2010 |
Behavioral and electrophysiological effects of 5-HT in globus pallidus of 6-hydroxydopamine lesioned rats.
Topics: Action Potentials; Animals; Behavior, Animal; Dopamine Agents; Drug Combinations; Functional Laterality; Globus Pallidus; Levodopa; Male; Microinjections; Neural Inhibition; Neurons; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin | 2010 |
L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Microdialysis; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2010 |
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Time Factors | 2010 |
Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Animals; Antiparkinson Agents; Brain; Citalopram; Cobra Neurotoxin Proteins; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Extracellular Fluid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Raphe Nuclei; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Sympatholytics; Synaptic Transmission | 2010 |
High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Extracellular Space; Hippocampus; Hydroxyindoleacetic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinson Disease, Secondary; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin 5-HT1 Receptor Agonists; Subthalamic Nucleus | 2010 |
The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced Dyskinesia in a Hemiparkinsonian rat model.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tyrosine 3-Monooxygenase | 2010 |
Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
Topics: Animals; Circadian Rhythm; Corpus Striatum; Dopamine; Humans; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Sympatholytics; Telemetry | 2010 |
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Dose-Response Relationship, Drug; Dyskinesias; Endocytosis; G-Protein-Coupled Receptor Kinases; Gene Knockdown Techniques; Genetic Therapy; Humans; Lentivirus; Levodopa; Macaca; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Signal Transduction | 2010 |
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Oxidopamine; Parkinsonian Disorders; Piribedil; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotation; Time Factors | 2010 |
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca mulatta; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2010 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2010 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Salicylates | 2010 |
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparasitic Agents; Corpus Striatum; Cyclin-Dependent Kinase 5; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Kinase Inhibitors; Purines; Random Allocation; Rats; Rats, Sprague-Dawley; Roscovitine; Severity of Illness Index; Treatment Outcome | 2010 |
Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Dyskinesias; Functional Laterality; Gene Expression Regulation; Gene Transfer Techniques; Genetic Vectors; Green Fluorescent Proteins; Levodopa; Male; Motor Activity; Mutation; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Sympatholytics; Time Factors | 2010 |
Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
Topics: Action Potentials; Animals; Antiparkinson Agents; Behavior, Animal; Cholera Toxin; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Fluorescent Dyes; Levodopa; Long-Term Potentiation; Neuronal Plasticity; Neurons; Oxidopamine; Parkinson Disease; Rats; Substantia Nigra; Tyrosine 3-Monooxygenase | 2010 |
Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease.
Topics: Amides; Animals; Drug Design; Levodopa; Male; Oxidopamine; Parkinson Disease; Prodrugs; Rats; Rats, Wistar | 2010 |
Deep brain stimulation of the center median-parafascicular complex of the thalamus has efficient anti-parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Denervation; Disease Models, Animal; Electron Transport Complex IV; Feedback, Sensory; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Protein Precursors; Rats; Rats, Wistar; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus; Tachykinins; Thalamus | 2010 |
Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Nerve Fibers; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2011 |
L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
Topics: Adenylyl Cyclases; Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; gamma-Aminobutyric Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Severity of Illness Index; Substantia Nigra; Up-Regulation | 2011 |
Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Caffeine; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinson Disease; Protein Precursors; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Receptor, Adenosine A2A; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2011 |
Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat.
Topics: Amygdala; Animals; Anxiety; Behavioral Research; Biogenic Monoamines; Chromatography, High Pressure Liquid; Corpus Striatum; Depression; Dopamine; Dopamine Agents; Hippocampus; Humans; Levodopa; Male; Models, Animal; Motor Activity; Oxidopamine; Parkinson Disease; Prefrontal Cortex; Rats; Rats, Sprague-Dawley | 2010 |
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Neuronal Plasticity; Oxidopamine; Parkinson Disease; Presynaptic Terminals; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2010 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics | 2011 |
BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Area Under Curve; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles | 2011 |
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Fear; In Vitro Techniques; Levodopa; Male; Maze Learning; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Pain Measurement; Parkinson Disease, Secondary; Picolinic Acids; Psychomotor Performance; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Tandem Mass Spectrometry; Time Factors | 2011 |
Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
Topics: Animals; Benserazide; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin | 2011 |
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
Topics: Animals; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; Levodopa; Long-Term Synaptic Depression; Male; Microinjections; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Piperazines; Purinones; Pyrimidinones; Rats; Rats, Wistar | 2011 |
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.
Topics: Analysis of Variance; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Profiling; Gene Expression Regulation; Levodopa; Male; Nerve Tissue Proteins; Neurotrophin 3; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinsonian Disorders; Pulsatile Flow; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2011 |
Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat.
Topics: Animals; Conditioning, Psychological; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2011 |
Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Azetidines; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotinic Agonists; Oxidopamine; Parkinson Disease; Quinoxalines; Rats; Rats, Sprague-Dawley; Varenicline | 2011 |
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Time Factors | 2011 |
Flibanserin attenuates L: -DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Stereotypic Movement Disorder; Time Factors | 2011 |
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Motor Activity; Neural Pathways; Neurons; Oxidopamine; Parkinson Disease; Substantia Nigra | 2011 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists | 2011 |
Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Benzoxazines; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Molecular Targeted Therapy; Motor Activity; Oxazines; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Time Factors | 2011 |
Progressive motor cortex functional reorganization following 6-hydroxydopamine lesioning in rats.
Topics: Animals; Behavior, Animal; Bicuculline; Denervation; Dopamine Agents; Electric Stimulation; GABA Antagonists; Immunohistochemistry; Levodopa; Lidocaine; Male; Motor Activity; Motor Cortex; Oxidopamine; Postural Balance; Rats; Rats, Wistar; Receptors, GABA-A; Sodium Channel Blockers; Sympatholytics; Tyrosine 3-Monooxygenase | 2011 |
Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopa Decarboxylase; Dopamine; Dyskinesia, Drug-Induced; Electrochemistry; Female; Functional Laterality; Levodopa; Oxidopamine; Potassium Chloride; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Severity of Illness Index; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2011 |
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; RNA, Messenger | 2012 |
Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.
Topics: Animals; Antiparkinson Agents; Aporphines; Binding, Competitive; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Stereoisomerism; Structure-Activity Relationship; Thioctic Acid | 2011 |
Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Combined Modality Therapy; Dopamine; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Serotonin; Sympatholytics | 2011 |
Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Topics: Animals; Antiparkinson Agents; Autoradiography; Bridged Bicyclo Compounds, Heterocyclic; Corpus Striatum; Cotinine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Nicotinic Agonists; Oxidopamine; Pyridines; Receptors, Nicotinic; Substantia Nigra; Sympatholytics | 2011 |
Endogenous morphine-like compound immunoreactivity increases in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; alpha-Methyltyrosine; Analysis of Variance; Animals; Brain; Choline O-Acetyltransferase; Chromatography, High Pressure Liquid; Dendrites; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Functional Laterality; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Glutamate Decarboxylase; Humans; Levodopa; Macaca fascicularis; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Immunoelectron; Middle Aged; Nerve Growth Factors; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Postmortem Changes; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Tandem Mass Spectrometry | 2011 |
Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl)phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson's disease mouse model.
Topics: Animals; Antioxidants; Ascorbic Acid; Catalase; Corpus Striatum; Disease Models, Animal; Dopamine; Eugenol; Free Radical Scavengers; Glutathione; Glutathione Peroxidase; Guaiacol; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Superoxide Dismutase | 2011 |
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Gene Expression Regulation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Membrane Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Subcellular Fractions; Time Factors | 2012 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles | 2012 |
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Drug Combinations; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time | 2011 |
Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.
Topics: Administration, Oral; Animals; Corpus Striatum; Disease Models, Animal; Injections, Intraperitoneal; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotation | 2012 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra | 2011 |
Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Topics: Action Potentials; Animals; Antiparkinson Agents; Corpus Striatum; D-Aspartate Oxidase; D-Aspartic Acid; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Methylaspartate; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Sympatholytics; Synapses | 2011 |
Extent of pre-operative L-DOPA-induced dyskinesia predicts the severity of graft-induced dyskinesia after fetal dopamine cell transplantation.
Topics: Amphetamines; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Postoperative Complications; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Sympatholytics | 2011 |
Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Mice; Motor Activity; Neurons; Oxidopamine; Rotarod Performance Test; Substantia Nigra | 2012 |
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Benserazide; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; RGS Proteins | 2011 |
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adrenergic Neurons; Animals; Behavior, Animal; Corpus Striatum; Desipramine; Disease Models, Animal; Dyskinesia, Drug-Induced; Hippocampus; Idazoxan; Levodopa; Male; Molecular Targeted Therapy; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Propranolol; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Sympathectomy, Chemical | 2012 |
Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Buspirone; Catalepsy; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Serotonin 5-HT1 Receptor Agonists; Time Factors | 2011 |
Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy.
Topics: Animals; Cell Count; Corpus Striatum; Dopamine; Gait; Humans; Levodopa; Male; Medial Forebrain Bundle; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred Strains; Substantia Nigra; Tyrosine 3-Monooxygenase | 2012 |
Striatal inhibition of calpains prevents levodopa-induced neurochemical changes and abnormal involuntary movements in the hemiparkinsonian rat model.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Calpain; Corpus Striatum; Cyclin-Dependent Kinase 5; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2012 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Electrochemistry; Exploratory Behavior; Forelimb; Functional Laterality; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Motor Activity; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics | 2012 |
Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Carbon Isotopes; Cocaine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Microdialysis; Motor Activity; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Protein Binding; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Serotonin; Serotonergic Neurons; Serotonin Receptor Agonists | 2012 |
The grid-walking test: assessment of sensorimotor deficits after moderate or severe dopamine depletion by 6-hydroxydopamine lesions in the dorsal striatum and medial forebrain bundle.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Uptake Inhibitors; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Nervous System Diseases; Oxidopamine; Parkinson Disease, Secondary; Psychomotor Performance; Rats; Rats, Wistar; Sympatholytics; Walking | 2012 |
Rhes, a striatal-enriched small G protein, mediates mTOR signaling and L-DOPA-induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Adrenergic Agents; Animals; Antiparkinson Agents; Cell Line, Transformed; Corpus Striatum; Culture Media, Serum-Free; Disability Evaluation; Disease Models, Animal; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Regulation; GTP-Binding Proteins; Humans; Immunosuppressive Agents; Levodopa; Mice; Mice, Knockout; Movement; Mutation; Neurons; Neurotoxicity Syndromes; Oxidopamine; Phosphorylation; Protein Binding; Radioligand Assay; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transfection | 2011 |
The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats.
Topics: Animals; Behavior, Animal; Benzoxazines; Cannabinoids; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Levodopa; Male; Morpholines; Motor Activity; Naphthalenes; Oxidopamine; Parkinson Disease, Secondary; Phosphorylation; Rats; Rats, Wistar | 2012 |
Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Levodopa; Male; Microinjections; Motor Activity; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2012 |
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
Topics: Algorithms; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Benserazide; Blood-Brain Barrier; Capillaries; Cerebrovascular Circulation; Dyskinesias; Female; Glucose; Immunohistochemistry; Intermediate Filament Proteins; Levodopa; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinson Disease, Secondary; Permeability; Rats; Rats, Sprague-Dawley; Sympatholytics; Tyrosine 3-Monooxygenase | 2012 |
Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.
Topics: Animals; Anti-Dyskinesia Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Infusions, Intraventricular; Levodopa; Male; Oxidopamine; Phenols; Piperidines; Putamen; Quinoxalines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus; Thiazoles | 2012 |
Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study.
Topics: Amphetamine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Rotation | 2012 |
Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Drug Synergism; Dyskinesias; Exenatide; Glucagon-Like Peptide 1; Levodopa; Lizards; Male; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Venoms | 2012 |
Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Topics: Allosteric Regulation; Aminobutyrates; Anilides; Animals; Catalepsy; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Phosphinic Acids; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Synaptic Transmission | 2013 |
Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopaminergic Neurons; Fluoxetine; Histones; Levodopa; Male; MAP Kinase Signaling System; Oxidopamine; Parkinson Disease; Phosphorylation; Piperazines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonergic Neurons; Serotonin; Serotonin 5-HT1 Receptor Antagonists; Substantia Nigra; Tyrosine 3-Monooxygenase | 2012 |
Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Brain; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; GTP-Binding Protein alpha Subunits; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Movement; Mutation; Oxidopamine; Psychomotor Performance; Receptors, AMPA; Signal Transduction; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2012 |
Preparation of rotigotine-loaded microspheres and their combination use with L-DOPA to modify dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Dopamine Agonists; Drug Carriers; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Microspheres; Oxidopamine; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Thiophenes | 2012 |
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Biophysical Phenomena; Disease Models, Animal; Dopamine; Electric Stimulation; Excitatory Postsynaptic Potentials; Exploratory Behavior; Hippocampus; Humans; Levodopa; Long-Term Potentiation; Male; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microdialysis; Mutation; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Radionuclide Imaging; Rats; Subcellular Fractions; Sympatholytics; Synaptosomes; Tritium; Tyrosine 3-Monooxygenase | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Buspirone; Cell Count; Creatinine; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin Receptor Agonists; Time Factors | 2012 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Benserazide; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dystonia; Facial Asymmetry; Idazoxan; Levodopa; Locomotion; Oxidopamine; Parkinson Disease; Piribedil; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Statistics, Nonparametric; Upper Extremity | 2013 |
L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients.
Topics: Animals; Brain; Dopaminergic Neurons; Humans; Levodopa; Models, Neurological; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders | 2012 |
L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anxiety; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin | 2012 |
Impact of dopamine versus serotonin cell transplantation for the development of graft-induced dyskinesia in a rat Parkinson model.
Topics: Adrenergic Agents; Amphetamines; Analysis of Variance; Animals; Antiparkinson Agents; Cell Transplantation; Central Nervous System Stimulants; Disease Models, Animal; Dopaminergic Neurons; Dyskinesias; Female; Functional Laterality; Levodopa; Nerve Fibers; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Serotonergic Neurons; Statistics as Topic; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2012 |
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Topics: Amantadine; Animals; Antiparkinson Agents; Cycloserine; Dextromethorphan; Dopamine Agents; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists | 2012 |
The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Levodopa; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Regression Analysis; Subthalamic Nucleus | 2012 |
Novel codrugs with GABAergic activity for dopamine delivery in the brain.
Topics: 1-Octanol; Acetamides; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Cattle; Cell Membrane; Cells, Cultured; Dogs; Dopamine; Dopamine Agents; Endothelial Cells; Levodopa; Madin Darby Canine Kidney Cells; Male; Oxidopamine; Parkinson Disease; Prodrugs; Rats; Rats, Wistar; Receptors, GABA-A; Rhodamine 123; Water | 2012 |
Eppendorf finalist. Striatal interneurons: causes of or cures for movement disorders?
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Interneurons; Levodopa; Mice; Mice, Transgenic; Movement Disorders; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Receptors, AMPA; Receptors, Kainic Acid; Treatment Failure | 2012 |
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2013 |
Effect of zonisamide co-administration with levodopa on global gene expression in the striata of rats with Parkinson's disease.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Gene Expression; Gene Expression Profiling; Isoxazoles; Levodopa; Male; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Zonisamide | 2012 |
Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Area Under Curve; Disease Models, Animal; Dyskinesias; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Time Factors | 2013 |
The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model.
Topics: Animals; Central Nervous System Sensitization; Dopamine; Dopamine Agents; Levodopa; Locomotion; Male; Oxidopamine; Piperidines; Rats; Rats, Sprague-Dawley; Rotation; Time Factors | 2013 |
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Autoradiography; Behavior, Animal; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Microinjections; Nociceptin; Opioid Peptides; Oxidopamine; Postural Balance; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2012 |
Levodopa-induced dyskinesia is strongly associated with resonant cortical oscillations.
Topics: Algorithms; Animals; Antiparkinson Agents; Cerebral Cortex; Dyskinesia, Drug-Induced; Electrodes, Implanted; Electroencephalography; Evoked Potentials; Female; Fluorescent Antibody Technique; Levodopa; Microelectrodes; Neostriatum; Neurons; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tyrosine 3-Monooxygenase | 2012 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA | 2012 |
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate | 2012 |
Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake.
Topics: Animals; Biological Transport; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation; Levodopa; Male; Neostriatum; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Synapses; Synaptosomes; Tyrosine 3-Monooxygenase | 2012 |
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Dyskinesia, Drug-Induced; Immunoprecipitation; Levodopa; Male; MAP Kinase Signaling System; Oxidopamine; Parkinsonian Disorders; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Rats; Rats, Wistar; Receptors, Dopamine D1 | 2013 |
Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat.
Topics: Animals; Cocaine; Conditioning, Psychological; Dopamine Agonists; Dopaminergic Neurons; Levodopa; Male; Motivation; Motor Activity; Oxidopamine; Rats; Receptors, Dopamine; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Iodine Isotopes; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; RNA, Messenger; Sympatholytics | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Movement; Neurons; Oxidopamine; Quinolinic Acid; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2013 |
Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; Microinjections; Motor Activity; Nitric Oxide Synthase Type I; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar | 2013 |
Selective effects of dopamine depletion and L-DOPA therapy on learning-related firing dynamics of striatal neurons.
Topics: Action Potentials; Analysis of Variance; Animals; Animals, Newborn; Conditioning, Operant; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Electric Stimulation; Electrochemical Techniques; Learning Disabilities; Levodopa; Male; Maze Learning; Neural Pathways; Neurotoxins; Oxidopamine; Rats; Rats, Sprague-Dawley; Reaction Time; Time Factors | 2013 |
Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Berberine; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2013 |
Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Physical Conditioning, Animal | 2013 |
Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.
Topics: Animals; Antioxidants; Antiparkinson Agents; Cell Line, Tumor; Cell Survival; Disulfides; Dopamine; Dopaminergic Neurons; Enzyme Induction; Gene Expression; Glutamate-Cysteine Ligase; Heme Oxygenase-1; Humans; Levodopa; Lipid Peroxidation; Male; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Response Elements; Substantia Nigra | 2013 |
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2013 |
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion; Disease Models, Animal; Immunohistochemistry; Levodopa; Mood Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Rats; Rats, Wistar | 2013 |
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Cerebral Cortex; Corpus Striatum; Dendritic Spines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Membrane Potentials; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2014 |
Transplantation of melanocytes obtained from the skin ameliorates apomorphine-induced abnormal behavior in rodent hemi-parkinsonian models.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Dopamine; Immunohistochemistry; Levodopa; Melanocytes; Mice; Monophenol Monooxygenase; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation | 2013 |
Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Nitric Oxide Synthase; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra | 2014 |
Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease, Secondary; Raphe Nuclei; Serotonergic Neurons; Serotonin | 2013 |
A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Analysis of Variance; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors | 2013 |
Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse.
Topics: Adrenergic Agents; Amphetamine; Animals; Antiparkinson Agents; Cell Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Parkinson Disease; Stereotyped Behavior | 2012 |
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Adrenergic Agents; Aminobutyrates; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Phosphinic Acids; Receptors, Metabotropic Glutamate; Time Factors | 2011 |
Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Corpus Striatum; Disease Models, Animal; Dopamine; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Receptor, Serotonin, 5-HT1B; Receptors, Dopamine; Serotonin; Tetrazoles | 2014 |
Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.
Topics: 5,7-Dihydroxytryptamine; Animals; Antiparkinson Agents; Basal Ganglia; Clorgyline; Dopamine; Dopamine Agents; Dopaminergic Neurons; Fluorescent Antibody Technique; Glial Fibrillary Acidic Protein; Indans; Levodopa; Male; Microdialysis; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Organic Anion Transporters, Sodium-Independent; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonergic Neurons | 2013 |
5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Topics: 5-Hydroxytryptophan; Adrenergic Agents; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin | 2013 |
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Citalopram; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2014 |
Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
Topics: Animals; Behavior, Animal; Corpus Striatum; Levodopa; Male; Molsidomine; Nitric Oxide Donors; Oxidopamine; Rats; Rats, Wistar; Substantia Nigra | 2013 |
Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Immunohistochemistry; Levodopa; Male; Molsidomine; NADPH Dehydrogenase; Neurons; Nitric Oxide Donors; Nitric Oxide Synthase Type I; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Subthalamic Nucleus | 2013 |
Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Endocannabinoids; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oleic Acids; Oxidopamine; Parkinson Disease; TRPV Cation Channels | 2014 |
Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Count; Cell Survival; Dopamine Agents; Dopaminergic Neurons; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neural Stem Cells; Neurogenesis; Neuroprotective Agents; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Selegiline | 2014 |
Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance.
Topics: Acupuncture Therapy; Animals; Antiparkinson Agents; Brain Chemistry; Combined Modality Therapy; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Movement; Oxidopamine; Parkinson Disease, Secondary; Proto-Oncogene Proteins c-fos; Substantia Nigra | 2014 |
Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Catalepsy; Cysteine Proteinase Inhibitors; Dopamine Agonists; Dose-Response Relationship, Drug; Functional Laterality; Levodopa; Male; Oxidopamine; Rats; Rats, Wistar; Reaction Time; Serotonin; Substantia Nigra | 2014 |
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Benserazide; Benzothiazoles; Corpus Striatum; Hippocampus; Levodopa; Male; Motor Activity; Neurogenesis; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Substantia Nigra; Time Factors | 2014 |
Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dendritic Spines; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Pyramidal Cells; Rats; Rats, Wistar; Telencephalon | 2014 |
The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.
Topics: Animals; Anti-Bacterial Agents; Antiparkinson Agents; Ceftriaxone; Central Nervous System Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Forelimb; Kainic Acid; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Long-Evans | 2014 |
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Cannabinoid Receptor Antagonists; Cholinesterase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Rimonabant; Tacrine; Time Factors; Tremor | 2014 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley | 2014 |
Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Endocannabinoids; Gene Expression; Gene Ontology; Levodopa; Male; Microarray Analysis; Motor Activity; Oxidopamine; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2014 |
Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Area Under Curve; Disease Models, Animal; Dopamine Agents; Female; Levodopa; Mice; Movement Disorders; Oxidopamine; Receptors, G-Protein-Coupled; Rotarod Performance Test; Substantia Nigra; Tyrosine 3-Monooxygenase | 2014 |
The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Time Factors; Tryptophan; Tyrosine 3-Monooxygenase | 2014 |
Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Gastrodia; Levodopa; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos | 2014 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, Animal; Drug Combinations; Levodopa; Minocycline; Motor Activity; Oxidopamine; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Sympatholytics; Vitamin E; Zebrafish; Zebrafish Proteins | 2014 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benzylamines; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Nerve Degeneration; Oxidopamine; Parkinson Disease; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins; Stereotyped Behavior | 2014 |
Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Agonists; Dopamine beta-Hydroxylase; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Neurons; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Ribosome Inactivating Proteins, Type 1; Saporins | 2014 |
Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Butadienes; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Mice, Knockout; Neuronal Plasticity; Neurons; Nitriles; Oxidopamine; Parkinsonian Disorders; Protein Kinase Inhibitors; ras-GRF1; Tissue Culture Techniques | 2015 |
Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
Topics: Acetylation; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Endorphins; Histones; Immunohistochemistry; Kv Channel-Interacting Proteins; Levodopa; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, AMPA; Repressor Proteins; Rotarod Performance Test | 2015 |
NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Extracellular Space; Functional Laterality; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus | 2014 |
Deuterium-substituted L-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by L-DOPA and an MAO-B inhibitor.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Deuterium; Disease Models, Animal; Dopamine; Forelimb; Levodopa; Male; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Selegiline; Tyrosine 3-Monooxygenase | 2015 |
(6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Aporphines; Base Sequence; Disease Models, Animal; DNA Primers; Dopamine Agonists; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Serotonin Receptor Agonists | 2014 |
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Gene Expression; Genetic Therapy; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RGS Proteins; RNA, Messenger; Up-Regulation | 2014 |
L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzylamines; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Microdialysis; Neurotransmitter Agents; Norepinephrine; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2014 |
[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats | 2014 |
l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via β-adrenergic receptors.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dentate Gyrus; Disease Models, Animal; Dopamine; Dopamine Antagonists; Electric Stimulation; Functional Laterality; Levodopa; Long-Term Synaptic Depression; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sulpiride | 2014 |
Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats.
Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Brain Waves; Disease Models, Animal; Dopamine Antagonists; Functional Laterality; Levodopa; Male; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats; Rats, Long-Evans; Salicylamides; Serotonin Antagonists; Substantia Nigra | 2014 |
Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Daunorubicin; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1 | 2016 |
The H3 receptor agonist immepip does not affect l-dopa-induced abnormal involuntary movements in 6-OHDA-lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Dyskinesias; Histamine Agonists; Imidazoles; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Wistar | 2014 |
Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
Topics: Adrenergic Agents; Angiotensin II Type 1 Receptor Blockers; Animals; Antiparkinson Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Dyskinesia, Drug-Induced; In Vitro Techniques; Interleukin-1beta; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease; Tetrazoles; Vascular Endothelial Growth Factor A | 2014 |
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.
Topics: Animals; Animals, Newborn; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Functional Laterality; Green Fluorescent Proteins; In Vitro Techniques; Levodopa; Mice; Mice, Transgenic; Neural Pathways; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Purinergic Agents; Receptor, Adenosine A2A; Receptors, Dopamine D1 | 2014 |
A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neostriatum; Neurons; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fos; Ribosomal Protein S6 Kinases, 90-kDa | 2016 |
Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Topics: Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Nitric Oxide Synthase Type I; Oxidopamine; Rats; Rats, Wistar | 2015 |
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Species Specificity | 2015 |
Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.
Topics: Acetamides; Animals; Brain; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyrrolidinones; Rats, Sprague-Dawley | 2015 |
New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Constipation; Gastrointestinal Transit; Ghrelin; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2014 |
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Corpus Striatum; Dimerization; Dominance, Cerebral; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Gene Expression Regulation; Levodopa; Macaca fascicularis; Male; Oxidopamine; Parkinsonian Disorders; Putamen; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D3 | 2015 |
Interactions of CaMKII with dopamine D2 receptors: roles in levodopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's rats.
Topics: Amino Acid Motifs; Animals; Binding Sites; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dyskinesias; Female; Levodopa; Neurons; Oxidopamine; Parkinson Disease; Protein Binding; Protein Interaction Domains and Motifs; Rats; Receptors, Dopamine D2 | 2014 |
The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Female; Levodopa; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oxidopamine; Parkinson Disease; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1 | 2014 |
A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Glucose; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Quinolinic Acid; Rats; Rats, Wistar; Striatonigral Degeneration; Touch | 2014 |
Nitric oxide regulates synaptic transmission between spiny projection neurons.
Topics: Animals; Axons; Basal Ganglia; Cyclic AMP; Dopamine; Electrophysiology; Feedback, Physiological; Female; gamma-Aminobutyric Acid; Green Fluorescent Proteins; Guanylate Cyclase; Levodopa; Male; Mice; Neuronal Plasticity; Neurons; Nitric Oxide; Oxidopamine; Signal Transduction; Synaptic Transmission; Vesicular Inhibitory Amino Acid Transport Proteins | 2014 |
β-asarone and levodopa co-administration protects against 6-hydroxydopamine-induced damage in parkinsonian rat mesencephalon by regulating autophagy: down-expression Beclin-1 and light chain 3B and up-expression P62.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Dopaminergic Neurons; Down-Regulation; Drug Interactions; Female; Levodopa; Male; Mesencephalon; Microtubule-Associated Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Transcription Factor TFIIH; Transcription Factors; Up-Regulation | 2015 |
Inhibiting Lateral Habenula Improves L-DOPA-Induced Dyskinesia.
Topics: Animals; Corpus Striatum; Daunorubicin; Deoxyglucose; Disease Models, Animal; Dyskinesia, Drug-Induced; Electrophysiology; Female; Genes, Immediate-Early; Habenula; Levodopa; Macaca fascicularis; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2016 |
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2015 |
Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
Topics: Adrenergic Agents; Animals; Benserazide; Blotting, Western; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Fluorescent Antibody Technique; Lactic Acid; Levodopa; Microspheres; Neurons; Oxidopamine; Parkinson Disease; Phosphoproteins; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; tau Proteins; Transcription Factors | 2014 |
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Benzothiazoles; Drug Therapy, Combination; Levodopa; Mass Spectrometry; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Purines; Pyrimidines; Rats; Receptors, N-Methyl-D-Aspartate; Triazoles | 2014 |
Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.
Topics: Animals; Disease Models, Animal; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Female; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Oxidopamine; Parkinson Disease; Phosphorylation; Proto-Oncogene Proteins c-fyn; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2015 |
Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dopamine Agents; Levodopa; Mice, Inbred C57BL; Motor Activity; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2; Synapses; Tissue Culture Techniques | 2015 |
Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion.
Topics: Animals; Antiparkinson Agents; Astrocytes; Carbidopa; Corpus Striatum; Gliosis; Levodopa; Male; Maze Learning; Memory Disorders; Memory, Short-Term; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Prefrontal Cortex; Rats, Wistar; Spatial Memory | 2015 |
Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Piperidines; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tyrosine 3-Monooxygenase | 2015 |
Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Humans; Levodopa; Male; Mice; Oxidopamine; Parkinson Disease, Secondary; Prepulse Inhibition; Rats; Rats, Wistar | 2015 |
Cardiovascular and autonomic alterations in rats with Parkinsonism induced by 6-OHDA and treated with L-DOPA.
Topics: Animals; Antiparkinson Agents; Autonomic Nervous System; Baroreflex; Biogenic Monoamines; Blood Pressure; Dopamine; Heart Rate; Hemodynamics; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Sympatholytics | 2015 |
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Catalepsy; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Haloperidol; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphinic Acids; Picolinic Acids; Random Allocation; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2015 |
Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration.
Topics: Aging; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Embryo, Mammalian; Functional Laterality; Levodopa; Neurites; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred F344; Recovery of Function; Stem Cell Transplantation; Substance P | 2015 |
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Male; MAP Kinase Signaling System; Oncogene Proteins v-fos; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Simvastatin; Time Factors | 2015 |
Deep brain stimulation of different pedunculopontine targets in a novel rodent model of parkinsonism.
Topics: Animals; Cell Survival; Cholinergic Neurons; Deep Brain Stimulation; Disease Models, Animal; Dopaminergic Neurons; Gait; Ibotenic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Postural Balance; Rats | 2015 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic | 2015 |
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Clonidine; Dyskinesia, Drug-Induced; Imidazoles; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2 | 2015 |
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Hippocampus; Levodopa; Male; Mice, Inbred C57BL; Neurogenesis; Neurons; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation | 2015 |
Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Carbidopa; Chromatography, High Pressure Liquid; Corpus Striatum; Dependovirus; Dopamine; Electrochemical Techniques; Genetic Therapy; Genetic Vectors; Humans; Immunohistochemistry; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2015 |
Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Amphetamine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Parkinson Disease; Phosphopyruvate Hydratase; Proto-Oncogene Proteins c-fos; Serotonin Plasma Membrane Transport Proteins; Statistics, Nonparametric; Tyrosine 3-Monooxygenase | 2015 |
Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ethanol; Gynostemma; Levodopa; Locomotion; Male; MAP Kinase Signaling System; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Solvents | 2015 |
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Citalopram; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Chalcone; Disease Models, Animal; Levodopa; Male; Motor Activity; Olfaction Disorders; Oxidopamine; Parkinson Disease; Quinones; Rats; Receptors, Dopamine D3; Time Factors | 2015 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Gene Deletion; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction; Up-Regulation | 2015 |
Subthalamic nucleus activity in the awake hemiparkinsonian rat: relationships with motor and cognitive networks.
Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Benzazepines; Cognition Disorders; Disease Models, Animal; Dopamine Antagonists; Evoked Potentials; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Subthalamic Nucleus; Time Factors; Tyrosine 3-Monooxygenase; Wakefulness | 2015 |
Similar L-dopa-stimulated motor activity in mice with adult-onset 6-hydroxydopamine-induced symmetric dopamine denervation and in transcription factor Pitx3 null mice with perinatal-onset symmetric dopamine denervation.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Homeodomain Proteins; Levodopa; Male; Mice; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Transcription Factors | 2015 |
Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Benzothiazoles; Cluster Analysis; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Levodopa; Male; Microarray Analysis; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 2016 |
Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Gene Expression Regulation; Indoles; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neurokinin-1 Receptor Antagonists; Oxidopamine; Parkinson Disease; Piperidines; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2015 |
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
Topics: Animals; Calbindins; Cyclooxygenase 2; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Nitric Oxide; Nitric Oxide Synthase; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2015 |
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Haloperidol; Levodopa; Movement; Neurotransmitter Agents; Oxidopamine; Piperidines; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists; Serotonin Syndrome; Swimming; Vocalization, Animal | 2015 |
Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Topics: Animals; Apomorphine; Benserazide; Combined Modality Therapy; Drug Combinations; Glial Fibrillary Acidic Protein; Glutathione Peroxidase; Hyperbaric Oxygenation; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Superoxide Dismutase; Tyrosine 3-Monooxygenase | 2015 |
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger | 2015 |
Medial frontal ∼4-Hz activity in humans and rodents is attenuated in PD patients and in rodents with cortical dopamine depletion.
Topics: Animals; Antiparkinson Agents; Conditioning, Operant; Delta Rhythm; Dopamine; Electroencephalography; Female; Frontal Lobe; Humans; Levodopa; Male; Middle Aged; Neurons; Neuropsychological Tests; Oxidopamine; Parkinson Disease; Rats, Long-Evans; Theta Rhythm; Time Perception | 2015 |
Loss of glutamic acid decarboxylase (Gad67) in striatal neurons expressing the Drdr1a dopamine receptor prevents L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Glutamate Decarboxylase; Levodopa; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine D1; Receptors, G-Protein-Coupled | 2015 |
The 5-HT4 Agonist Prucalopride Stimulates L-DOPA-Induced Dopamine Release in Restricted Brain Regions of the Hemiparkinsonian Rat In Vivo.
Topics: Animals; Benzofurans; Brain; Dopamine; Dopamine Agents; Functional Laterality; Indoles; Levodopa; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats; Serotonin 5-HT4 Receptor Agonists; Serotonin 5-HT4 Receptor Antagonists; Sulfonamides | 2015 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors | 2015 |
The preferential nNOS inhibitor 7-nitroindazole and the non-selective one N(G)-nitro-L-arginine methyl ester administered alone or jointly with L-DOPA differentially affect motor behavior and monoamine metabolism in sham-operated and 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Apomorphine; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Indazoles; Levodopa; Locomotion; Male; Movement Disorders; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Oxidopamine; Rats; Rats, Wistar; Time Factors | 2015 |
Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs.
Topics: Adenosine A2 Receptor Antagonists; Animals; Benserazide; Benzothiazoles; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Combinations; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate | 2015 |
Depressive-like behavior observed with a minimal loss of locus coeruleus (LC) neurons following administration of 6-hydroxydopamine is associated with electrophysiological changes and reversed with precursors of norepinephrine.
Topics: Action Potentials; Adrenergic Agents; Animals; Catecholamines; Depression; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Food Preferences; Levodopa; Locus Coeruleus; Male; Mice; Mice, Inbred C57BL; Neurons; Oxidopamine; Phenazines; Sucrose; Swimming; Time Factors | 2016 |
Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
Topics: AIDS-Related Complex; Animals; Benzazepines; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Medial Forebrain Bundle; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Synaptic Transmission | 2015 |
L-DOPA modulates cell viability through the ERK-c-Jun system in PC12 and dopaminergic neuronal cells.
Topics: Adrenergic Agents; Animals; Caspase 3; Cell Survival; Cells, Cultured; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Embryo, Mammalian; Enzyme Inhibitors; Gene Expression Regulation; Levodopa; MAP Kinase Signaling System; Mesencephalon; Oxidopamine; Parkinson Disease; PC12 Cells; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Time Factors | 2016 |
Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
Topics: Adrenergic Agents; Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Catalase; Disease Models, Animal; Dyskinesia, Drug-Induced; Extremities; Female; Glutathione; Levodopa; Male; Movement; Oleanolic Acid; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric | 2016 |
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Topics: Adrenergic Agents; Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligodeoxyribonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Radiopharmaceuticals; Receptors, G-Protein-Coupled; Stereotyped Behavior; Synaptic Transmission; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzazepines; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Gamma Rhythm; Levodopa; Male; Motor Activity; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists | 2016 |
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neuronal Plasticity; Neurons; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Wistar; Serotonin Receptor Agonists; Synapses; Synaptic Transmission; TOR Serine-Threonine Kinases | 2016 |
Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Topics: Action Potentials; Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Buspirone; Desipramine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Subthalamic Nucleus | 2016 |
Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.
Topics: Amino Acid Transport Systems, Acidic; Animals; Antiparkinson Agents; Cell Count; Cell Size; Choline O-Acetyltransferase; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Ribosomal Protein S6; Vesicular Acetylcholine Transport Proteins | 2016 |
Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2016 |
Yokukansan, a Traditional Japanese Medicine, Enhances the L-DOPA-Induced Rotational Response in 6-Hydroxydopamine-Lesioned Rats: Possible Inhibition of COMT.
Topics: Animals; Benserazide; Catechols; Cell Line; Corpus Striatum; Dopamine; Drugs, Chinese Herbal; Hydrazines; Levodopa; Male; Medicine, East Asian Traditional; Nitriles; Oxidopamine; Pargyline; Rats; Rats, Wistar | 2016 |
CART modulates the effects of levodopa in rat model of Parkinson's disease.
Topics: Animals; Antibodies; Antiparkinson Agents; Apomorphine; Brain; Dopamine Agonists; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Levodopa; Male; Movement; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2016 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists | 2016 |
Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Dopamine; Dyskinesias; Levodopa; Male; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins | 2016 |
The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats.
Topics: Animals; Dopamine Agents; Dorsal Raphe Nucleus; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin | 2016 |
Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
Topics: Action Potentials; Animals; Brain; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesia, Drug-Induced; GABAergic Neurons; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Pars Reticulata; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2016 |
DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Topics: Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Carbidopa; Central Nervous System Stimulants; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Rotation; Sympatholytics; Time Factors | 2016 |
Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
Topics: Animals; Antigens, Differentiation; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; RNA, Messenger; Substantia Nigra | 2016 |
Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
Topics: Animals; Dyskinesia, Drug-Induced; Female; Levodopa; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate | 2016 |
L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Forelimb; gamma-Aminobutyric Acid; Glutamic Acid; Glycine; Levodopa; Mice; Oxidopamine; Rotarod Performance Test; Taurine; Tyrosine | 2016 |
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats, Wistar; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
Topics: Allylbenzene Derivatives; Animals; Anisoles; ATP Binding Cassette Transporter, Subfamily B; Blood-Brain Barrier; Corpus Striatum; Dopamine; Drug Therapy, Combination; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Tight Junction Proteins | 2016 |
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cyclic AMP-Dependent Protein Kinases; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glycogen Synthase Kinase 3 beta; Levodopa; Mitogen-Activated Protein Kinase 3; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Rats; Receptors, Dopamine D1; tau Proteins; Thiadiazoles; Tyrosine 3-Monooxygenase | 2016 |
Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Carbidopa; Communication Disorders; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Combinations; Fourier Analysis; Levodopa; Male; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Long-Evans; Stereotyped Behavior; Time Factors; Ultrasonics; Vocalization, Animal | 2016 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indazoles; Levodopa; Male; Medial Forebrain Bundle; Microinjections; Nitroprusside; Oxidopamine; Parkinson Disease; Rats | 2016 |
Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; RNA, Messenger; Statistics as Topic; Sympatholytics; Tyrosine 3-Monooxygenase | 2016 |
Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Animals; Behavior, Animal; Brain; Cell Line; Cell- and Tissue-Based Therapy; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Neural Stem Cells; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2016 |
Effect of the C-terminal domain of the heavy chain of tetanus toxin on dyskinesia caused by levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Cell Death; Corpus Striatum; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Peptide Fragments; Protein Domains; Proto-Oncogene Proteins c-fos; Rats; Substantia Nigra; Tetanus Toxin; Tyrosine 3-Monooxygenase | 2016 |
The network of causal interactions for beta oscillations in the pedunculopontine nucleus, primary motor cortex, and subthalamic nucleus of walking parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Beta Rhythm; Disease Models, Animal; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Rats; Rats, Sprague-Dawley; Spectrum Analysis; Subthalamic Nucleus; Tyrosine 3-Monooxygenase; Walking | 2016 |
LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias.
Topics: Animals; Disease Models, Animal; Dyskinesias; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Phosphorylation; Protein Kinase Inhibitors; Rats, Sprague-Dawley | 2016 |
Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Dioxygenases; Disease Models, Animal; DNA Methylation; Dopamine; Dyskinesia, Drug-Induced; Enzyme Inhibitors; GADD45 Proteins; Gene Expression Regulation; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Phthalimides; Rats; Rats, Sprague-Dawley; Tryptophan | 2016 |
Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
Topics: Aging; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinson Disease | 2016 |
l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neuronal Plasticity; Neurons; Oxidopamine; Protein Precursors; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.
Topics: Animals; Anti-Dyskinesia Agents; Arachidonic Acids; Brain; Cannabidiol; Capsaicin; Cyclooxygenase 2; Dyskinesia, Drug-Induced; Endocannabinoids; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice, Inbred C57BL; NF-kappa B; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; PPAR gamma; Receptor, Cannabinoid, CB1; TRPV Cation Channels; Tyrosine 3-Monooxygenase | 2016 |
Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors.
Topics: Alcohol Drinking; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Agents; Homeostasis; Interpersonal Relations; Ivermectin; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Oxidopamine; Receptors, Purinergic P2X4; Reflex, Startle; Synaptic Transmission | 2016 |
Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benserazide; Conditioning, Operant; Disease Models, Animal; Evoked Potentials; Fourier Analysis; Levodopa; Locomotion; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar; Time Factors | 2016 |
Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.
Topics: Analgesics; Animals; Antiparkinson Agents; Cerebrovascular Circulation; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Hemodynamics; Isoflurane; Ketamine; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Sympatholytics | 2016 |
Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Choline O-Acetyltransferase; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Functional Laterality; Genotype; Hypokinesia; Levodopa; Luminescent Proteins; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Optogenetics; Oxidopamine; Parkinson Disease; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Transduction, Genetic | 2016 |
Validation of an improved scale for rating l-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agents; Dopamine Antagonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Exploratory Behavior; Levodopa; Male; Mice; Mice, Inbred C57BL; Movement; Outcome Assessment, Health Care; Oxidopamine; Parkinson Disease; Reproducibility of Results; Time Factors | 2016 |
L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Female; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinson Disease, Secondary; Receptors, Dopamine D1; Receptors, Dopamine D2; Spine; Sympatholytics | 2016 |
The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agents; GABA Agents; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Motor Cortex; Movement; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Signal Transduction; Sympatholytics; Tardive Dyskinesia | 2016 |
The impact of l-dopa on attentional impairments in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Rats, Sprague-Dawley | 2016 |
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Cytokines; Disease Models, Animal; Drug Delivery Systems; Dyskinesia, Drug-Induced; Encephalitis; Functional Laterality; Gene Expression Regulation; Levodopa; Lipopolysaccharides; Male; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics; Tumor Necrosis Factor-alpha | 2016 |
Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease.
Topics: Animals; Benzylamines; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Norepinephrine; Oxidopamine; Pain; Parkinson Disease; Rats, Sprague-Dawley; Spinal Cord | 2016 |
Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Blood Pressure; Levodopa; Male; Molsidomine; Nitric Oxide Donors; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2017 |
Levodopa-induced morphologic changes of prefrontal pyramidal tract-type neurons in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dendritic Spines; Dopamine Agents; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Prefrontal Cortex; Pyramidal Tracts; Rats, Wistar | 2017 |
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Channelrhodopsins; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; Sympatholytics | 2017 |
Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Brain; Channelrhodopsins; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesias; Functional Laterality; Levodopa; Male; Optogenetics; Oxidopamine; Parkinson Disease; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2017 |
Dysregulation of BET proteins in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Domains; Proteins; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Triazoles | 2017 |
Moderate traumatic brain injury increases the vulnerability to neurotoxicity induced by systemic administration of 6-hydroxydopamine in mice.
Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Brain; Brain Injuries; Brain Injuries, Traumatic; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Levodopa; Mice; Neurodegenerative Diseases; Neurotoxicity Syndromes; Oxidopamine; Tyrosine 3-Monooxygenase | 2017 |
Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
Topics: Animals; Antiparkinson Agents; Armadillo Domain Proteins; Catechol O-Methyltransferase; Cell Adhesion Molecules; Corpus Striatum; Disease Models, Animal; Disease Susceptibility; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphoproteins; Proto-Oncogene Proteins c-fos; Serotonin; Thioredoxin Reductase 2 | 2017 |
Morphological dendritic spine changes of medium spiny neurons in the nucleus accumbens in 6-hydroxydopamine-lesioned rats treated with levodopa.
Topics: Animals; Apomorphine; Dendritic Spines; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Medial Forebrain Bundle; Neurons; Nucleus Accumbens; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Statistics, Nonparametric; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2017 |
Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamate Decarboxylase; Levodopa; Motor Cortex; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, GABA; RNA, Messenger; Sympatholytics; Tandem Mass Spectrometry | 2017 |
Long-term Levodopa Treatment Accelerates the Circadian Rhythm Dysfunction in a 6-hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Blotting, Western; Body Weight; Circadian Rhythm; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction | 2017 |
Dopamine Depletion Impairs Bilateral Sensory Processing in the Striatum in a Pathway-Dependent Manner.
Topics: Animals; Dopamine; Dopamine Agents; Functional Laterality; Levodopa; Mice; Neostriatum; Neural Pathways; Neurons; Oxidopamine; Parkinson Disease; Patch-Clamp Techniques; Receptors, Dopamine D1; Receptors, Dopamine D2; Somatosensory Cortex; Touch; Vibrissae | 2017 |
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
Topics: Acetylcholine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Choline O-Acetyltransferase; Colon; Gastrointestinal Transit; Inflammation; Interleukin-1beta; Levodopa; Male; Muscle, Smooth; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Synaptic Transmission; Tissue Culture Techniques; Tumor Necrosis Factor-alpha | 2017 |
Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease, Secondary; Positron-Emission Tomography; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Dopamine D2; Sympatholytics | 2017 |
Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
Topics: Animals; Anti-Bacterial Agents; Ceftriaxone; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Sympatholytics | 2017 |
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dyskinesia, Drug-Induced; Gene Expression; HEK293 Cells; Humans; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonergic Neurons | 2017 |
β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antiparkinson Agents; Behavior, Animal; Benserazide; Catechol O-Methyltransferase; Corpus Striatum; Dopa Decarboxylase; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Drug Combinations; Drug Therapy, Combination; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2017 |
Granger causality supports abnormal functional connectivity of beta oscillations in the dorsolateral striatum and substantia nigra pars reticulata in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Beta Rhythm; Corpus Striatum; Disease Models, Animal; Electroencephalography Phase Synchronization; Levodopa; Male; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Pars Reticulata; Rats; Rats, Sprague-Dawley | 2017 |
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca mulatta; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Post-Synaptic Density; Protein Binding; Rabphilin-3A; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses; Tissue Culture Techniques; Vesicular Transport Proteins | 2017 |
Interaction between central GABAA receptor and dopaminergic system on food intake in neonatal chicks: role of D
Topics: Adrenergic Agents; Analysis of Variance; Animals; Animals, Newborn; Benzazepines; Chickens; Dopamine; Dopamine Agents; Eating; Female; Food Deprivation; GABA Agents; gamma-Aminobutyric Acid; Injections, Intraventricular; Isoxazoles; Levodopa; Oxidopamine; Receptors, Dopamine D1; Receptors, GABA-A | 2018 |
Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia.
Topics: Acute Disease; Animals; Cerebral Cortex; Disease Models, Animal; Dyskinesias; Female; Glutamine; Levodopa; Oxidopamine; Parkinson Disease; Positron-Emission Tomography; Proton Magnetic Resonance Spectroscopy; Putamen; Rats, Wistar; Receptor, Metabotropic Glutamate 5 | 2018 |
Neuroprotective and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson's Disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug Administration Schedule; Embryo, Nonmammalian; Indans; Isradipine; Levodopa; Locomotion; Minocycline; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Time Factors; Tyrosine 3-Monooxygenase; Zebrafish | 2017 |
Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine.
Topics: Animals; Apomorphine; Area Under Curve; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relationship, Drug; Immunohistochemistry; Levodopa; Male; Methamphetamine; Motor Activity; Oxidopamine; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2017 |
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Topics: Adrenergic Agents; Analgesics, Opioid; Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Guinea Pigs; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Movement; Narcotic Antagonists; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Vas Deferens | 2018 |
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Acetamides; Animals; Antiparkinson Agents; Corpus Striatum; Cricetinae; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Nociceptin Receptor; Oxidopamine; Phosphorylation; Piperidines; Radioligand Assay; Rats; Receptors, Opioid | 2018 |
Cortical stimulation relieves parkinsonian pathological activity in vitro.
Topics: Animals; Corpus Striatum; Dopamine; Levodopa; Mice; Neurons; Oxidopamine; Parkinsonian Disorders | 2019 |
CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; PC12 Cells; Protein Kinase Inhibitors; Rats; Signal Transduction; Sulfonamides; Sympatholytics; Tyrosine 3-Monooxygenase | 2018 |
Correlation between dopamine receptor D2 expression and presence of abnormal involuntary movements in Wistar rats with hemiparkinsonism and dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2021 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Topics: Animals; Antiparkinson Agents; Apomorphine; Arachidonic Acids; Biomarkers; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Endocannabinoids; Glycerides; Levodopa; Male; Metabolome; Metabolomics; Motor Activity; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; Rats, Sprague-Dawley | 2018 |
Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation; Levodopa; Male; Nociceptive Pain; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats, Wistar | 2018 |
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Green Fluorescent Proteins; Levodopa; Mice; Mice, Transgenic; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Rats; Sensation Disorders; Sympatholytics; Time Factors; Xenon | 2018 |
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine; Receptors, Nicotinic; RNA, Messenger | 2018 |
Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease.
Topics: Anacardic Acids; Animals; Antiparkinson Agents; Curcumin; Cytoskeletal Proteins; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Fos-Related Antigen-2; Gene Expression Regulation; Histone Acetyltransferases; Histone Code; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Specific Pathogen-Free Organisms; Substantia Nigra; Terpenes | 2018 |
Repurposing an established drug: an emerging role for methylene blue in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Drug Repositioning; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Quinoxalines; Rats, Wistar; Signal Transduction | 2019 |
Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.
Topics: Acupuncture Therapy; Animals; Aphakia; Dyskinesia, Drug-Induced; Gene Expression Regulation; Homeodomain Proteins; Hypothalamic Hormones; Hypothalamus; Levodopa; Melanins; Mice, Inbred C57BL; Neostriatum; Oxidopamine; Pituitary Hormones; Reproducibility of Results; RNA, Messenger; Transcription Factors; Up-Regulation | 2019 |
Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats.
Topics: Animals; Behavior, Animal; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Corpus Striatum; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Oxidopamine; Parkinson Disease; Phosphorylation; Protein Binding; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sulfonamides | 2018 |
The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dizocilpine Maleate; Drug Synergism; Dyskinesia, Drug-Induced; Glycopeptides; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats | 2018 |
Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Drug Interactions; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Substantia Nigra | 2018 |
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Riluzole Attenuates L-DOPA-Induced Abnormal Involuntary Movements Through Decreasing CREB1 Activity: Insights from a Rat Model.
Topics: Animals; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Protein Interaction Maps; Random Allocation; Rats; Rats, Wistar; Riluzole | 2019 |
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Time Factors; Vilazodone Hydrochloride | 2018 |
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; Forelimb; Gait Disorders, Neurologic; Interpersonal Relations; Levodopa; Locomotion; Male; Maze Learning; Memory Disorders; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2019 |
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinsonian Disorders; Treatment Outcome; Zonisamide | 2019 |
Spike and Local Field Synchronization Between the Pedunculopontine Nucleus and Primary Motor Cortex in a Rat Model of Parkinson's Disease.
Topics: Action Potentials; Animals; Disease Models, Animal; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar | 2019 |
Changes in Dendritic Spine Density and Inhibitory Perisomatic Connectivity onto Medium Spiny Neurons in L-Dopa-Induced Dyskinesia.
Topics: Animals; Corpus Striatum; Cytoskeletal Proteins; Dendritic Spines; Dyskinesias; Female; Interneurons; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Nerve Net; Nerve Tissue Proteins; Oxidopamine; Parvalbumins; Plant Lectins; Proto-Oncogene Proteins c-fos; Receptors, N-Acetylglucosamine | 2019 |
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Random Allocation; Treatment Failure | 2019 |
Chronic administration of the histamine H
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Histamine Agonists; Imidazoles; Levodopa; Male; Oxidopamine; Piperidines; Rats; Rats, Wistar; Receptors, Histamine H3; Substantia Nigra | 2019 |
Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Lasers; Levodopa; Mice, Inbred C57BL; Optogenetics; Oxidopamine; Parkinsonian Disorders; Photic Stimulation; Substantia Nigra | 2019 |
Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism.
Topics: Animals; Dopamine Agents; Eating; Feeding Behavior; Food Preferences; Levodopa; Long-Term Potentiation; Male; Nucleus Accumbens; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Weight Gain | 2019 |
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Calcium Channels; Disease Models, Animal; Dyskinesia, Drug-Induced; Green Fluorescent Proteins; Levodopa; Luminescent Agents; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; RNA Interference; RNA, Small Interfering; Substantia Nigra; Tyrosine 3-Monooxygenase | 2019 |
Brain state-dependent alterations of corticostriatal synchronized oscillations in awake and anesthetized parkinsonian rats.
Topics: Anesthesia; Animals; Basal Ganglia; Beta Rhythm; Brain; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Wakefulness | 2019 |
Video-based assessments of the hind limb stepping in a mouse model of hemi-parkinsonism.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Gait; Hindlimb; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Tyrosine 3-Monooxygenase | 2020 |
Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson's Disease Model.
Topics: Administration, Intranasal; Animals; Antioxidants; Behavior, Animal; Emulsions; Female; Flavanones; Levodopa; Male; Nanoparticles; Oxidative Stress; Oxidopamine; Parkinson Disease; Particle Size; Rats; Rats, Wistar; Solubility; Viscosity; Vitamin E | 2019 |
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Angiogenesis Inhibitors; Animals; Antiparkinson Agents; Cytokines; Dyskinesia, Drug-Induced; Immunologic Factors; Interleukin-10; Levodopa; Male; Neostriatum; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substantia Nigra; Thalidomide; Tumor Necrosis Factor-alpha | 2019 |
Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2019 |
Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
Topics: Animals; Cyclic AMP; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Signal Transduction | 2019 |
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Levodopa; Locomotion; Male; Medial Forebrain Bundle; Mice; Mice, Knockout; Movement; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Receptors, G-Protein-Coupled; RNA, Messenger; Serotonin; Tacrine; Tremor | 2020 |
Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Motor Disorders; Oxidopamine; Parkinsonian Disorders; Tapentadol | 2020 |
c-Fos Expression after Stochastic Vestibular Stimulation and Levodopa in 6-OHDA Hemilesioned Rats.
Topics: Animals; Dopamine Agents; Gene Expression; Levodopa; Male; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Stochastic Processes; Vestibular Nuclei; Vestibule, Labyrinth | 2020 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Drug Repositioning; Indans; Isradipine; Larva; Levodopa; Locomotion; Motor Activity; Oxidopamine; Parkinson Disease; Phenotype; Zebrafish | 2020 |
Phenotypic chemical and mutant screening of zebrafish larvae using an on-demand response to electric stimulation.
Topics: Animals; Animals, Genetically Modified; Behavior, Animal; Connexins; DNA Mutational Analysis; Electric Stimulation; Lab-On-A-Chip Devices; Levodopa; Mutation; Oxidopamine; Phenotype; Risk Factors; Zebrafish; Zebrafish Proteins | 2019 |
Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Humans; Levodopa; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Motor Activity; Neostriatum; Oxidopamine; Parkinson Disease; Phenotype; Rats, Sprague-Dawley; Reproducibility of Results; Substantia Nigra | 2020 |
The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia.
Topics: Animals; Cholinergic Neurons; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Interneurons; Levodopa; MAP Kinase Signaling System; Mice; Mice, Knockout; Oxidopamine; Parkinson Disease; Receptors, Dopamine D5 | 2020 |
Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
Topics: Amantadine; Animals; Antiparkinson Agents; Bridged Bicyclo Compounds; Corpus Striatum; Dyskinesia, Drug-Induced; Electrophysiology; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2020 |
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; Glutamic Acid; Levodopa; Male; Nerve Net; Organ Culture Techniques; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2020 |
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats, Sprague-Dawley | 2020 |
Genetic lack of histamine upregulates dopamine neurotransmission and alters rotational behavior but not levodopa-induced dyskinesia in a mouse model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease; Synaptic Transmission; Up-Regulation | 2020 |
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Aged; Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Rats, Inbred Lew; Rats, Sprague-Dawley | 2020 |
L-DOPA-elicited abnormal involuntary movements in the rats damaged severely in substantia nigra by 6-hydroxydopamine.
Topics: Animals; Apomorphine; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Substantia Nigra | 2020 |
Acute and Chronic Dopaminergic Depletion Differently Affect Motor Thalamic Function.
Topics: Adrenergic Agents; Animals; Basal Ganglia; Cerebral Cortex; Deep Brain Stimulation; Dopamine; Dopamine Agents; gamma-Aminobutyric Acid; Glutamic Acid; Immunohistochemistry; Levodopa; Male; Medial Forebrain Bundle; Microdialysis; Neurons; Oxidopamine; Rats; Rats, Sprague-Dawley; Tetrodotoxin; Thalamus | 2020 |
Eugenol and its association with levodopa in 6-hydroxydopamine-induced hemiparkinsonian rats: Behavioural and neurochemical alterations.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Disease Models, Animal; Eugenol; Glutathione; Levodopa; Lipid Peroxidation; Male; Motor Activity; Neuroprotective Agents; Nitrites; Oxidative Stress; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar | 2020 |
Deep brain stimulation-guided optogenetic rescue of parkinsonian symptoms.
Topics: Algorithms; Animals; Antiparkinson Agents; Deep Brain Stimulation; Disease Models, Animal; Electrophysiological Phenomena; Female; Humans; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Motor Cortex; Optogenetics; Oxidopamine; Parkinsonian Disorders; Pyramidal Cells; Somatostatin; Subthalamic Nucleus | 2020 |
Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; RNA, Messenger | 2020 |
Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.
Topics: Animals; Behavior, Animal; Cistanche; Cornus; Corpus Striatum; Dioscorea; Disease Models, Animal; Dopaminergic Neurons; Drugs, Chinese Herbal; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Fallopia multiflora; Forelimb; Levodopa; Medial Forebrain Bundle; Mesencephalon; Open Field Test; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rehmannia | 2020 |
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Muscarinic Antagonists; Neostriatum; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Substantia Nigra; Sympatholytics | 2020 |
K channel blockage with 3,4-diaminopyridine potentiates the effect of L-DOPA on dopamine release in striatal slices prepared from 6-OHDA pre-treated rats.
Topics: Amifampridine; Animals; Corpus Striatum; Dopamine; Levodopa; Oxidopamine; Rats | 2020 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; rho-Associated Kinases | 2020 |
The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Cell Transplantation; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Dyskinesias; Embryo, Mammalian; Gene Knock-In Techniques; Levodopa; Mesencephalon; Oxidopamine; Parkinson Disease, Secondary; Rats; Sympatholytics; Vesicular Glutamate Transport Protein 2 | 2021 |
Dyskinesia is Closely Associated with Synchronization of Theta Oscillatory Activity Between the Substantia Nigra Pars Reticulata and Motor Cortex in the Off L-dopa State in Rats.
Topics: Aged; Animals; Antiparkinson Agents; Dyskinesias; Humans; Levodopa; Motor Cortex; Oxidopamine; Pars Reticulata; Rats; Substantia Nigra | 2021 |
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2021 |
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Granisetron; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin 5-HT3 Receptor Antagonists | 2021 |
Inhibition of striatal dopamine D
Topics: Animals; Benzazepines; Dopamine; Dopamine Antagonists; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats, Sprague-Dawley; Receptors, Dopamine D5 | 2021 |
Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cholinergic Agents; Disease Models, Animal; Dyskinesias; Gait; Gait Disorders, Neurologic; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2021 |
Involvement of Autophagy in Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Autophagy; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders | 2021 |
β‑Lapachone ameliorates L‑DOPA‑induced dyskinesia in a 6‑OHDA‑induced mouse model of Parkinson's disease.
Topics: Animals; Dyskinesias; Levodopa; Male; Mice; Naphthoquinones; Oxidopamine; Parkinson Disease, Secondary | 2021 |
Levodopa Causes Striatal Cholinergic Interneuron Burst-Pause Activity in Parkinsonian Mice.
Topics: Animals; Cholinergic Agents; Corpus Striatum; Interneurons; Levodopa; Mice; Oxidopamine | 2021 |
Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and NGF-1 in rat model of the Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Carbidopa; Dopaminergic Neurons; Drug Combinations; Electroencephalography; Insulin-Like Growth Factor I; Levodopa; Male; Medial Forebrain Bundle; Mesenchymal Stem Cell Transplantation; Motor Activity; Nerve Growth Factor; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Substantia Nigra; Wharton Jelly | 2021 |
Levodopa affects spike and local field synchronisation in the pedunculopontine nucleus of a rat model of Parkinson's disease.
Topics: Action Potentials; Animals; Disease Models, Animal; Dopaminergic Neurons; Levodopa; Locomotion; Male; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar | 2021 |
Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
Topics: Analgesics; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gamma Rhythm; Ketamine; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2021 |
The effect of 5-HT
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Entopeduncular Nucleus; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A | 2021 |
Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation Mediators; Interferon-gamma; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders | 2021 |
Striatal ΔFosB gene suppression inhibits the development of abnormal involuntary movements induced by L-Dopa in rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Oxidopamine; Rats | 2021 |
Doxycycline and its derivative, COL-3, decrease dyskinesia induced by l-DOPA in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Doxycycline; Dyskinesia, Drug-Induced; Levodopa; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 9; Oxidopamine; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Tetracyclines | 2021 |
The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Growth Factor | 2021 |
Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models.
Topics: Animals; Antiparkinson Agents; Cell Line, Tumor; Exosomes; Humans; Levodopa; Liposomes; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Dopamine D2; Signal Transduction; Substantia Nigra; Tyrosine 3-Monooxygenase | 2021 |
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate Nucleus; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Interleukin-10; Interleukin-1beta; Levodopa; Microfilament Proteins; Neuroinflammatory Diseases; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Piperazines; Putamen; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Triazoles; Tumor Necrosis Factor-alpha | 2021 |
Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats.
Topics: Animals; Biomarkers; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Resveratrol; Substantia Nigra | 2021 |
Lactiplantibacillus plantarum PS128 Alleviates Exaggerated Cortical Beta Oscillations and Motor Deficits in the 6-Hydroxydopamine Rat Model of Parkinson's Disease.
Topics: Animals; Deep Brain Stimulation; Dopamine; Levodopa; Oxidopamine; Parkinson Disease; Rats; Subthalamic Nucleus | 2023 |
The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra; Sympatholytics | 2021 |
Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; GABAergic Neurons; Humans; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats; Severity of Illness Index | 2021 |
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic Neurons; Levodopa; Neostriatum; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; RNA-Binding Proteins; Serotonergic Neurons; Serotonin Agents; Zonisamide | 2021 |
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease.
Topics: Animals; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease.
Topics: Animals; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2021 |
L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.
Topics: Animals; Cell Movement; Corpus Striatum; Dopaminergic Neurons; Drug Interactions; Embryo, Mammalian; Exenatide; Female; Gene Expression; Glucagon-Like Peptide-1 Receptor; Graft Survival; Insulin Resistance; Leukocytes; Levodopa; Liraglutide; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2021 |
Autoradiographic labelling of 5-HT
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ondansetron; Oxidopamine; Rats; Rats, Sprague-Dawley; Serotonin; Subthalamic Nucleus | 2022 |
Cabergoline, a long-acting dopamine agonist, attenuates L-dopa-induced dyskinesia without L-dopa sparing in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2022 |
Striatal Neuronal Ensembles Reveal Differential Actions of Amantadine and Clozapine to Ameliorate Mice L-DOPA-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Calcium; Clozapine; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Neurons; Oxidopamine | 2022 |
Fucoxanthin Prevents Long-Term Administration l-DOPA-Induced Neurotoxicity through the ERK/JNK-c-Jun System in 6-OHDA-Lesioned Mice and PC12 Cells.
Topics: Animals; Antioxidants; Humans; Levodopa; Mice; Neurotoxicity Syndromes; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Xanthophylls | 2022 |
Human Embryonic Stem Cell-Derived Dopaminergic Grafts Alleviate L-DOPA Induced Dyskinesia.
Topics: Amphetamines; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Human Embryonic Stem Cells; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2022 |
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Vilazodone Hydrochloride | 2022 |
D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice.
Topics: Animals; Antiparkinson Agents; Cholinergic Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Interneurons; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2022 |
Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Tetrabenazine | 2022 |
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine Plasma Membrane Transport Proteins; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats; Sulfones | 2022 |
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2022 |
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidinones; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin; Serotonin 5-HT1 Receptor Agonists; Tryptamines | 2022 |
Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Antipruritics; Corpus Striatum; Desipramine; Dopamine; Levodopa; Norepinephrine; Oxidopamine; Parkinson Disease; Platelet Aggregation Inhibitors; Rats; Serotonin | 2022 |
Agmatine-mediated inhibition of NMDA receptor expression and amelioration of dyskinesia via activation of Nrf2 and suppression of HMGB1/RAGE/TLR4/MYD88/NF-κB signaling cascade in rotenone lesioned rats.
Topics: Agmatine; Animals; Antioxidants; Dyskinesias; HMGB1 Protein; Levodopa; Myeloid Differentiation Factor 88; NF-E2-Related Factor 2; NF-kappa B; Oxidopamine; Parkinson Disease; Rats; Receptors, N-Methyl-D-Aspartate; Rotenone; Signal Transduction; Toll-Like Receptor 4 | 2022 |
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Psychotic Disorders; Quality of Life; Rats; Rats, Sprague-Dawley | 2023 |
The cannabinoid CB
Topics: Angiotensins; Animals; Cannabinoids; Corpus Striatum; Levodopa; Oxidopamine; Parkinson Disease; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Angiotensin; Receptors, Cannabinoid | 2023 |
Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Rats; Rats, Sprague-Dawley | 2023 |
ONO-2506 Can Delay Levodopa-induced Dyskinesia in the Early Stage.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats | 2023 |
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dutasteride; Dyskinesia, Drug-Induced; Levodopa; Male; Neurosteroids; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Delayed-Action Preparations; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Glucagon-Like Peptide-1 Receptor; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
The Dynamics of Dopamine D
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Receptors, Dopamine D2 | 2023 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |
Chronic H
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Rats; RNA, Messenger | 2023 |
Amphiregulin blockade decreases the levodopa-induced dyskinesia in a 6-hydroxydopamine Parkinson's disease mouse model.
Topics: Amphiregulin; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinson Disease | 2023 |
Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats.
Topics: Animals; Corpus Striatum; Dopamine; Gain of Function Mutation; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins | 2023 |
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration.
Topics: Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonia; Humans; Hyperkinesis; Levodopa; Oxidopamine; Parkinson Disease | 2023 |
BDNF/TrkB pathway activation in D1 receptor-expressing striatal projection neurons plays a protective role against L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Transgenic; Oxidopamine; Receptor, trkB; Receptors, Dopamine D2 | 2023 |
Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.
Topics: Animals; Antiparkinson Agents; Brain Stem; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2023 |
Evoked responses to single pulse electrical stimulation reveal impaired striatal excitability in a rat model of Parkinson's disease.
Topics: Animals; Dopamine; Electric Stimulation; Levodopa; Oxidopamine; Parkinson Disease; Quality of Life; Rats | 2023 |
D2 dopamine receptors and the striatopallidal pathway modulate L-DOPA-induced dyskinesia in the mouse.
Topics: Animals; Dopamine Agonists; Dyskinesias; Levodopa; Mice; Oxidopamine; Quinpirole; Receptors, Dopamine D2 | 2023 |
Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders | 2023 |
Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa | 2023 |
The ratio of M1 to M2 microglia in the striatum determines the severity of L-Dopa-induced dyskinesias.
Topics: Animals; Anti-Inflammatory Agents; Antiparkinson Agents; Corpus Striatum; Dyskinesias; Indomethacin; Inflammation; Levodopa; Mice; Microglia; Minocycline; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2023 |